var title_f23_5_23632="Ulcerated stricture on cholangioscopy";
var content_f23_5_23632=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50986&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50986&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ulcerated stricture on cholangioscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 371px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Catheter-based cholangioscopy showing an ulcerated bile duct stricture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_5_23632=[""].join("\n");
var outline_f23_5_23632=null;
var title_f23_5_23633="Lateral thrust";
var content_f23_5_23633=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72639&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72639&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 475px\">",
"   <div class=\"ttl\">",
"    Lateral thrust",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 455px; height: 650px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A lateral thrust is a brief lateral shift at the head of the fibula and upper tibia during the stance phase of gait. It suggests incompetence of the knee ligaments with increased risk of progression.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_5_23633=[""].join("\n");
var outline_f23_5_23633=null;
var title_f23_5_23634="Anatomy AV accessory pathways";
var content_f23_5_23634=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69078&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69078&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 477px\">",
"   <div class=\"ttl\">",
"    Accessory pathways with preexcitation syndromes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 457px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A number of atrioventricular (AV) accessory pathways resulting in preexcitation syndromes have been identified. The muscular AV fiber (AVF), which is also called the Kent bundle, traverses the AV annulus and is responsible for most cases of Wolff-Parkinson-White syndrome. Proposed pathways responsible for the Lown-Ganong-Levine syndrome or enhanced AV nodal conduction include an intranodal bypass tract (INBT) and atrionodal tracts (ANT), also known as James fibers. Traditionally, the etiology for a Mahaim fiber tachycardia was thought to result from a nodoventricular (NVF) and fasciculoventricular (FVF) fiber. However, the true etiology is likely an atriofascicular fiber (AFF) that arises from the right atrium close to the annulus, inserting into the apical part of the right ventricle close to a fascicular branch of the right bundle branch.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_5_23634=[""].join("\n");
var outline_f23_5_23634=null;
var title_f23_5_23635="Patient information: Atherosclerosis (The Basics)";
var content_f23_5_23635=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83344\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/31/44533\">",
"         Carotid artery disease",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/16/3331\">",
"          Heart attack",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/23/6514\">",
"           Peripheral artery disease",
"          </a>",
"          <li>",
"           <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/15/27891\">",
"            Atherosclerosis",
"           </a>",
"          </li>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?12/14/12512\">",
"         Patient information: Carotid artery disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/10/27809\">",
"         Patient information: Coronary heart disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/34/30242\">",
"         Patient information: Doppler ultrasound (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/53/10068\">",
"         Patient information: Heart attack (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/58/34722\">",
"         Patient information: High blood pressure in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?10/48/11011\">",
"         Patient information: High cholesterol (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/49/34578\">",
"         Patient information: Peripheral artery disease and claudication (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/20/37186\">",
"         Patient information: Renovascular hypertension (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/55/24435\">",
"         Patient information: Stroke (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?4/35/4660\">",
"         Patient information: Children and heart disease (atherosclerosis) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/16/40195\">",
"         Patient information: Heart attack (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/4/6212\">",
"         Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/53/19286\">",
"         Patient information: Ischemic stroke treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/35/14900\">",
"         Patient information: Peripheral artery disease and claudication (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Atherosclerosis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/atherosclerosis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H12090562\">",
"      <span class=\"h1\">",
"       What is atherosclerosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Atherosclerosis is a condition in which fatty deposits called &ldquo;plaques&rdquo; build up inside the arteries in the body. (Arteries are the blood vessels that carry blood away from the heart out to the body.) Atherosclerosis is the reason most people have a heart attack or a stroke.",
"     </p>",
"     <p>",
"      Atherosclerosis can affect arteries all over the body. There are different names for atherosclerosis depending on which arteries it affects.",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Carotid artery disease",
"        </strong>",
"        is a form of atherosclerosis that affects the carotid arteries, which bring blood to the brain (",
"        <a class=\"graphic graphic_figure graphicRef72617 \" href=\"UTD.htm?43/31/44533\">",
"         figure 1",
"        </a>",
"        ). This form of atherosclerosis can lead to stroke.",
"       </li>",
"       <li>",
"        <strong>",
"         Coronary heart disease",
"        </strong>",
"        is a form of atherosclerosis that affects the coronary arteries, which bring blood to the heart muscle. This form of atherosclerosis can cause chest pain and lead to heart attack (",
"        <a class=\"graphic graphic_figure graphicRef60394 \" href=\"UTD.htm?3/16/3331\">",
"         figure 2",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        <strong>",
"         Renal artery stenosis",
"        </strong>",
"        is a form of atherosclerosis that affects the renal arteries, which bring blood to the kidneys. This form of atherosclerosis can cause high blood pressure or lead to kidney disease.",
"       </li>",
"       <li>",
"        <strong>",
"         Peripheral artery disease",
"        </strong>",
"        is a form of atherosclerosis that affects the arteries that bring blood to the arms and legs (",
"        <a class=\"graphic graphic_figure graphicRef60105 \" href=\"UTD.htm?6/23/6514\">",
"         figure 3",
"        </a>",
"        ). People with this condition sometimes have pain, tingling, or numbness in their legs when they walk.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12090577\">",
"      <span class=\"h1\">",
"       How does atherosclerosis cause heart attacks, strokes, and other problems?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Atherosclerosis-related plaques can cause problems in 2 ways:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Plaques can get too big and reduce blood flow to certain body parts (",
"        <a class=\"graphic graphic_figure graphicRef83222 \" href=\"UTD.htm?27/15/27891\">",
"         figure 4",
"        </a>",
"        ). This can cause symptoms (such as pain) in the part of the body that is not getting enough blood.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Plaques can break open, or rupture. When that happens, blood clots form inside the artery and block the blood supply to tissues past the clot. This is what happens during a stroke or a heart attack (",
"        <a class=\"graphic graphic_figure graphicRef60394 \" href=\"UTD.htm?3/16/3331\">",
"         figure 2",
"        </a>",
"        ).",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12090592\">",
"      <span class=\"h1\">",
"       Who is at risk for atherosclerosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A person has a higher chance of getting atherosclerosis if he or she:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Has a high cholesterol or triglycerides (triglycerides are a type of fat found in blood)",
"       </li>",
"       <li>",
"        Has high blood pressure",
"       </li>",
"       <li>",
"        Has diabetes",
"       </li>",
"       <li>",
"        Smokes",
"       </li>",
"       <li>",
"        Has an unhealthy diet",
"       </li>",
"       <li>",
"        Is overweight or does very little physical activity",
"       </li>",
"       <li>",
"        Has a mother or father who got atherosclerosis before the age of 50 years",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12090607\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. Doctors do not typically order tests to check for atherosclerosis in general. Instead, they order tests if they think a patient might have a specific form of atherosclerosis, such as coronary heart disease or peripheral artery disease. The tests for each of these conditions are all very different.",
"     </p>",
"     <p>",
"      A general test that is often done in people who might have atherosclerosis is called a &ldquo;lipid profile.&rdquo; This is a blood test that measures the amounts of different forms of fat and cholesterol.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12090622\">",
"      <span class=\"h1\">",
"       Can the problems caused by atherosclerosis be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To reduce your chances of having a heart attack, stroke, or related problem, do the following:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Take the medicines your doctor prescribes to treat high blood pressure, high cholesterol, and to prevent clots.",
"       </li>",
"       <li>",
"        Lose weight (if you are overweight).",
"       </li>",
"       <li>",
"        Choose a diet rich in fruits, vegetables, and low-fat dairy products. Don&rsquo;t eat a lot of meats, sweets, or refined grains.",
"       </li>",
"       <li>",
"        Do something active for at least 30 minutes a day on most days of the week.",
"       </li>",
"       <li>",
"        Quit smoking (if you smoke). Ask your doctor for help.",
"       </li>",
"       <li>",
"        Limit the amount of alcohol you drink. Have no more than 2 drinks a day if you are a man. Have no more than 1 drink a day if you are a woman.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12090637\">",
"      <span class=\"h1\">",
"       What if my child gets atherosclerosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your child gets atherosclerosis, work with your child to change his or her lifestyle. Having atherosclerosis increases a child&rsquo;s chance of having a heart attack or stroke at an early age. Try to make sure that your child eats right, exercises, and stays at a healthy weight. The habits your child learns now will have lasting effects on his or her health.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12090652\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/58/34722?source=see_link\">",
"       Patient information: High blood pressure in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/48/11011?source=see_link\">",
"       Patient information: High cholesterol (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=see_link\">",
"       Patient information: Stroke (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/14/12512?source=see_link\">",
"       Patient information: Carotid artery disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/10/27809?source=see_link\">",
"       Patient information: Coronary heart disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/53/10068?source=see_link\">",
"       Patient information: Heart attack (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/20/37186?source=see_link\">",
"       Patient information: Renovascular hypertension (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/49/34578?source=see_link\">",
"       Patient information: Peripheral artery disease and claudication (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/34/30242?source=see_link\">",
"       Patient information: Doppler ultrasound (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=see_link\">",
"       Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/53/19286?source=see_link\">",
"       Patient information: Ischemic stroke treatment (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/16/40195?source=see_link\">",
"       Patient information: Heart attack (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/35/14900?source=see_link\">",
"       Patient information: Peripheral artery disease and claudication (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?4/35/4660?source=see_link\">",
"       Patient information: Children and heart disease (atherosclerosis) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?23/5/23635?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83344 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-C50D28AF5E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_5_23635=[""].join("\n");
var outline_f23_5_23635=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12090562\">",
"      What is atherosclerosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12090577\">",
"      How does atherosclerosis cause heart attacks, strokes, and other problems?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12090592\">",
"      Who is at risk for atherosclerosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12090607\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12090622\">",
"      Can the problems caused by atherosclerosis be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12090637\">",
"      What if my child gets atherosclerosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12090652\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83344\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/31/44533\">",
"      Carotid artery disease",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/16/3331\">",
"       Heart attack",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/23/6514\">",
"        Peripheral artery disease",
"       </a>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/15/27891\">",
"         Atherosclerosis",
"        </a>",
"       </li>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/14/12512?source=related_link\">",
"      Patient information: Carotid artery disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/35/4660?source=related_link\">",
"      Patient information: Children and heart disease (atherosclerosis) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/10/27809?source=related_link\">",
"      Patient information: Coronary heart disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/34/30242?source=related_link\">",
"      Patient information: Doppler ultrasound (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/16/40195?source=related_link\">",
"      Patient information: Heart attack (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/53/10068?source=related_link\">",
"      Patient information: Heart attack (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/58/34722?source=related_link\">",
"      Patient information: High blood pressure in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/48/11011?source=related_link\">",
"      Patient information: High cholesterol (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=related_link\">",
"      Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/53/19286?source=related_link\">",
"      Patient information: Ischemic stroke treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/35/14900?source=related_link\">",
"      Patient information: Peripheral artery disease and claudication (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/49/34578?source=related_link\">",
"      Patient information: Peripheral artery disease and claudication (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/20/37186?source=related_link\">",
"      Patient information: Renovascular hypertension (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=related_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_5_23636="Rasburicase: Pediatric drug information";
var content_f23_5_23636=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Rasburicase: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"    see \"Rasburicase: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?20/30/20964?source=see_link\">",
"    see \"Rasburicase: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F217416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Elitek&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F854900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Fasturtec&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1061808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Enzyme",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Uric Acid Lowering Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1061801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"      see \"Rasburicase: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Hyperuricemia associated with malignancy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children and Adults: 0.2 mg/kg/dose once daily for up to 5 days (manufacturer-recommended dose and duration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Limited data suggest that a single prechemotherapy dose (versus multiple-day administration) may be sufficiently efficacious. Monitoring electrolytes, hydration status, and uric acid concentrations are necessary to identify the need for additional doses. Other clinical manifestations of tumor lysis syndrome (eg, hyperphosphatemia, hypocalcemia, and hyperkalemia) may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Alternate dosing",
"     </i>",
"     (Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome; Coiffier, 2008): 0.05-0.2 mg/kg once daily for 1-7 days (average of 2-3 days) with the duration of treatment dependant on plasma uric acid levels and clinical judgment (patients with significant tumor burden may require an increase to twice daily); the following dose levels are recommended based on risk of tumor lysis syndrome (TLS):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     High risk and baseline uric acid level &gt;7.5 mg/dL: 0.2 mg/kg once daily (duration is based on plasma uric acid levels)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Intermediate risk  and baseline uric acid level &lt;7.5 mg/dL: 0.15 mg/kg once daily (duration is based on plasma uric acid levels); may consider managing initially with a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Low risk and baseline uric acid level &lt;7.5 mg/dL: 0.1 mg/kg once daily (duration is based on clinical judgment); a dose of 0.05 mg/kg was used (with good results) in one trial",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Single-dose rasburicase (unlabeled use; based on limited data):",
"     </i>",
"     0.15 mg/kg; additional doses may be needed based on serum uric acid levels (Liu, 2005)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F217400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elitek&reg;: 1.5 mg, 7.5 mg [supplied with diluent]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F217386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1061811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Dilute each 1.5 mg vial with 1 mL or 7.5 mg vial with 5 mL of provided diluent; gently swirl, do not shake; further dilute desired dose in NS to a final volume of 50 mL; infuse over 30 minutes, do not bolus; do not filter or mix with other medications; chemotherapy may be initiated 4 hours after the first dose of rasburicase",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1061805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store rasburicase and diluent in the refrigerator; protect from light and do not freeze; reconstituted solution and final dilution are stable refrigerated, but must be used within 24 hours due to the lack of a preservative",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1061810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initial management of plasma uric acid levels in patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid (FDA approved in ages &ge;1 month and adults)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F217443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Fluid overload, ischemic coronary disease, peripheral edema, supraventricular arrhythmia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, fever, headache,",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyper-/hypophosphatemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal/gastrointestinal infection, abdominal pain, constipation, diarrhea, mucositis, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Neutropenia, neutropenia with fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased, hyperbilirubinemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pharyngolaryngeal pain, pulmonary hemorrhage, respiratory distress/failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Antibody formation, hypersensitivity, sepsis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Acute renal failure, anaphylaxis, arrhythmia, cardiac arrest, cardiac failure, cellulitis, cerebrovascular disorder, chest pain, cyanosis, dehydration, hemolysis, hemorrhage, hot flashes, ileus, infection, intestinal obstruction, liver enzymes increased, methemoglobinemia, MI, pancytopenia, paresthesia, pneumonia, pulmonary edema, pulmonary hypertension, retinal hemorrhage, rigors, seizure, thrombosis, thrombophlebitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1061814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     History of anaphylaxis or severe hypersensitivity to rasburicase or any component; history of hemolytic reaction or methemoglobinemia associated with rasburicase; glucose-6-phosphatase dehydrogenase (G6PD) deficiency",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1061800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients receiving rasburicase should receive I.V. hydration as appropriate for the management of tumor lysis syndrome. Enzymatic degradation of uric acid in blood samples will occur if left at room temperature",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ;",
"     <b>",
"      may interfere with serum uric acid measurements",
"     </b>",
"     ; specific guidelines for the collection of plasma uric acid samples must be followed. Use of alkalinization (with sodium bicarbonate) concurrently with rasburicase is not recommended (Coiffier, 2008). Rasburicase is immunogenic and can elicit an antibody response; administration of more than one course is not recommended. Data suggest that children &lt;2 years of age may experience a higher frequency of adverse effects than adults, particularly vomiting (75% vs 55%), diarrhea (63% vs 20%), fever (50% vs 38%), and rash (38% vs 10%).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1061799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rasburicase may cause severe hypersensitivity reactions, including anaphylaxis, at any time during the course of therapy including with the first dose",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ;",
"     <b>",
"      discontinue immediately and permanently",
"     </b>",
"     in any patient exhibiting signs and symptoms of severe allergy, including chest pain, dyspnea, hypotension, and/or urticaria",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Severe hemolytic reactions may occur in patients with G6PD deficiency (eg, African, Mediterranean, or Southeast Asian ancestry) due to the by-product, hydrogen peroxide",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; contraindicated in patients with G6PD deficiency; patients at high risk for G6PD deficiency should be screened prior to treatment with rasburicase;",
"     <b>",
"      discontinue treatment immediately and permanently",
"     </b>",
"     in any patient developing hemolysis (usually develops within 2-4 days of treatment initiation); rasburicase has been associated with methemoglobinemia",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ;",
"     <b>",
"      discontinue treatment immediately",
"     </b>",
"     in any patient developing methemoglobinemia; initiate appropriate treatment (eg, transfusion, methylene blue) if methemoglobinemia occurs",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F217396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F217407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were observed in animal reproduction studies. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if the benefit to the mother outweighs the potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1061807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Plasma uric acid levels; BUN, serum creatinine, phosphorus, urine output, CBC with differential, G6PD deficiency screening (in patients at high risk for deficiency); monitor for hypersensitivity",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1061798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rasburicase is a recombinant urate-oxidase enzyme that catalyzes the enzymatic oxidation of uric acid into an inactive and soluble metabolite, allantoin; it does not inhibit the formation of uric acid",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F9890324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Onset: Uric acid levels decrease within 4 hours of initial administration",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1061813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Children: 110-127 mL/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Children: 18 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Coiffier B, Altman A, Pui CH, et al, \"Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(16):2767-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/5/23636/abstract-text/18509186/pubmed\" id=\"18509186\" target=\"_blank\">",
"        18509186",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coiffier B, Mounier N, Bologna S, et al, \"Efficacy and Safety of Rasburicase (Recombinant Urate Oxidase) for the Prevention and Treatment of Hyperuricemia During Induction Chemotherapy of Aggressive Non-Hodgkin's Lymphoma: Results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) Study,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2003, 21(23):4402-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/5/23636/abstract-text/14581437/pubmed\" id=\"14581437\" target=\"_blank\">",
"        14581437",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goldman SC, Holcenberg JS, Finklestein JZ, et al, &ldquo;A Randomized Comparison Between Rasburicase and Allopurinol in Children With Lymphoma or Leukemia at High Risk for Tumor Lysis,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2001, 97(10):2998-3003.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/5/23636/abstract-text/11342423/pubmed\" id=\"11342423\" target=\"_blank\">",
"        11342423",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jeha S, Kantarjian H, Irwin D, et al, \"Efficacy and Safety of Rasburicase, a Recombinant Urate Oxidase (Elitek), in the Management of Malignancy-Associated Hyperuricemia in Pediatric and Adult Patients: Final Results of a Multicenter Compassionate Use Trial,\"",
"      <i>",
"       Leukemia",
"      </i>",
"      , 2005, 19(1):34-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/5/23636/abstract-text/15510203/pubmed\" id=\"15510203\" target=\"_blank\">",
"        15510203",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liu CY, Sims-McCallum RP, and Schiffer CA, \"A Single Dose of Rasburicase Is Sufficient for the Treatment of Hyperuricemia in Patients Receiving Chemotherapy,\"",
"      <i>",
"       Leuk Res",
"      </i>",
"      , 2005, 29(4):463-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/5/23636/abstract-text/15725482/pubmed\" id=\"15725482\" target=\"_blank\">",
"        15725482",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pui CH, Mahmoud HH, Wiley JM, et al, &ldquo;Recombinant Urate Oxidase for the Prophylaxis or Treatment of Hyperuricemia in Patients With Leukemia or Lymphoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2001, 19(3):697-704.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/5/23636/abstract-text/11157020 /pubmed\" id=\"11157020 \" target=\"_blank\">",
"        11157020",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12760 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-782CD78CC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_5_23636=[""].join("\n");
var outline_f23_5_23636=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709399\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217416\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854900\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061808\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061801\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217400\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217386\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061811\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061805\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061810\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217443\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061814\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061800\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061799\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299985\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222722\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217396\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217407\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061807\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061798\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9890324\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061813\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12760\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12760|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=related_link\">",
"      Rasburicase: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/30/20964?source=related_link\">",
"      Rasburicase: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_5_23637="Carpal bone angles";
var content_f23_5_23637=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80973&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80973&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Carpal bone angles",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 639px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAJ/AhQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKo660yaJqDW11DZzrbyGO5mI2QttOHbPGAeT7Cvm/wTLfeFvFfhyDx/o3iGDWby4Ih1211yS7h1F8EhXi3FQhBA4Hp0oA+nqK8d8G+OPFeueED421C98M6f4emgupUtXimaSARh9hZw3znKZZQo+XOOeKxvDXxW8Utq2pWeq29rPB/wAI/PrVjctp8ln5hQfL8jSMWjPr8poA97orwzSfiL4qnuvBg1z+xZbDxbp08qQWMMkc1q6QeZuJZ23Keh4GPw5wPgz4w8T6Hovw2sL/APs260DW47uKMRpIbuNot77mYnacnjAHT86APpKivC/D3xQ8VXVr4O8RahHor6B4n1UaZFYW6SfabXczqjmQsQ2Ch3fKPwzxl/DLxjqGhaV4bsYRbyw6z4pvrKd7jczIgYkbDuGDnjnP0oA+iKK8Nvfit4kawnOnW2jG7PjtvCsBmjkMfkY+V2w+d+cZI4x/DUtv8SvENt4e8VQa5daNba5pGrx6ZDcQWc00dwZMFVSENuaTGcDcB0z0JIB7bRXzB4s+I/jTU/h34pgnkTSdW0TVbKF7mGOW0leGU5AKiQlGztz8xBUkYzzXX+MPiB440rxJaeFbO20+fXE01tRuZ7TTZ7iOXMrLGkcQfcq4A3OSeTwKAPcKK4/SfFF5N8L/APhI9at4tG1COxkmuIrpW8u3kQMDuUfNtyucD5scda808NfFbxS2ralZ6rb2s8H/AAj8+tWNy2nyWfmFB8vyNIxaM+vymgD3uivCvDvxS8WR3/h248SWujT6Zrmi3GqQw6dHKksRhi8wqS7EHd0x7+3MnhT4jeMLvUvAMuqv4el03xa87CG1gl821RELBd5kwzdAcrwQRQB7jRXy/wCCfH+teH/AXhHRtDh87UNYvdSJuJLaS7KJFKxISJWBdjkd8ACvcfhZr2t+IfC32jxRpp07VoZ3t5Y/KaIOFwVkCMSygqRwfegDr6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKz/EN5Np2ganfW0XnT21rLNHHjO9lQkD8SMV438I9BPiLwpoXjjV/G+vvqtxcLcz7dR2WuRNj7MYvuhDgKV65PGOBQB7pRXhnhT4ta9qHjrw/pt3Dpd7oetSzwwX1lZXVuoaNSfkebiUZGCVApmkfFjxVNpPhnxBfWOh/2Jqutf2PJbw+b9pDGR0Eiktt425K4OfUZ4APdqK+ZbvxT4iaPRf8AhFTbaaZvG91YTJJc3DrcMMbd+WY+Wfm3KMAYXaBzXZa38Q/GcV14sTS7Tw6I/CNlDPqguTMTdSND5riDBGxQAwUsCTx68AHtFFfP8fjm6h8W+M/FFkjmNPCNnqtvZ3DsUVmTeAQCOecEjFdRc/E3UotRsbdbOzKXHhF/EJb5siZRkIOfufr70AesUV4p4T+KHie51rw0niS00C30vxBpM2o28ls8oa3MUYdjKW4247AcepxzneHfiv4p1XX4dJmg0qaHVdNurjTr+Cyu7SMyRxlgR5pzJH0+ZQDzmgD3yivnLwt8SfF+g/Bzw5qmpLaateazdx2OnTMs8825nl3tOq5ZyNgCqnJr1D4T+Ktf8SW+rReKNHksLmynVYp/sU9pHdRsCQyxzDeCCCDye1AHe0V4Xrfxc13TfGcVvbRaVqegHW10iWS3s7pDCzPtwbhj5TSDqVUH696Zr3xY8W2D+ItRttO0J9C0LXRpU6yNKLmVCyqCuDtB+YcnP045APd6K8V8XfE3xRa3nji48P2eiLpPhQIk6Xwla4uZGXOV2sAqjPGc5x+WBefEK78MeJviJ4jkie7aLS9IkhtC7eUskyAdOcDLZOOTj1oA+iaK8z+FvjLxRruu6jpvijRWt4ooFnt7+PTbqyikOcNGVuBksMg5B5HavTKACiiigAooooAKKKKACiiigAooooAKKKKACgkDqao61ejT7EzH+8qj6k4rAS/nnkyXIHtXFicdDDyUGrtnRSw8qi5lsdPdRQXVtNb3KRywTIY5I3GVdSMEEdwRXK+HPht4O8O6kmoaNoVpb3kefLlyzmLPXZuJ2Zyfu4pbi5mQ8OaqzatcwDIc1y/2vBOzibfUZNXTLMHwz8G2+pXV/D4esluLpZEl+U7GEgKuNmdo3AkHA71Xj+F/haw0y/t9B0m10y6urGawF0il3RJFIPU5YA4OM9scV0/h+9/tHSILru+4H6hiv9K0a9WElOKkupxSi4tp9Dg/h/8AC3w54OsrMwWNvcavFaLaS6gyENKNuGIUswTd3C/rW9Z+ENAs49HS10q2iTRy5sAoP+jl/vbee+TW9RVCOT034deEdM8Qf23YaBZQanvaRZlU/IzfeZVztUn1AFLqPw88J6lof9j3uhWkum/aWuxCQQBM2dzgg5BOTnnvXV0UAczZeAvC1jZwWlnodlBa29+uqRRRptWO6UYWUAdCAAPSnan4F8M6pa6nb3+jWs8OpTLc3YYHMsqjAfOchgO4xXSUUAcpF8OvCMWkajpcWgWS2Go7PtcIU4mKfdJ5zkHnPXPPWoLv4YeDbvS7DT7jQbZ7aw3i2+dxJEHYswEgbfglicZ712VFAGVZ+HtIs/Do0G20+3TRvKaD7HszGY2zuUg9QcnP1rG0b4beD9FMh0zQLO3aS2e0dgCWaF/vISSSQa66igDFtvCuh2s2lSwaZbpJpULW9kwH+ojYYZV9iBivNvBnwRg0DxnYeIb3VLK4ksWkkhistJjsdzupUtIVY7sA8KAoB7dRXsdc1qest9untoTgxMFP1wD/AFrnxOIjh4c8jWlSdWXLEhvPh/4Su9Dh0a50OyfToJWnhiwR5UjHLMrA7lJJ7GtTwzoGj+GdN+waDZxWdpvMpjQk7nPViSSSTgck1li4maLcXOaqtezoTiQ158s2ivsnSsE31O1orjtH1yVtXt7WY5WYlR9cE/0rsa9DDYiOIhzxOatSdKXKwoooroMgooooAKKKKACiiigAooooAKKKKACiiigAozWZrWpCw8lB/rJQxUfTGf5isqPUJ5SSWxXDXx9OjP2b1Z0U8NKcebodRkeorhIPhH4Et9fTWYPDttHfJOLldskgiWUHIcRbvLBB/wBmrsmoXCNw5qCXxFNa5Z8FRyawjm1JuzTNHgp2uhdE+F/g7Q9QtL7StFSC5tJHlt28+VhCzghtgZiFBBPAGPasP4dfBzQfC8Vjc6lEmp61ZzyzRXbNIEQu5YFYi5QMAQN2M8V6dG4kjV1+6wBFOr1TjOR1D4b+E9Q0mTTLrR0azkvm1Iqs0iMLlusiurBlP0Iqtqnwp8F6rLbyX+iJK8EEdsD9olXzI4wAiyYcebgAff3Hiu3ooAwpPCOgSXWoXD6XbtLf2gsLng7ZIAMCPbnAGDjgVjaD8K/BegmU6VocUDS2slm7GaV2aF/vISzE4P6dsV21FAHOJ4J8OKNLA0qErplrJZWgZmIihddrpgnkFeOc1R8P/DPwh4evra80jRkhubVZEhdp5ZDGrjDKN7H5SO3QdsV2NFAHD2vwo8E2ukX2lw6FH/Z166SS27zyuoZSxUoGY+WQXb7m3rWz4U8IaJ4TS6XQrR4DdFWmeS4lneQqCFy0jMeMnvW/RQBxbfC7wY2rS6kdEj+1y3Yvmbzpdvng58wJu2g55OAM96v3PgXw3dWWp2k+lRPb6ndi/u0Lv+9nBBDnng5UcDA4rpaKAPG/iZ8GH8beI72++36XZ296kccrjTS9yFUAHD+YFYnHDMpK9ugrvx4G8NlNQWXS4ZxqFtFaXfnEv58US7YwwJxwO4APeulrl5ddedswfcPQ1zYnFQw6Tn1NaVGVV+6J4U8B+G/Cd3JdaDYPb3EkXkF5LqaYiPIOxfMdtq5A4GK6nI9a5eS8nEYO85qsdWuIwTuzXG82pp2aZusFJ7M7GisDw5rJ1C4mt5Mb0UOPpnFb9ehRqxrQU47HNUpunLlkFFFFakBRRRQAUUUUAFFFFABRRRQBzvj47fDFw/dJISP+/ij+tZGl/NtNa3xD/wCRQvv96L/0alZGjn90n0rwM0X7+PoenhP4L9f8ia9GGrI1M4hNa9596sbVv+Pc15M/jO2HwnUfDty3hiEH+GWUf+Pk/wBa6WuX+G5z4YT2mkH/AI8a6ivr8N/Cj6I8Sv8AxJeoUUUVsZBRRRQAUUUUAFFFFABRRRQAV57qZC+L9UQdzG3/AJDX/CvQq861f/kd9RH+xEf/AB0V5mbL9x8ztwP8R+hsIP8ARqz5eprQU/6PWfJ1NfP1tkehT3Zk2cmzxTpeDj/SAPzBFep15Rbnb4r0r/r4WvV697Kf4T9Thx/xr0CiiivVOAKKKKACiiigAooooAKKKKACiiigAooooA47x62y/wBGb1Mq/mF/wpNPGUJpvxF4n0U/9NnH/jop9gcRV85jl/tTPWofwF/XUgufvmsDXzi3k/3TW/c/fNc74j/493+hrzPtnXHY9N0RzJotg55LW8bH8VFXaz/Dpz4f0w/9OsX/AKAK0K+0h8KPAl8TCiiiqJCiiigAooooAKKKKACiiigArzLQ2ysif3JXXH0Y16bXl+hcXN6v925lGP8AgZrx84XuR9T0MB9o6O4GIRWXP9w1qXB/dD6Vlz/cavEr/EjupbDfA0v/ABVdwn961Y/k6/416HXmvgU/8VlMP+nR/wD0NK9Kr6TLf4CPMxv8UKKKK7zkCiiigAooooAKKKKACiiigDnfiF/yKF99Yv8A0YtYmkf6pPpWp8SJNvhox95p4kH/AH1n/wBlrO0sbY1+leBmjvXj6HqYT+C/Umu+tY2sH9wa2Lo81kaouYTXkyfvnZDY6X4cgDwvFx1lk/8AQjXT1zXw7wPDEWP+esn/AKGa6Wvr8N/Cj6I8Sv8AxJeoUUUVsZBRRRQAUUUUAFFFFABRRRQAV51rP/I735H/ADzi/wDQRXotea3LGbxlrEnUCREH4IBXmZs/3FvM7cCv3jfkbcf+oqjJ1NXh/qaoy96+eq7I9GnuzFtBu8V6Xn/n4WvV68rs1A8VaWT/AM9x/WvVK9/Kf4T9Tz8f8a9Aooor1ThCiiigAooooAKKKKACiiigAooooAKKKKAON+Iw50f/AK+G/wDQabYH93UfxDfdqmhxA95XI+m0D+ZqWy4jr5vHu+KZ62HX7hEVx981zniM/uGHsa6K45c1z/iBcwOfavNXxnXHY9J8PALoGmqBgC1iH/jgrQqjoIxoenAf8+0f/oIq9X2kPhR4EviYUUUVRIUUUUAFFFFABRRRQAUUUUAFeYaRxf6j/wBfcv8A6Ga9Pryzwwxlikm6+ZK75+pNePnD9yK8z0MAviZ0k3+qFZs/EbVpTn92KzZ+UavDq/Ejup7FbwIobxhMxHItXx/32lelV534EQDxVcnuLVgP++1r0Svpct/gI8zG/wAUKKKK7zkCiiigAooooAKKKKACiikZgqlmICgZJPagDj/iJJ5v9k2S8tJcGY/RFI/mwpLVNiCstLhtZ1q41Fs+TnyrcekY7/jyfxrZI2qK+YxVVVq7mtloexTg6dNQe5WuTzWZqI/0dq0JzzVS7TfCw9q86T9650x2Nf4Zyb/D8yf887qRf0B/rXW1w/wwkITV7bPCTrJj/eXH/stdxX1+DlzUIvyPFxKtVkFFFFdJgFFFFABRRRQAUUUUAFFFFABXmmkH7XfaheY+We5d1/3c8fpiuo8b6k1ppi2ls2Lu9PlLg8qv8Tflx9SKytKtlt7ZEQYCjArxM1qqUo0l6s9HBwcYub6lp+I8VQfqauTNwapt1rxar1O2mjDmk8nxDpTnoLuIH6FgP616zXkPiMm3MVyBkxSLJ+RBr11SGAIOQeQa93J5XpyRw49axYtFFFeweeFFFFABRRRQAUUUUAFFFFABRRRQAUUVBfXUVjZzXVw22KFC7H2FDdtWCV9EcT4sYXPjG2jXkW9tlvYsx4/ICr0K7UrI0gTXdxPf3Y/f3L7yP7o7L+AwK2XOBivla1RVasqi2PajHkgoFKb7xrE8QD/RX+hralPzVmazHvtW+lcKfvHRHY7rws4k8NaUw/59Yvz2jNalc98P5vO8I2GTkoHjPttcgfoBXQ19pSfNCL8jwKitNrzCiiitCAooooAKKKKACiiigAooooAqavciz0q8uGOBFC7/AJA1wPhi2MWmQAjB2jNbPjq9M8lvo8Dcy4luCOyA8L+JH6e9NtIxHCAOgFeBmdRVKqproenhIuFNyfUdcfcxVCTlTVyc5FU25BryKrvI7ILQqeDn2eNcH+O2kUfmp/pXpVeW6O32bxvpjdA7Oh/FDj9cV6lX0mVyvQ+Z5uOVqnyCiiivSOIKKKKACiiigAooooAK5fx9qDW+lx2MJ/0i/byhjsn8Z/Lj8a6ivPvFEv2nxukXVbW2AA9GYkn9MVx46q6VCTW50YWCnUV+hY0q3WKJEUYCjFXLj0qS0j2xZpsqHBJr55Qagei5XkUJOTTJEyhqcrzTtg8ps1zKF2bc1jP8ASeT4p1CDOBNAHx6lW/+yNeiV5n4aPl+OrcD+OORT+Wf6V6ZX02WSvQXkeXjVarcKKKK9A5AooooAKKKKACiiigAoorP8Q3RsdC1C5U4eKB2X/ewcfrik3ZXY0ruxw8t1/bXiG6vRzBEfIg91U8n8Tk/lW7Eu2KsLwrbhNPt1A/hBro5EOABXyqcqspVWezO0EoLoUJT1qvtyatTrg4qNU+auWUW2aRehg+J4t1i/wBK9D8Ozm50DTZics9vGWPvtGf1rivEUYNo30rpfh+5fwjp5PYOv5SMP6V7GUe7OUTkxutNS8zoaKKK908wKKKKACiiigAooooAKKKKACiiigArivHl79pu7TR4jkEi4nx/dB+VT+PP4Cu1rzSKT7d4n1i5POJzCv0T5f6V5+Z1XTo2W70OvBwUql30Nmwi2oMDgU6c/MasxpshGBzWSdVsJNYm0pLuJtShiE0lsG+dUJwGI9Oa8JwahZHcpJyuOcZaq19Hm2b6Vd20l3GPsreuK5lC+pvzWJvhhLnR7yA/eium49iAf55rsq4L4aPt1DWYe37p/wD0IV3tfWYKXNQizx8UrVZBRRRXUc4UUUUAFFFFABRRRQAVFdTx2ttLcTttiiQu7egAyalrmPiNcGHw08SkhrqVIB9Ccn9FNRVn7ODl2Lpx55KPc5vSnk1C6uNSnBEl05cA/wAK9FH4DFdCRtiqlpEAWNFA4AArQmUk47V8tC8k6j3Z682k1FdChKah25qxKvzYpI0y3tXK43ZqnZHN6m/2TWNOuc4EVzGxPtuGf0r1mvJfGKAW7kdhXq8DmSCNz1ZQf0r3sofuyicGP15ZD6KKK9g88KKKKACiiigAooooAK811DA8e6uT1/dD/wAhrXpVea+KiNP8ayyycJdQo4J9QNp/kK83NU3Q07nbgX+8fodBBOBGBUc9ynOSK5q61qKFfvj86Wzt9Y1cBrKzcQt0llOxceozyfwzXiQdSouWKud7hGPvSdjZNzHu6imz3aCM/MKrt4TuIUEmq65bWidwo4/76Yj+VQ/2L4cdgsnidmJ4yJ4wPzxWywNbrZfMj29Ppr8g8GRm88ZSXC8x20DZP+03AH5Z/KvSay/D+jWOjWrJp4LLKQ7SM25n9OfStSvewlB0KSg9zzcRVVWfMtgooorpMAooooAKKKKACiiigArnviB/yKGo/wC6v/oa10NZXiu1a98N6lBGCXaFioHcgZA/MVnVV4SS7Mum7TTfc5XQnCW0XptFa73K45NcfpWqRfYIjuGQOeaRtXkupxBZxyTzHokSlj+lfJ05zXupHtzppu7OkmuY88kZpi3KY6iqFv4Z129G6YwWaHtI25vyHH61I/huwtpRDqXiUJMeqKUjI/Ak10rBV5e81b10Mva0lpe/oUfEV6gtJPmHSu48G2jWXhjToXGH8oOwPYsdxH61lWvgPTI5kluJ7u6CkMEkcbD9QBzXXV6mAwcqDcp7s48ViI1EowCiiivTOIKKKKACiiigAooooAKKKKACiiigAryzw0QJLtj1Nw5P/fRr1OvKLJxZarqltLw8dzJj3BYkH8q8jN78kWu56GA3kjsROuwV5Jpki/8ADRviFieP7Eh/9DWuxu9ZjhXlwPxrzTQEv9V+PWtnT7dnkbR4idxCALvXnnt9K4KEp1VKKXT/ACN6lNQs2+p7IJkz1FQ31wohbkdKhi8J6yVL3WoWlsv+yC+PrnFSR+CzcvtbxAJR3WOIZ/8AQjSWAxD6FOvRT3JPhjCWk1e9IO2SRIlP+6CT/wChCu7qjoumW+kadFZ2gPlpyWbqxPUn3q9X0OHpeypqHY8utU9pNyQUUUVsZBRRRQAUUUUAFFFFABXGfEzm10pT0+1g/wDjrV2dch8TY2/sW1uAPlt7pHY+ikMv8yK5sYr0JW7G+GdqsTj/AIi32sad8O9ZvfDVx5GqWsPno+wP8qkFxgg/whq6Tw3r0Gv+GtM1aDAS9t0nC/3Sygkfgcj8KzJLu3ks3jlCvFIhRlPQgjBFeYfBbU5rHTdV8JIstxc6NfSwwqilmaF2LI34/NXz1GbdFxS1T/BnpTh+8u+p7RLMgPUUCdAvUVlQeH/EN5z5UNqp7zyc/kuf1q+vgnUXX99rKIfRLcn9Swqo4LET1UQdalHRyOe8UMbpUt4fmlmcRoB3JOBXrUaCONUHRQAK5TRfBcNhqEV7eXkl5NEd0YKBFB9cZPT611texl+GlQi+fdnDi60ajSjsgooor0DkCiiigAooooAKKKKACs3XdM0zUbYf2vFE0UfId22bPo2QRWlXmUKP4hvpry/ZpYxKwhjb7qKDgYHrjqa5MZiI0Ie8r36HRh6TqO6drGh9s8OabIV0HTI7+5Xo6/Mi/wDbRs/+O5pk93rWoHNze/ZYj/yytRt/Nuv5Yq8IYLVAsaKMegqu7bjxXg4jGVPhi+VdkejTpR3evmylHo1oX8yVDLKf45SXY/iatSWUEaYESY+lODHIqWY5iBNcfNzI21TNLwFIzaNNEfuQXMkaD0Xg4/U10lc14AXGizPnIkupWH54/pXS19dhr+xjfseLX/iS9QooorcyCiiigAooooAKKKKACiiigDBk8IaFJctO2nx72OSAzBc/7oOP0q+w0/RLJ3CQWlsvXYoUH8B1P61NqN7Bp9pJc3T7Y0/MnsAO5NcPdTz6vdi6vRtRf9TB2jHqfVveuHE16WEV0lzM6qNOdf4noi1e6vf6u5SAyWVkegBxLIPc/wAI9hzVNtJt0gKGBNp6nHP51cgIQE96sBw6Ed68Kdadd803qegoqnpFaF3wTcltMeykYtJZv5YyckoeVP5ZH4V0VcTos32PxHFk4ju0MLf7w5X+o/Gu2r6DA1fa0U3utDzcTDkqPzCiiius5wooooAKKKKACiiigAooooAKKKKACud17wvpOo3LX12ZLeXA8yWOTYGA/vZ4rW1q9/s3SL2927zbwvKF9SASBXmlvazattutZuJLqVvm2u3yJ7KvQVy4mpBJRkr3OvC0ZTvNSskaRvPDGky7dH086rdr0kzvRT7u3A/4CDXmdlqGp3vx6125M/2K4k0iJG+zf3A64GTn8xivSTHDCu2NQAPQV5ppjAfHXWyP+gTF/wChrXGqrSklZK3Q9FUIKzerv1O6fSIZ233Ze5k677iQyH9TVa70u3ijaSCNYZ4xuSSP5WUjoQRWospNQ6k22xmb0Qn9K4+a+qZ1q60Z6LoFzJe6Hp11NzLNbxyP9SoJq/Wb4ZXZ4b0pf7tpEP8AxwVpV9BHZHzU/idgoooqiQooooAKKKKACiiigAqC9tIL60ltruMSQSja6HuKnopNX0YJ2OVg8CaNE+WF1KmchHmO0flg15/eQW3gL9oTSrmARWmj+KdNe0lBO1FuYPmVifddqjPcmvY727gsbSW5u5FigiXczt0Ar56+PF9e+JfDQ1e2g8qHRbhL61iYDe4U4ZmPb5STgenesLUqLSSSbOqEKuI1b0R6jrPjWWeRrfw5CsoHBu5gdn/AR/F9en1rHg8T69pU63GoXC31nuHmxmJVKr3KlQOfrSaFcW19pNne2mDBcQpLGf8AZYAj+dWL2BZImGOGGCK8+eIq35r/ACPUhh6KXJy/M9JikSaJJI2DRuAysOhB6Gn1y/w6vWufD4tpT++sZDbH/dHK/wDjpA/Cuor1oS5oqSPEqQdObi+gUUUVRAUUUUAFFFeK6hrfif4Ta7PP4kubzxF4DvZy/wDaDDfc6Wzt0kAHzR5OBjp2xwpAPaqKq6XqFpqun29/ptzFdWdwgkimibcrqehBq1QAHoa858I4/s+NhyGyw/Ou91ORotNu5EGWSJ2A9wDXB+HAE0i22HjyxXjZtKzh8zvwa92RdnYs5qOlY5JpK+fbu7npJWQUSk+QfoaKgv5RFZzSE4CqaI7gzo/AYx4WtD3ZpW/ORjXQVj+DojF4X0wEYLQK5H+9839a2K+1oq1OK8keDVd5t+YUUUVoQFFFFABRRUVvcQ3Ac280coRzG5Rg21gcFTjoQeooAlooooAKrajeRafZTXVwcRRLuOOp9APcnirNZviSybUNDu7ePmRk3IPVlIYD8wKmbai3HcqCTkk9jlg11rVylzf4VV5igH3Yx6n1b3qWZViYqOTS6LOstujr0ZQRTLn/AFpr5StJzXPLVs9mKs+VaJEeaFYqaSiuW5rYr6iHMBlh/wBdCwljP+0pyK76xuUvLOC5j+5MiuPoRmuJxkEetdB4Kdm0CJW6RySIp9QHOP8AD8K9rKKj5pQ+Zw46PuqRu0UUV7p5oUUUUAFFFFABRRRQAUUUUAFFFFAGJ43cJ4S1UnvAy/nx/WuQtSEtEA9BXSfEdynhG7A6u8SfnItcojkRhfavMx0+Wa9D2Mvjek/UWVyze1ecaX/yXLWv+wTF/wChrXonXmvO9L/5LlrX/YJi/wDQ1ripO6n6fqjunpy+p6GKr6xJjTLn2jb+VT1U1VDNZPApw0xES/ViB/WsI3vY0fdnrGnxiKwto1GAkSqB9AKsUAYAA6Civp0fKt3CiiigAooooAKKKKACiiigAqvf3lvp9pJdXkqxQRjLM3+etWK4L4mh2vNFRyxtS0hYdi/y7c++N361nVn7ODkbUKXtaig+plavqNx4nvEd1aHTYjuhhbqx/vt7+g7VHf2UNzYXFnMu6GeNonHqrDB/Q1biwkXyioWOTXhVajk+Z7nvwgorlitEcF8F72ZPDFzol22bzRLuWxfJ5KhsqfpgkD/dr0ESErg15rD/AMU/8aZo/uWniKyEg7A3EXB/8dyfq1ejU67fPzL7Wv8An+IU1pbsXfB1yLHxVJbscR38XH/XRMkf+O7vyr0SvIdRmazNvfp9+0lWXjuAeR+IyK9dUhgCDkHkGvSwFTmp8vY8rMafLNT7i0UUV3HnhRRRQAVHcQxXMEkFxGksMilHjdQysp4IIPUVJVDV9Vs9JtxNey7N3CIBlnPoo70m0ldjjFydlueP6n4b134Q6hca34Cgm1TwhM5l1Dw8CWe3J6y2x/mv8xgr3Wk/Evw5rWj2+o6NcyXyTLnyok+eM/3XBxtI9D9RkYrN1TWdR1wmMbrKxP8AyyRvncf7TDt7D9a818ReBr/RdQfxD4D2QX+M3WmscQ3qj26K/Xnj8Oc8csWpNxp/f0PQhgeVKVX7kerzeOplbjRmaHuTON35bcfrVDw5IjaTAqApkEqh7DJwPyrkfB3irT/FVnIbZXttQtzsu7GYYlgccEEdxnv/ACPFdVo650237ED8q8fHVqjtGp0O6NGlCN6fU1/JJGaa0JWpraUNhH4b+dWimRXIqKkrozdRp6maVxVKHT5Nf1T7DythDhrpxxnPRB7n9B+FaNwNpNXvAC5sdQmP/LS7bB9gqj+YNb4DDxqV7S2RNeq4U+ZHTooRQqgBQMADoBS0UV9SeMFFFFABRRRQAV5F4k+GureH9auvE3wpvl0/UrhzLe6PcMWs785yTgn5HPPIx7Fec+u0UAee/D74oad4nvn0XVrabQfFdvxPpV78rE+sTHHmL345xzjHNd9PPFbxNJcSpFGvV3YKB+Jry/4w6R4d8W266fPaefrVucwX9u3ly2LA5BEg5687eR64ODXmU2t+IfCN7DH8Q3uNY0UbY4dZQFzCOgEqdj0+Ycn/AGjWE66TcY6vsddLCSklKeiPopfEuitL5Y1O03epkAH59K1UdXQMjBlIyCDkGvJ7aOw1LT4rmwmhubWVdySRkMrD2Iqxo2pXPhyfMIaWwY/vLfP3fdPQ+3esIYz3rVFY6J5enG9N3ZrbPsOrX9sOFjlLp/ut8w/mR+FSSsHbNP1l4dQWLXNLlWWFU8u5UcMozkEjsRk59vpUaqCMg8V4mMpOnUaWz1RvSlzRTe6GAc4pKmKHrTDGcVx8prchnfy4ZHAyVUnFdf4dhSDQ7FIzlTEr59SwyT+ZNcm69j0NdB4MlL6IsLHLW0jQ/gDkfoRXq5RJKcovexyY5NwTN2iiivoDywooooAKKKKACiiigAoorP1bVrTS4g11Id7fciQbnf6D+vSlKSiryeg1FydkaFYuo+JtMsZGiMxnnU4Mduu8j644H4mufvbrUdcJWYtaWR/5YRt8zj/bb+g4+tPttMgt4wqRhQPSvKrZlrair+Z2wwiWtR/Iq+LPFWnah4fv7SS2vYXePMbSxDG8EMvIJxyBWfGN0akEHIFWvE1sg0e8YKMrGTWbbkxbSvKkciuOWIlX/iHpYanGEHylxY6860xP+L664B20iL/0Na9Liw4DKcg155pK5+PWuj/qDxf+hrXRRpq0vT/IqctV6nbsCOtWvC2myazrEd04xp1jJuBP/LWUdAPZTz9cVDefIjt6Amu08EwiDwnpagYLwLKfq/zH+dPB0FKo2+hlja7hS93qbdFFFeyeEFFFFABRRRQAUUU2WRIo2kldUjUZZmOAB6k0AOqG7u7ezj33c8UCf3pHCj9a5jUvEs12TDoa/L0N3IvA/wBxT1+p4+tZKaV5kpmume4nPWSU7mP59K82vmUKb5aa5n+B2U8I5K83Y62LxJo0r7F1O1Df7UgXP0z1qr42sBqXhydowGltx9piI55Xnj6jI/GucutMhZCDGp9iKg02/udAkxCrT6ef9ZbHnA7lPQ+3Q/rWEMzU3yVVa5v9U5Gp0nqitZyiW2RgchlyKdWbpckcc01rFIHjRiYj/ejJ+X/AjsQRWmo55Fcco2dj1U+p558ZoJLbRtN8Q2qbrnQ72O546mIkK6/j8v5V3tvNHcW8U8LBopVDow7gjINN1rSotX0i90+4H7q6haFuM4DDGa5H4MXk154HhsrvIvtJlfTp1PVTGcAfgpUfhW7g5Ul5P8H/AF+JnzJT9TptYie4tktYv9bcyLCv1Y4H869fRQiKo6KMCvJr+Y2RgvAMm1mSY+4VgSPyzXrKkMAQcg8g125clyy7nn5k3ePbUWiiivRPLCiiigAryzVbh7jxPqZuyfNil8pFP8EY6Y+vX8a9TrD1/wAM2OsuJZd8N0BgTwnDY9D2I+tc2Koyqw5Ys68HXjRneSORhkVBxipHmB7ikvPCGs2YLWdzDfRj+Bh5b/1B/MVk29yTK8MyPFPGdrxuMMp9xXlVI1aKtJHsU5U6usHc57xr4J/ti7TW9Auf7L8TW4/dXacLKP7ko/iB6ZwfxHFHw38bpqN1L4d8QQf2X4ntS3mWrnCzDk74jn5hjnH8xzXWCdYhudwq+pOBXM+M/B+meKwq3LtbXgxLY6jAcS28o9COo4Bxnn2IzWdScatPlqdOvb/gE1ISjrA9CVQwxUyTvEMPl19e9eU+EvHOo6FrEXhb4ihLfUX+Wx1VeLe/HQc9Ffpxxn2JGfT5HyOK45KVHf8A4cxTVQi1GeMWssoYbVUkn0ro/B9qbTw5ZI4Id085geoLktj9cfhXCa3+/jaCJgGP327KPQ/4V0fhLxcl/Mun6kY0vOkcqcJN7D0b2/L0r0cqceZylo2ZYujN0047I7GiiivdPJCiiigAooooAK4nxfrdxJfS6VYStCsYH2iVeGJIyEU9uCCT7121cL4s8PX/APas2p6XGLlZwvnQ7gGDAAZGeCMAcVz4rn9m/Z7nXgvZ+1/ef0zKsLWKBAqKFUdhVq4SGeF4po0khcFWR1BVgeoIPUViS6lJaNsvbe4tW9Joyv8AOrMN4JlBVgR7V46m6as0e24c+tzg9Q8Gap4UvJdV+HMyrE7b7jRJ2/cTepjJ+43+c44rT8O+PtN1/daPDcWetRfLPps67ZYyOuM4yPf8wK6e8vHhjCRYM0nC+3vXN+IvAWm+JLZJbgy22qRfNDqEB2zRt657j2P4Y61r7WNVWqff/n3IVN09Y/ca9szmSWSwke2nKlJI2HDqezDoRW9o18XtVS4XEsfyOV5GR3ryWw8T6p4N1mKx8fqJbJ18qDWrdPkbkY81R90+/wDPk16ZFPCjwX1tKk1ncAKZI2DKQfusCOo7fiK58RRqKF1qug5SjP1OohKSD5WB+lSvCMZFZigcHv2Iq5FcmMYkO5PXuK5ac4y0Zyzi1sQ3C47Vf8GsRc6nF2DRyY9ypH/stU7ohunSrvgqIsNQvCPkmlCJ7hBjP5kj8K68ui/rN0ZYl/uXc6aiiivojygooooAKKKKACiiigBsrbInYDdtBOPWvN9Kl+3D7dcsJLmf5nc84/2R6AelelVymqeEQ0zz6Rc/ZHclmhZd0ZPt3X9fpXnZjhqleCVPp0OzCVYU2+fqNhkRBgU9pQehrCurXWtMBa+tBJAvJmt23qB6kdR+VS2t0s8YeNgQe4rwqjqUfdnGx6ChGesXctazGbjSbyNR8zwuB9dprnrJhJawv2ZAf0rpIZf4WIweK5axQ2kk1jJ96Biq+6fwn8q0py5lc3o6XiaCAodyHHt2NcBo0o/4XxrhfCk6PEP/AB9a9AVgBXm+n/N8c9c9P7Ii/wDQ1rvoztGXp/kFSN2vU9A1je9o8cP+tlIiT/eY4H869RtoVt7eKGPhI1CL9AMV5NDJcJfRXNsI3hs38xhKfkZh0Gfbr7HFej+HtdtNctTJauBKnEsRYFkP4dR7104CpBtq+pwZjGWltka1FFFekeWFFFFABRRRQAVwGq3Taxql0k7H7JbTNDHD/CWU4LN6nOceld/XJ634ZuGvJb3R5o0klO6WCXIVm9QR0J/ziuHMKdWpS5aR1YScITvMjtUjjUcCp3kHauduJ9S0/wD5CVhPAg6yAb0/76GQPxqY6lGtq9wz5jUZ4PWvn250vccbHpcnPqncualfW9nBvuCcnhVHLMfQCucnvb+fLxRxQp2VhuP4mm24kvrk3Nzy7fdHZB6CtCZFSPAFbKkmrtHTCCho9zEmjISLVYk2Mj7J0HQgnGfzwa24J45MA/K3oan0OzS50PDjKymQMPX5iKx7RHieW0uOZoG2EnuOx/EYNODcbp7IakpNx7G2BzXnGgj/AIR/4z63ppG20161TUIOOPNTKuPqfmY/hXeRO8fQ7h6GvKvjH4n0bTde8L6jBqEJ1jSr799bodzi3cYkDY6HAGAfWvRwz524rqY1Vy6s9R1OIPDKh6MpFd54RuTd+GNMmY5cwIrH1YDB/UVw17IjQF1YMpXII6EV2HgFGTwjpu8EbkZwPZmJH6EVeB0qSRzZgv3UX5nQUUUV6Z5AUUUUAFFFFABXMeM/Dx1KD7ZYqF1KBfl7eav9w/0/+vXT0VM4Ka5ZF06kqclKO54laOuo3JaQHEYC7GHRu/41dktmgB8pd8ROWiJx+IPY1o+KrMWXi24eBAq3EazlR3PIJ+uRn8afGUmQGvBqU3Cbiuh9JGqpwUu5zPiPTdM8TaLLpessJLV+dtxF88bdmVhjBHqK870TxzceBtfn8LeJNSudT0e3VPs+pIn7yJWHyrKT1HbOf06e2G1jYdjXmdjptrd/GzxJZX0Mc1rNo8QeN1yrDcowRW1CnFpxnHTc56ijdSjudtCn9owxOmwWbAOgRtwcHkMT3pNXthDbbo/kePDIy8FSOhrhZrbVPhVcPPpqz6r4Kdt0trndPp+TyyH+JPb88dT2E+s2Ws6NHe6VcJdW06/u3Tv7Y6g+x5qKtHktKLujanU5nZ6HsWl3P2zTbS5PBmhST81B/rVmq+nwfZbC2tx0iiWP8gBVivcR83K13YKKKKYgooooAKKKKAEdVdSrqGU8EEZBrjfE3hJHDXuiRrDcry9uvCS/Qdm/Q/rXZ0VFSnGorSRrSrTpS5os8Ts5jdX0jsrKU+TawwVI6gj1zXSQjCACqGuWbWnivU9o5eQTAf3gwBz+eR+FSC9ht7V5rmVIYYwWd5GCqoHck9K8Jx5KjifQ83tIKSKmtWkUi4uoEntyCssTqGV0PUEHrXlXifZ8MLuCbwrqUV1p+oOA3hydmkZ9xwWhxkr+Pf14FdBqPjLVvGVzJpvw8tQ0CHZPrdyuII/URgj52/zjHNaHhbwHbeFZzfq7anrEg/f3l2Mux77D/APp+Oa6of7Onz7Pp/n2/Mxf723Lv3Lngb4gaXrkT25kkt7qA7ZLe5GyWI9MOP69PocgdpJewLHuaaML6lhXnXjTwtpviJ0vglzpWuQ/6rULZfnB9GwfnX68/SubsvGM+gTLpvjiyt4nb5YNWt4x5E/+8MfI35fQDk8NTBwqvmov5f5dyuVr4/vPbdHgm16IpasUs0cpLcdz/sr74PXtXdWtvFa28cECBIo1Cqo7CsTwHZ/Y/DFpkqXnBuGKnI+fkc/TFdBXs4TDRoQVt2eNiqvPNpbIKKKK6zmCiiigAooooAKKKKACiiigArg/FOk/2NMdSsUxYu37+JRxGSfvD2Pcdq7ymTRJNE8UqK8bgqysMgg9QawxFCNeDhI1o1nSlzI8ZhjGqSy3M5LgsRGM8KoPGKmmUqUF28v7sYjuUG50H91h/EP1pLCH+zr28tCMJBcPGMnOAGOP0xWyY0k5FeHyOL5V0Po3JNIzovOcfur/AEuRf7zyGM/iuDivPdNMQ+OOtreTmVf7Ji/48juDncvy57fXivT306Jjkoh/CvP9Et0T4762mAANHiOAP9ta3owfvadP8jGo9tep2Zt3vSiyxiG2T/V26nge5Pc1JYP/AGV4i06eEbQ0ywyAdCrHB/nn8K1SEUfL2rFm/wBI8QaTbpyz3cZP+6GBP6A1EI8k423uW2pQkntY9dooor3z5oKKKKACiiigAooooADz1rzP4haRFp09tNZZjhupD5kIHyggZyPT6V6ZXI/EqI/2PbXKjPkXClvZWBX+ZFc+KpqdN3Wx1YKbjWj5nM6eAFH0q5Mm6In0rOt28rDf8sz+lcxrfxM0iyuf7O0eKfXtYbhbTTxvAP8Atv0UevUj0ryKNNzvFI9upJRdzuvDU6p51izYdGMiD1U/4HP51w/xE8faBpOrwwadO2q68MxvYWCmV2Uc/MRwpB9ecHpWFP4U8YeLv3/inUV0SwYELp2mN+8IPaSX+YGQfQV3HgnTfD3hKyFpp2lwaY+AJJVUsZfdpDlj9CeKJQhSd5avsv8AP/I55Kblz09jhItP8ZeNUEmsX6+HNHfkWdg2+4df9qTt17fita8/w/0Gz8K6lpWlWMUL3du8bXD/ADSMxHBZzzwcHHT2ruLnSreVzcaXc+QH5KoA8ZPsM8fgax9VsbsR7GvS7uQqpFHsLE8AZyazeLd+WLt5I3ioNXe/mc78JL278XeEtJ02MOLu3T7JeuR/qRGduT7lQPqTX0Lbwx28EcMKhYo1CKo7ADAFeNfC62Hgv4x+LvCBbFnqNvDrViGJySfkm6/7WfwWvaa92lSjTba6niYjEOrZdEFFFFbHMFFFFABRRRQAUUU2WRIo2kldURRlmY4AHuaAOV+IOnSTWMOpWylprIkuAOWiP3vywD+Brk7adJ1DxMASM57GvSLXWtMvJPLtdQtJZM42pKpJ/DvXO6z4KR5Hn0WVbWRjloHGYifbHK/hke1cGIoe0fPTPSwuJVNezq6GEJZFHzKfqOa860uf/i+uttg86REOn+2td9cWGt2LFZ9NuWA/jgHmqf8Avnn8xXnOjSX0vxw1kQWl29wdJiBj8ohgN68kHoPc1zU4TXMmnt/kd8pwdmmtz0mRpJEI2YUjB39K8zm8K6r4b8RSa34AsjqEEJF3qGiKcRygMOYv7rHsB1wcDHFerWvhvWb8b7549OtRyzSMGkx7AcD8T+FLd6xZ6TanS/CmXkc5mvPvEn2Pc+/QdvZ019X9+pou3f5GVaqqi5Ker/L5nRfD/wAb6N470Qajoc5O07Li2lG2a2k7o69j156HHBrpq+ZPFPh3VdD1weLvCN81n4jBzceaxaG9XukoPXOOv8jgj134Y/Emy8ZCfTry3fSfE9kMXulz8Oh4+dD/ABIcjB9x6gnvw+JhiI80Dya1GVF2kd9RRRXQYhRRRQAUUUUAFFVdU1Gz0nT577U7qG0s4F3yTTOFRB7k14/ceOPFPxLuJLD4XwHTNBDGOfxNfREBsHkW8Z+8fc/+O8GgC58bfGGjeGr6wYTfa9eYGNdMt/mmkQgsGIH3QCDyexOM4rgbLwpq/ji4S/8AHtyLaxyHh0W0bCexmYfeP0/MdK9l8AfDTQfBkc0ttHJf6vdA/a9Tvm824uCfvZY9AfQfjk81U1rwxdaVI02kRPc2JOTApzJF/u/3l9uv1rjxEJR9+mtfx+R6OErxa9nUfoULG1XTraO1tLaOG2iG1I4FAVR7AdKteaGHzKfxFZ1rqUcmQknzKcFW4Kn0I7VYk1JYkJkkVR6k15ymup6jg+g6VAVJWM/jwKqaP4csfEettb6nZQXunxxN9pjlTdGSRhR9e/tir2n2Gpa6R9mRre0P3rmVcAj/AGB/F/L3ruLO20/w7pRUOsNvH8zyyNyzHqxPcn/6wrpw+HvL2jVkjjxWJUIunF3bPJZvC/i34TyveeAWm8QeEs7pvD1zIWnthnJNs55I6/L19mJyPQ/AHj3QfHWnNc6HdEzRcXFnMNk9u39107c8ZGR6GsPUPF+pXl4zaRtgs4z8peMM0nuc9B7D/wDVhal4LsPHcra/ol0/hvx1ZHB1Cy4Ehxx5qdHRhxzzxjJAweuli6VWbhF6nm1MNUpx5pHsdFeReHfijf6Dq8Phv4sWcWj6o52W2qxf8eN97hv4G6ZB4/3cgV64pDKCpBB5BHeukwFooooAKKKKACiiigAooooAKKKR3WNCzsFUckk4AoA848bWR03xAL8L/ot8ArnssoGP1AH5GqsbFVzGcj+6a9GvbWz1jT5LecJcW0gwdrZH1BHQiuEv/Cmq6WxOnP8A2ja9kYhZVH8m/T6V5uJw0ubnhrc9fC4qLiqdR2aIBc7fvAr9a860y4H/AAvXW3zwdIiH/j612U+p/ZG2X8NxaN0xNGV/nXAaNfCf42axLaRy3G7So1CwxlyTvXsK56XN7y8v8jsmlo/M9LlncqdoIHqeKs+AbE3/AIkm1FvmhslKK3YyMMcfRc/mKLTw5qupgvf40yxAyzSEGQj6dF/H8qkvddjsoI9I8JYjgi+/cgBtx74J6+7flTpxVD97W0/Mwr1faJ0qWre/ZHpFFcP4T8TXT6mumaxKJJJQTDMVCksOqnGB06Gu4r1KNaNaPPA8erSlSlyyCiiitTMKKKKACio7meG1t5J7mWOGGMFnkkYKqj1JPAFeVav8Zba+1CTSPhxpF14u1ZTtaS2+SzhPq8x4x9OD60AesO6xozyMFRRlmY4AHqa8j8a/FnRb37X4c8H2N14u1qVChh00boYiejPNyoAPcZ98VnaX4B1r4iq958SfFYvbGOd4n0HRJDDaRyI21o5XB3OVYEEHkEcNXrfh7QNJ8N6clhoOnW2n2i9I4IwoJ9T3J9zzSavoxptO6Pm5PCviXxDeS2njvVJLG2ibD6Rp52Bh/tyfxDp6j0Ir0Lw/oGm+HrTyNCsobaA8lYx8ze5Y8sfqc16D4q8NRa0izwOINQjGElxww/ut6j+VefXNzd6PN5Gr20kD5wHxlG+h6GvLxEKkHb7Pke5hqsKquviNqKcMMN17g1FPHEwJYjFZg1y0ZctIpx61Zs7XUNZYDTrFxEf+W8o2J/8AX/DNc9nPRK7N3aHvN2RR81rTUYU06OSWSZtrQRAtvGOuB6V2fhrw3c/bo9S1jCyJzDbA52H+8x9fatTw14bt9GDTM3n3zjDzEYwP7qjsP51q6jfW2nWj3N5KsUKdSe59B6n2rsoYGFNqrU3R5mJxjqPkp7fmeT/HI/8ACN+KvAnjlfli06/+wXzg9LacbSx9QvJ+pr2GvFfifql74y8Fa7o6WUAs7qAiIOD5gdSGQ5zj7yqcY/HvXZ/BTxIfFfwv8P6nK++6NuILgk5PmxnYxPoSV3fjXXRxFOtfkd7HHUozpW5up29FFFbGQUUUUAFFFFABXOfEGF5vCt35ecRlJHA7qGBP5Dn8K6OmyxpLE8cihkcFWU9CD1FRUhzxce5UJcklLseT2uk2t3aoUQHIqVYdY0w/8S6/uIkHRC25R/wFsj9KGjl8N61Lp02TATvt3P8AFGen4joa6KKVJ4vmGa+U/eUZuN7NHuOSnFO10zCXxpr9n8txBaXAHcoVY/iDj9K8xsvFuqn49a3f20NtBcz6NFEwYFwqh15HTn6165dWcUpI4ryrT7CMftD6pAfunQUf/wAioK7KONrSUk3sjCpRpJpqPU6m5l1bW3X+0rye4XP+r+7GP+AjAro9F0pYcbgM1cgtIoRwKvwFVXpiuFzlVl77OhtRjaKOb8XQq1u6YHTFc3D4Wg8c2EEJupNJ8ZaMu7S9Yg4k8sdEf++ozgg9jx1Oet1iMzSjP3e9ZeikweM9J+z5BaQqQO6lTn9K6cDXdOsktmZV6anSd+hc+H/xHvP7aHg/4iW0eleLYxiGQcW+pL0EkLdMn+7+XdR6nXM+P/BGjeOtFOna5ASUO+3uYjtmtn7Ojdj09j3rz3w9421r4eaxbeFvinN51jM3laZ4lxiKcdknP8D+5+pyPmP054p7RRSAhgCCCDyCKWgArz34gfFLS/C96mj6bBNr3imfiDSbH5nz6yEZEY78845xjmu41azOoaXd2YuJ7Y3ELxCe3fZJHuBG5W7MOoNc58P/AIf6B4Fsni0S1Ju5ubm+nO+4uDnJLv1684GB7UAec6X4Nn8Z+J4ZfjBrllc6nEBcW3hO2nCQW6nozrnMp4PPI4IyRwPb7eCK2gjgtokhhjUIkcahVVRwAAOAK8O/ah+Gdz4zsNG1XQoidZtLiO1cqOWhkcAE45+RyG9gzntXTfDSUeB7O28L+KrrUl1N2CwX1/dvcW96ewhkbAQ/9MiA3pvHzUAM8WWzX3jG7hvXYxoqGFSeAu0dB9d1Jbxarpq506/uIwOiFt6/98nI/Sug+Iemv5UOsWqky2g2zAd4uuf+Ann6E1R0m/juYV6EEV83jVUo4htO1z2aEozpLS9jIvdZuJ/+Q3othqDAYEoUxSY/3hn9MUlj4i8Pae/mReGZBOOQS4kwfYscj8K6C8tYpF4xzWPLoyOxIAqI46tF66l+zpyVtV82LefEPU7lSmn6dDa54DzOZD9cDAz+dY6JqOs3Im1O5luWHTfwq/RRwPwrYt9GjR+cVq28CRYUY/Cs62Lq1dJMcKdOn8KIbewSCyOQOlcvaau/hzxUl6il7SQeXcoBzsPce4PNdvesBbED0rjr21VhJI4+bnFZwn7GalHdDS9ompdT07XdG0jxVoclhq9pb6jplyoJSQblYEcMp6g85DDBHY15K2k+MfhA5l8N/avFfgdSS+lyNuvLBe/kt/Go/u/oOWr0P4Y3Mk/hgJIci3meJD/s8Eflux+FdZX1lKftIKXc8SpDkk49jnfA/jTQvG+kjUPDt8lzEMCWM/LLC39106qev17Zroq8x8cfCuK/1j/hJfBV83hvxamT9qgH7m677Z4+jAnqcfUNgVX8JfFSW31mLwx8S7BfD3iRuIZif9Dvu26KToM+hPXjOeKsg9WooooAKKKKACiiigArhvihG0kelq7EWzSsrjsWwNufwDV3NZniPSk1nR57NiFdhujf+445U/n+maxxFN1KUoLdmtCahUUmecw6N5DebYSywSEfficofzFW49c8SadwJ0u4x0E8ef1GD+ZqPQ9QkRmtrtDHcRMY5EbqCOorfkSOaPOBmvmKdWrSbSlZo9majL4ldGYvxFuYgVutHDN6xz4B/Ar/AFryyy8Y3p+PmvajYWUUM02jRQ7JmLhQHXnjFen3Olxyt0FeYaPpqf8AC/tchPRdHib/AMfWu2lj604yu9kc88PRi00up19xcavrsw/tK7lmTOREvyRj/gI4P1Oa6TR9MWFMlRmp4LSOEcVoIQsRx1rz3OVWV5s6G1FWijhvFyyRSxz2bFLiFxJGw7MDkGvTvCWuJr+jRXYURzj5J4v7jjqPp3Hsa4PUoBNcMZB8oq18NppIvFF9aof3D23mMP8AaVlA/RjXflldwqez6MwxdJSp83VHplFFFfQnkBRRRQBy3jvwLovjmGwg8RJcz2lpKZhbxztHHKcYw4UjcB1Hcfic7mj6Vp+i6fHY6RZW1jZx/cht4xGg/Ad6u0UAfK3wxHjrSvjTr13pduieH9c1W/mFtfymJLpY5zvaLg4kUOCOgYBuoUkfVNc9440SfWdHRtNdIdZsJVvNPmfos6g4Vv8AZdSyN/suat+Ftcg8RaHb6jbo8RfKTQScPBKpKyROOzKwKn6UAecrLqeoXt1LJqV5HMsrLtSZlCYJGAAeKvf2rrtrCY5nh1CA8GO6iDZH1GD+eam8V2raJ4j+2IpFnfnJI6LL3H49fzrRtZIbmMcDmvmKs61Cs48x7cfZzgpcuhmWHinTLJ1a58NQ28g/5aWsaH8eQP51rP8AEfRlXIhv2b+6IRn+eKo3+nRyA8A1jtoQJJAAFaRzKtHRkPDUp6/qX7/4i3k6ldK05Yc/8tLltx/75H+NY0KX+s3In1O4kuGzxu4Vf91RwPwrStNGVfvAVtWkCRkAAAD0rnrYurW0k9DWFOnS1iijc2McNhjAHFeefATXU8M/EHxR4Jujstbq4/tHTyTwC4G5R6DOAPce9en6y3+jkDmvCfibatoPjHwt4ljOyOSY6dcsONofmNs+zZOfYVtgavsarS6r/gmVeHtIXZ9YUVQ0G7a/0Swu5BiSeBJG+pUE1fr6RO6ujyGrOzCiiimIKKKKACiiigDnPHei/wBr6JIYV/022zNbkdcjqv4jj64rj/Dl/wDaLVCD2r1OvIoYhp3iPUbFBiOOdig9FJyB+RFeLm9FWVRHpYGd04M6QjJzXl1plf2kb04+94bB/wDJhK9UiOcV5gFx+0hc+/hgH/yZWvKoKym/JnTN6xXmek7iakBwKhFPZsLXKmbNFHVJVijJPWovh5aNe+JZ75wfKs49qn/bfj+WfzrN16Y85PAFeh+C9KOk6DDHIMXEv76b13Ht+AwPwr1sso89Tm6I5sXU5KVurN2vI/jZ8QPCtjHF4N1G0g1zVdWkjtv7OJysO9gFeRhypGQQAQ3QjH3h6nqd/aaXp9xfajcR21nboZJZpW2qijqSa8Ks/gxYeIfEtl42trV9FmTVbe+gspdxaa3STc7zbssJZPvY7AKDgliPozxzf8H6X4v+HHiey8Oxx3PiPwPeOY7S5LA3GlcE7ZCcZjAHB/AYOFPr9FFABRRRQAVW1Kws9UsZrLUrWC7tJl2yQzxh0cehB4NWaKAOJ/4R3XPDykeFL9L7TQMHSNXkZlUekVxhnQdtriQem0V5y2vQ+G/EL2etWl1oMcx3QJf7RH7qkykowyeOc4IyAeK98rivipYJcaJb3bor/ZpgGDDIKP8AKRj67a4sdRjVpNtbHThKjhUSXUggmWeBXRgysMgg5BFKcqK47TPCOlFPO0prvR5TyTp07QoT6mLmM/iprROmeKLVR9k1+zvUH8OoWHzn/gcTIB/3wa+a5IvaX3/0z1HJrRo6APgdKVGJNcwbzxXAcTaLpNyP71vqLqT/AMBaLA/76pya1rqff8LXLehivYCP/HmWo5Jd196K5kdNKcr7Vy2vXSxRvtPQc0y71rxEYm8vw2keef3+oIuB77Vbn8/rWNpOneKfEWuRWuNGsEB82Rj5t4FVT3H7rOTgdR1rejQlUmo6a+YvaKCcn0PYvBOntpnhixgkXbMy+bIO4ZjuIP0zj8Ki8ReLdH0iU2M968mqSL+7srKM3F0c9CIlDED/AGmG0dziqP8Awh13fD/iovE+sX6Hrb2rixh+n7kCQj2aQit3Q9C0rQbdoNG061sYmO5xBEE3n1Yjlj7nmvrIRUYqK6Hhyk5NyfU+Z7Gw+LPiH4rSeHZvEuvado8SJeTTSNEksNsxOxWMXyea2CMAnoSehA+i/EfhDRPEvh1dE1+yGoWKoFX7QxeRSBgOJCdwf/azk856mt1Y0V2dUUO+NzAcnHTNOqiTiPhr4Q1fwat9p114in1fQl2DTYrpMz2y85RpP4h90D0x2rt6KKACiiigAooooAKKKKAPPviRpf2WaDXbUbSGWK6A7g8Kx+hwPxFN02586BTnqK7XXLJdS0e9s2GfOiZBnsccH8Dg15h4VuPMt0B6gV89mtFQmprqetg6nPTcX0OkIIOa8u0ZsftD6/kf8wWH/wBDWvVU5BryrSxj9ojxB/2BYf8A0Na4aKtGb8v1RrN3cfU9PDEmpM/LioV60SvtUmuZM2aMrWJliQj+I1q/CyzYx6hqcg/1ziGMn+6vU/mcfhXK6qZbq6WCAbpZGCIvqScCvW9GsI9L0u2sofuwoFz/AHj3P4nJr2cqo3m6nY5MbU5YKHcuUUUV755IUUUUAFFFFABXDa8G8Ga9N4jgVjoN8VGsRKM/Z3ACrdgegACyY/hCt/Cc9zSOqurK6hlYYIIyCKAKGr6fa65pEltKwaGZQySIc4PVWU/rXmeiT3Fld3Fhe/8AHxbuY3x0OOhHsRg1txvP8OrsxTAyeBpD+6lzk6OemxvW3J6N/wAs+h+QArV8eQx2/iSx1GAq0V7DgspyGK4wc+6sv5V5eaUFOn7Rbo7sDUalyPZmmzb1yKYTgU2zfdEDU8ijFfO67no7aEe8AcU6Nu9Qmnr0qVJ3KaQl0dyHPSvLfi/p513whqGn28bSXDKHt1QZYyKcqB7nGPxr0XVJ9kJAqv4D046h4hN5KuYbMbhnvIeB+QyfyrrwcHOtG3czqtRpyb2Ok+EuuQ+I/hr4c1ODGJbKNHA/hkQbHH4Mprra8e+Bf/FO+JPHPgWQbI9M1D7dYrjA+zTjcqj2XAz7tXsNfW7HhBRRRQAUUUUAFFFFABXlXihfJ8fXJzxKsb/+Ogf0r1WvMvH6eX4xtZP79uv6Mw/wrz8zV6B2YF2q/I17fotebzJt/aOf/a8K5/8AJuvRrPlFrzvUFI/aNj4O1vCu3I/6+j3rw6C9yfoztqfFH1Oz1LU7DSbc3GqXttZwD/lpcSrGv5k1J9pjuLOO4gYPDKgkRvVSMg/lXhvxF+B019qY1jw9fXF3IHDyWN9cF2cA5ISV8/k+R716be+Hr1ISP+Eq17y8f6si1/8AQvJ3frWU6VJRi4zu3/XmaRnNyacTT0mAal4msoGGUD+Y/wBF5/UgD8a7XXPGOj6TdGyM73uq4+XTrBPPuW+qL90c/ebao7kV5LouiaHZRaxrPiq+1W607T7YvJ5l7IoYseF2RlVctjAUggkgY6Unhn4jXll8Nda1Hw94M06xv7DXTpbaXZozAABcyOIlJYjc2SAc7e9fQ5bTUKN11POxs3KpZ9D0i10HUvEt9BqPjOOKG0gcS2mhxsJI43HIlnfpJIOyj5FPI3EBh2tefeDvFereJdB07V4bjQpLQTSrfSWry+XEqMvB81UdCF8zIK53bP4STXS3HirR18K6j4hsb+21HTLG3luJJrKZZlIjUswBUkZwOlegcZuUV4NafHG8/wCEQ1jWLuzsBfx29tcWelCOeKQLO4VGeSRQJE+ZTuQY9DyDXXeGPF3ibW9Q1zRntNNTV9Dv44Lp4Sxhlikj3oyhjlfQ9TjoD0oA9LooooAKKKKACsHx3F53hLUl44jD/wDfLBv6VvVneI4vO8P6nEBkvbSgfXacVFRXg15F03aafmee+F332a59Kl8Qa++hbJLjSr+503YWlu7RBL5BH96MHeRjnKg471T8It/o+K0dY8L6Z4glik1iKW7giXAtHlb7Oxznc8YO1z/vA18nSUef3tj2a11seb/ET4qLottpd34e+w3thfW09yl3IXdGMfHlhU+YEt8u44APXviPX/idqtoJpNN0yxaOw0m31W9WWcsT5pH7uNl4OASd3IPpXX+KfAWj65dQTObqxlht3s82Evk7oH+9ERjG36Yqjqnwx8OX6QJsu7aCOzjsHit7gos8CEMqSdScEdcg+9aRnhlZOPr9/wDkQ41XezL9tf310k9xdLEtnKqyWu0fMVOTzz/d2enzbu2DXa/DezCaZPfMPnuZCqn/AGF4/nurjtaKwxrHGAiKNoA4AA7V6d4Yg+zeHtOixgiBCw/2iMn9Sa7MqgpVHO2xnjZONNR7mnRRRXvnlBRRRQAUUUUAFFFFABRRRQAUUUUAFePaKPJ1m+g6COd1/JiK9hryN0EHjLVEHe4dvzOf615ObL92md+AfvSR1MIryrThj9onxB/2BYf/AENa9WtuSK8rsRj9ovxD/wBgSH/0Na8qkv3c35f5HTJ+/H1PSVqveybENWB0rM1h9sLVwx1Z1k/ga2W98SSXDjK2se4f7zcD9N1ek1xnwxhxpt7cH70k+38FUf1Y12dfW4CnyUI+Z4uLlzVX5BRRRXYcwUUUUAFFFFABRXmt78Qr3RfGi6Df2lprX2m4ZYhojmS6tYy3ym4gOdoAxmQNjgnaOlLY6/4hX4/3Xhu+vraTQzoB1K3t4bcIUb7SsYLuSWZsBuhC8j5cjNAHpDqrqyuoZWGCCMgivGviR4cufCdjZ3PhsmfRxckf2O7ACAspJNu5+6Dt/wBWflz0K85yvBfiPxhdeOX8PeK/EFys2pwXUunLbR2csHlqTtYvDiRSB7jPqDXofjuxmt/BEEVxctcy28yFpWBG7kjuSeN2OSTxyScmsMUr0pehth3+9ic/4Q1/T9ZtylrMRdQj99azKY5ov95DyB79D2JrpnGY81yUeg6Zrlnbvf2wNxCP3NzExjnh/wByRSGX8DU4sPFGkw/8S/ULbWrUD/U6kPJnA9BNGpB/4EmfVu9fMRhGV+V/16nqzbi9TbPWlJwtcwfFqWrldc0nVdMI6yPbmeH6+ZFvAHu22tLTvEGj6sh/svVLG8PpBOrkfUA5Fc0qclrY1Uk+pBrMwCMDXd+C7AWHh62BXEs48+T1y3Iz9BgfhXm+oqbq+itgeZpFj/76IH9a9Z1TUbHRdOe91O6hs7GHaHmmYIiZIUZJ4AyQK9vKKfxTOLHztFRPKvHwHhX46+CvEqnZaa3HJoN6QONxO6DPuXwPotew15t8fNGPiX4TapLpjrJd2KpqllLGd3zRHflcdSU3gfWuu8Ea9F4o8IaPrcOAt9bJMVHRWI+ZfwOR+Fe4eYbdFFFABRRRQAUUUUAFecfEkAeItMbuYSP/AB6vR688+Ja/8TrSj6xuP1H+NcWYfwJHVg/4yLNgcxp9Kt3n3BVDTj8iCr93ylfNxfuM9KS99FAVQ1RsQtV8Vk60+IyPWueO5uXvAWl2Or6frFtqtlbX1lM8SyW9zEssb7csMqwIODg/UVY034VeH9I07VbTQpdQ0c6jfnUJJ9OmFvKjcgRKyqMRLltqHIG41b+FyAaRetjk3RH/AI4tdnX1+CVqETxMU71ZGH4N8Lab4Q0UaZpCzeUZHnklnkMks0jnLO7HksfWtW/tINQsbmyvIlmtbiNoZY26OjAhgfqCRU9FdRznnFr8GvCkWlajp9wt/exXtrFZeZdXJd4IImDRxxNxtVWAI9wM5rpfB/hHT/CqX7WUl3c3WoTfaLu7vJfMmmfAA3HAGABgAAV0VFABRRRQAUUUUAFQ3qh7OdT0aNgfyqamyruidfUEUmCPIfB5/ciuzt/uGuI8JcQqfau1tT8hr5CHxs96stCpP981E5wpqW4/1lQzHEdc0viLjscvr5Mj7F+83yj617NEoSNVXooAFeNXP77VrVOzTxr+bCvZx0FfQ5QrRk/Q8/MH8KCiiivYPOCiiigAooooAKKKKACiiigAooooAK8p1lfL8eaiPVkP5opr1avGviHrNjoHi27u9SldElkhhjWONpHkkZFCoqqCWJx0Arzs0i5UUl3O3AtKbv2Ozsz0rh4/DWoW/wAX9W8RyCL+zrnTY7WMh/n3qwJyPTitLw54z0fVn08adM8y3hZUbZsKsuQVZWw2QVOQAccE4BBPSXvWvCvKnTaa30O1JSmmVh0rF1x8QkVBaeM/D97bazPZ6nDcQaOhe9khVnWMBSxIIGG4U/dz0x1rl73x5oWp6fJd6dPPPbx7csbaSIEMGIIMgUEYU9M9h1IBxhRnf4Wbc8e57D8O4wnha3bvI8jH/vsj+QFdLWJ4Kj8rwtp6+se78yT/AFrbr6+grU4ryR4dZ3qSfmFFFFamYUUUUAFFFFAFWx0+y0/z/sNpb23nytPL5MYTzJGOWdsDliSSSeTWR/whXhn+3/7c/sLTv7Y8zzftnkL5u/pu3dc10NFAGJonhLw9oV9cXui6Hpthd3AIlmtrZI3YE5IJA6Z5xVf4hpv8IX3qDGf/ACItdHWD46Xd4T1Ef7AP5MKyr/w5ejNKP8SPqjj/AA4f9ET6V0Y/1Fcx4cOLZfpXTKf3FfKU92ezV3M9/v1ka3oekaqpOqaXY3h9Z7dXI/Eitd/vmq92dsZPtXMm07o0smrM4fS/B2kSeKLCC2W9s1MoI+yX08IXAJ4CuB29K6z4keAtSvfBGrWGgarrl5d3cJt0trq+R4iHIBLmQE4UEng7uOKr+El83xnZt2TzG/8AHCP616xX1GWNuk231PLx1lNJdjxL4JfB3XfAi7tX8XXE9s6kSaTarutGyOcmQH81VD79qvfs8SNo0XirwPcOTJ4c1N1twSc/ZZsvEef+BH8RXr9cza+DrK1+IV94ugnuEvbyxSymgBHlPtbIkIxndgKo5xgH1r0TiOmooooAKKKKACiiigArgPiSP+JtpB/2JB+q139cn460yW9l0+eIZ8neD+O3/CuTHRcqEkjowslGqmzN07gCr1yf3dU7SN41G5TU8zErivl1dRaZ6r1lcrCsbXOVraCn0rO1OynnGI0JzWdOLb0Rq2ludB8Mv+QJdf8AX03/AKAlddXO+B7CTT9KljlGGeYyf+OqP6V0VfYYVONGKfY8PENOpJoKKKK3MQooooAKKKKACiiigAooooA8e8LjEA4rsbY4jrm9LsZrJ3ilUjDH+ddBE2F5r47WFR3Pem+ZaENx/rDUE/8AqjU0py1QzAmM4Fc71Za2Obi/5Dljnp9qi/8AQxXsteS2lhPNrFuyodqTI5P0YGvWq+kypNU3c83HtOSCiiivVOAKKKKACiiigAooooAKKKKACiiigArwj4xaDfax4xs7jSvIa80y9t71Ip3KJKFXBTcASpOeDg17vXAeKLCb/hJ5LpVPluic/QYrhzByVLmj0Z1YOzm0+xzHwx8MXWh+Gb601OdVvdRu7i7mNo5xE0p6IxAPAxzjrXQadpS6PaNbpe394Gcv5l7cGZxkAYDHtx09zV62yqjIpbhsmvnJ1ZSi79T0owSkrHk+j+F/EEWoeN3vdK0kWmvxYSH7c5VSIzHsbbGpwwJywII7A9ap+DvDGp6Bc6m98ILSzuDGLbTbe5kuI7cKuCQz88+gGOB+HruCQeKxNSs5ricCNCcmqjXnO8Ut7fgUqcYtPseh+Ev+RZ0z/rgn8q1qzfDkLW+hWUMn3o4wp/CtKvrKfwL0PEqfEwoooqyAooooAKKKKACiiigArF8af8itqX/XL+orarL8UxNP4d1GNBlmhbArOqrwkvIum7TXqcFoP+oSukX/AFOK57Ro2jhRXBBFbgf92a+Rg7N3PbqalV/vmqmof6k/SrTfeNVr4EwnHpWHU0KXgcZ8WQ/9c5P5V6nXmXgi3lHiSKUqQgVwT+Fem19TlitR+Z5OOd6nyCiiivQOMKKKKACiiigAooooAKR1DDDAEe9LXJ+KvH2h+FvEmhaLrMk0NzrLsltIEBiVgQMO2eMllA4784oA6NrKFv4RVd9LiJzisKy+Inhmfw/HrN5qcGmWMlzLaI+oSJDukjcowGTzypP05rYfxJoSXtvaPrWmLd3Co0MJuow8of7hVc5IbBxjr2rGWHpy3iaKrNbMmTTIl7A1YS0iX+EVzrfEbwWElf8A4SzQSkSq7st/EQATgHIb1q7d+MPDdnrFvpN3rumQ6lcBTDbSXKLI+77uAT37evanGhTh8KE6kpbs3FAUYAwKWsHwj4mtvEyau1pDNENN1K40yTzcfM8LYZhg/dPbPNb1akBRRRQAUUUUAFFFFABRRRQAUUVysfjzQZPH8ng1bl/7cSHzjHsOzG0NtDf3tpDY9KAN+ewhlYkqMmq0ukxkfLWP4S+IHh7xPC5sr6GC5Rpg1nczRrOFidkZygYnZlSc+npWtp/iTQ9Smni07WtMu5YIxNKkF1HI0aH+JgDwPc8VhPD06nxI0jVnHZkf9jLnmpo9JiXqM0y08T6DeWJvbPW9LnsxKIDPFdxtGJD0TcDjd7dabP4q8PW7QLPr2kxNPtEQe8jXzNxIXbk85IIGOuDWccFRi7qJTxFR9S/BYwQnKoM/SrVYr+LPDkemy6i+v6QunxTfZ5Lo3kYiSX+4X3YDe2c1VHjLSJfEOjaTaSm8fVrea6trq2ZJICkRUN84b/aGMA9D0rqUVFWRk23udJRRRTEFFFFABRRRQAUUUUAFFFFABRRRQAVFNBHN99Qalrk/FXj7Q/C3iTQtF1mSaG51l2S2kCAxKwIGHbPGSygcd+cUmk9GCdjdfTISOBiq50dCax7L4jeF59Dh1a81W20uzmuZbWM6hKkBd43KNjJ5GR+XpW3N4i0SG/hsZtY02O9nCGK3e6QSSByQm1c5O7BxjrjiueWEoy1cTVVprZix6TEvUVZjsYUOdgzXPt8RvBYSV/8AhLNBKRKruy38RABOAchvWrt34w8N2esW+k3eu6ZDqVwFMNtJcosj7vu4BPft69quGHp0/hQpVZS3ZugADA4AorB8I+JrbxMmrtaQzRDTdSuNMk83HzPC2GYYP3T2zzW9WxmFFFFABRRRQAUUUUAFFFFABSMoZSrDIIwaWuWvPHug2nj2z8Hz3LjW7qHzo0CEpjDEKW6BiEYgfT1oA1pNIgZiVUCq8uj/AN08VQ8NePdB8Qalf6bbXkdvqVpfXFgbS5ljSaVoTh3jQMSydcHHY5ArT0/xNoOo3bWun63pd1crH5xhgu43cJ/e2g52+/SuWpg6M9WjaNecdmVxovPNTpo0WMMM0tp4n0G9sZ72z1vS7izgcRyzxXcbxxsSAFZgcAkkDB9aZd+K/DtnGkl3r2kwRuCVaW8jUMA+w4JPPzAr9eOtTDAUYO6Q5Ymo+pfs7CG1OY1ANW6x28UeH0tLy7fXNKW1spPJupjdxhIH/uu2cK3scGqMnjfRTq/hyws7gagNeadLS5s3SWDMMZkfc4b0BAxnnriutRUVZGLberOmooopiCiiigAooooAKKKKACuA+IPw6g8a+IbC51KWM6bFp91ZSw7fnLS7NrqegKlMj3xXf0UAeJ6J8INa0bQfDyWut2FxrGli/ieS7t3khmS7PzNjcCHHHrnkGuh8CfC+Lwt4htb6S4hv4bTRrbTITLF+8WSJ2YyAnO0HdwB0xXpdFAHhum/BCe00GzsJL3T3mg8PX2jtJ5B5lncssv8AwHOPWna78Htf1OWziPiC2ewt4tPEcMomAga2VA+xVcId+zO51Zh0GBzXuFFAHK+APDE3hiLX1nuI5/7S1m71NNgI2LMwIU57iuqoooAKKKKACiiigAooooAKKKKACvD4vhB4hj1uy8TDxFAfEMetyarLCYx9m2Odjxq+zzeYlRcE7eDx3r3CigDw7RfhDrcFxZJf3ejpa6fLqNzBLbI5nme6V1CyMQAFUPzjOcAU5PgnMdM0+zW7sbMp4Zl0S6ntYyHkmdlIk6DcvynOSCcn1r2+igDxGf4QarqMV5NqVxoqT3V3pjSWlrEy2xgtCc5BHzO4YjBGAOMmrXxD+ED+I7rxC+mjSbWG90i306yRototnjnMjEAL8oI4+WvZKKAPHNX+Fms/aNdbQL7T7G1v9WgvltU3wgwpB5bR74wGjJPOU5xxkZNS/Dr4W6n4X1LwvcXd7ZSx6THqCSLEZDu+0Sh127hngDnJz9a9eooAKKKKACiiigAooooAKKKKACiiigAooooAK4D4g/DqDxr4hsLnUpYzpsWn3VlLDt+ctLs2up6AqUyPfFd/RQB4bo/wa1rR9B0uG11ywn1S2tr+ynku7Z5IpI7p9xcDcCHHvkHODXW+D/hpD4d8T2uoSTw3tvaaLa6Vb+dFmVWhJPmZOQM5HA6V6LRQB4bpvwQntNBs7CS9095oPD19o7SeQeZZ3LLL/wABzj1p2u/B7X9Tls4j4gtnsLeLTxHDKJgIGtlQPsVXCHfszudWYdBgc17hRQByvgDwxN4Yi19Z7iOf+0tZu9TTYCNizMCFOe4rqqKKACiiigAooooAKKKKACiiigArw/XfhB4h1HWNQ8SReIoIvED6zFqdrCYx9nVIvkiR32eZxEWBAO0k9O9e4UUAeNaX8LNZj8Vrc3tzpCaXH4luPEaSwI5u3Zy2yEkgAJhvm65x+NZ1j8DriLw94X05rywtp7HTdTsL+6tYyHmNyu1GHALBcnIYjrx1r3aigDw27+D2saj4c121vLvRoby/s9OsI4rSJ0t/LtZlcu+RkuwBAGMDpk1s+O/hOuvatfTabFpNrZP4dn0i1gMO0QXEkwkEoULhR97kc5J9a9ZooA8WuPhNrNsmvDQtQ06xF+NKCxRq0YYWqMsqllGY95YEOnzcds1J4H+FGq+H9a8PXtze2LR6bq2pag8cbyuSlzCI0VWfLEg9SxJPqTXstFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRXN/Eq7uLD4c+KryymeC6t9Ku5YpYzho3WFirA9iCAaAOkor5c+FHijXNS8b+BrG01vxM1xc2LXurxa5Mpt7iLZw1sp+Zstu5HYZ6Bq7XRvi/q1x460bTJrfSb7RtVvJbOK80+O6Cxuu7GJZEEcp452E455NAHt1FfOGs+PfE/i2z8B6/DFaaZ4Y1DxhaW1qLe5k+1zRrJIhEwGF2NtbK+w69a29G+Il7ZaRJa6Jp0cmr6n4qutJthfXkskKFeTIzHLBfRFwPSgD3Sivnvxl471vUbGDS9RVNO1vR/FmnWV2+mzv5NxHJlhtJw2COCpz0/LpdY+LN9YeHvGOoppls76Hrq6TGhdsSoXRd59D854HpQB6/RXiXjT4r+JtHvvGkml6NpE+l+Fp7Zbl7i5kWaVJQpwihcZyepPTsaT4l/F/VfC2pX76TbaTqNjYRwS3NqI7p7iNZAp/eSIhhi+9wGbn8QKAPbqK8T03xh4qj+LPjMSPZS+GtMs7a9lt5JX8yGAxM+YlC4MhxyCQM9DS/Dr4t694o8RaLDdaDGNJ1dZGWS1t7vNjhSyebLJGscgbGMocZ/DIB7XRXnvxW8Zan4ZuNKtNBbS5b+8WVhbXMF1cTSbduPLjt0ZscnLHAGB1zxy2nfFzXde0z4etoGjaaNR8VJfgpe3LpFA9twTuVSSDhjjGegz3oA9rorxLTPi5r2saV4WstO0jTk8Ua1fXlkwuJn+yRfZRmR8j5jkEYH159cm/wDHWt+Ib3w0t4I9PurDx2dEuUsJ38udYk+bOcEqSx4I7CgD6Dorwm3+NWs3/iRhpmgC50RNVOnPHHbXT3OwNtafzBH5IAPOwtnH517tQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUU2WRYkLucKKTdtWG46qmrafa6vpV7puoRedZXkL288e4rvjdSrDIIIyCeQQarvq8IbanzVE+sqhwVNcrxtBfaNlh6j6GXP8ADzwvPDoEb6Xt/sHaNNeO4lSS3AxgB1YMw4HDEg96o6P8KPB2j31nd2GmSpLZXDXVopvZ2jt3bOdkZfaoOTxjH5CuiXXbcff4rUt5knhSWM5RuhrWlXp1fgdyJ05Q+JHEW3wl8G2+pRXsWlyrJDfLqUEQvJxFDcKdwdIw+0c8kYwfTHFW7v4beFbrRrjS5NMItZr5tTO24lDpdN1lR925G+hA9q7CitiDjbP4aeFLXSotPTTGeBL5NTLyXMrSPcp92R5C25iPQkj2qpq3wi8FatrN9qeoaQ8lzeyLNOFu5kR5FIIfYrgbuOuPX1Oe9ooA5fUPAXhrUIvEEd5pvmJr7RtqQ8+UeeY8bOjfLjA+7j3rN1n4UeDtav7671DTJXe+jSO6jjvZ4o5ggAQsqOASABzXdUUAcpcfD/w7N4oi8QG0mj1NI0hdo7mRUmRBhVkQNtcAf3ge3oKq6F8MPC2harb32l2l3CbZ2kt7f7dO1vCzAglYi+wdT278V2tFAHNeKPBGheJ9SsNQ1a1la9sQywzwXMkDhW+8hKMCVPof6nMWj/D7wxo3/CPf2bpnk/2B9o/s3/SJW8jz8+b1Y7t2T97OO2K6qigDzHxn8K7G+8OWmmeGrPS7cQXz32L83Dje+S5WSOVZEJODw2OMYp3w++EumeHdCtrbWWTUr6HV31xJY98McNywCjYobJUKoGGJz1NemUUAcRdfC3wpcazPqRsrmKW4n+03EMF7PFBNLnO94lcKTnk8c988129U72/itDtc/NjOKpf2xuBKrxXNUxdKm+WT1NY0ZyV0jZorB/tzB+ZantNbgnuEhJw7HA+tTDHUJuylqVLD1Iq7Rr0UUV1mAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFYXjWV4PD00qHBWSLP0Mij+tbtc98QP+RSvvYxn/yItY4hXpSXkzSj/Ej6ox7A72BqW8GGqDRjmND7VYvTlq+St+7PZ+2ZN+cR5rp/AM5n8OR7iSUlkX/x4n+tcrqnEBrofhoc+HX/AOviT+lehk/8V+hjjv4XzOrooor6M8gKKKKACiiigAooooAKKKKACiiigDh/EkrL4okiJ+U28bgfiw/pVm3X9waz/Fhx41jHrZJ/6G9aUBxb18viV/tMz2IP9zEoS/eNY8sxh1bT2BOBdRE49N4rYl+8a57UT/xMrMf9PEf/AKEK46P8Vep0v4T12iiivtD54KKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsDx6M+EtQz/dX/wBDWt+ud+IEnl+Er71Yxp+bqKyr/wAOXozSj/Ej6ow9FP7mP/dFWrvrVbRxiJPpVm7618j/AMuz2n8Zj6qf9HNdB8MwR4dkz3uZMfpXP6tzAa6L4bDHhxv+viT+Yr0Mo/iv0MMb/C+Z1VFFFfRnkBRRRQAUUUUAFFFFABRRRQAUUUUAef8Ai/jxtbn/AKcl/wDQ3rRgP7is3xU3meNlH9yzQf8AjzH+taMHENfMYp/7TM9in/BiVJfvGuc1MFtTswDgmePn/gQro5fvGuevVJ1Wy/6+I/8A0MVx0f4iOl/CeuUUUV9mfPBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVynxJf8A4kVvF/z2uo0/LLf+y11dcN4tuRqOv21lFzHZZklPbzGHA/Af+hVyY6oqdCTfodGFjzVV5DtPTYi/SnXXWpol2Riq9wcmvl5LlhY9VO8rmbqIzAx9q3vhs+7w/KP7tzIP5H+tYl8M27fStH4Xyf6BqUB6pdb/AMGVf8DXdlDtWt5GWNX7o7WiiivpTxwooooAKKKKACiiigAooooAKKKrajeRafYz3dwcRQqWPv7D3PSk3ZXY0ruyOC1HFx411R1ORGI4wfogJ/U1roMRVkaHHJK013cKBPcyNM4HYk5x+FbEhwpFfKVJqdSVTuz2rcsVDsUZOprA1Z/JvLWTIAWeNufZhW+/Wub8VK32ZmXggZBrlpO00ze11Y9gopkMiyxJInKuoYfQ0+vtj50KKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAKOuaimlaVc3jgHylyq/3mPCj8TiuI0K3k2mW4O+4mYySN6seTV3x9ObnVdL00H92ubmQevZf/ZqsWEWFzjivAzKq6lZUlsj08ND2dLn6skl+UCqU3Jq5P8x9qqMMmvMrbnVT2K8q7o2B9KPhzIYtc1a3zw6JIB9CR/UVYMe6NvpWZ4UfyPHCLnHnQun1xhv/AGWujL3yV4snEe9Skj0uiiivqjxAooooAKKKKACiiigAooooAK4rxveG71C20iJsxpie4A/8cX+Z/Ku0YhQSTgDkmvMNDc6hc3eoycvdTM4J7L0UfgMCvNzOs6dLlW8jswVPmnzPodBZxhYximzHBNWgvlxCqsw614U48sUjui7yuVGHNZPiGLfYyfStoLzVTWov9Db6Vzxi9zfm6HW+Erj7T4Y0yTv9nRT9VGD+orXrl/hvKZPC0MZ/5YyyR/8AjxP9a6ivsqMuanF+R4VVcs5LzCiiitTMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA851xjL49u93SKCNB+Wf610FrtEIFc9rn7vx1e543xRsP++cf0q8LwRpy1fL16nJiZtnsxhzUo27GjMAFIHWqhAzisy61dEBy4rNGuiSUpCrzP/djUsf0rCb53ojSMGlqdMxCxkVhaCDJ4+sNnRFkZvpsI/mRTJLzVJF/daRqJB7/AGd/8K3PAmi3kF9danqcJgkdPKijb7wXOST6dB+tdWDoVJVotrRGVacYU5a7nbUUUV9KeOFFFFABRRRQAUUUUAFFFFAGf4hlaDQNSlT78dtKw+oUmuG8JIE063B7LXc+IYjNoGpxKMs9tKoHuUNef+HJwNNhbP8ADXh5u7Sgz0sCrwkjrmKkCqc+Cazp9SWMffFZN1rqB9qvljwAOSa86dXnVkjphSaOiXaTmqWsyD7M30rOt59WnGbfSr1wejGIqD+JxSXGleI7/wDdDTjEG4LySKAvueaI0KstFF/cVzQT1kjpvhkjDw0zsOJLiRl9xkD+YNdZVLRNPTS9KtbKM7hCgUtjG49SfxOTV2vqaMOSnGL6I8arLnm5IKKKK0MwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDjvGnh69vr631HSfLa4RPKkjZtu5c5BB6Z5PWsiHwrrl1zdy21nGOp3b2H4Dj9a3dT8Uzfb5rPR7VZmhYpLPKSEVh1AA5OO/Ss2ayvdUO7Vrppk6+Svyxj/gI6/jmvExTwvtHKzlLyPSousoJNpL8SvDF4X0twrNLrV4OoUeYufpwn5k1oJr2olBHpmlW1nEOgkOf/HVxj86jFpDbALEqr9BVmCVUwMCuT67NPlhaK8jZ0YtXleXqQvqniFF3eZZEjnaYWwf/AB6uj8O6p/a+mLcGPy5QxjkTOQrA849u/wCNY8sgdDU3gNcabeHHDXbkfko/pXbgK9SVXklK6sc+Ipx9nzJWZ0tFFFeyeeFFFFABRRRQAUUUUAFFFFACEBgQQCD1Brzl/BWr2tzJFptxatZliUMrMrIPQgA16PRWFfD066SmtjWlWlSvynE2HgRS4fVr6Sf/AKZQjYv4nqf0q/fajo/hnFtYWaPfMBiCBRvI7F27D3PP1qLxH4im+1NpmiFWuhxNcYysHsPVv5fpWbp1hFZhiSXmc7nkc5Z27kmvOrV6WF9yglfudcITq+9VenYjl1PxPcnzhdW1mOohjiDD6Etk/liuo8K6w2saezXCLHeQOYp0XoGHcexBz/8AqrMwrDiquiSf2f4sCniK/j8s+nmJkr+m79KywmKqe1SnK6ZValFwfKrNHb0UUV7p5oUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUU2VxHE7t91QSaAOC8LRhopnbljNIx+u41q3E2MqtY/hWQjR4Hf70i7z9TzVx23Ma+SnUstOp7fJeWojnceaSig1zM1Qu87DWr4EB/sHzD/y0nlb/AMfI/pWLIcRsfQGt/wADrt8MWfH3i7fm7H+teplGtVvyOTG6U/mbtFFFfRHlBRRRQAUUUUAFFFFABRRRQAVx/iPX5bm4fStEf99924ul5EQ7qp7t/L69N/xGZ10DUWtCRcC3kKFeudp6e9cd4XihTSoDABtK547mvOx+IlTShHr1OvDUoyvOXQsWFhDp9uEjHPcnqT605iWJPaprhu1Qk8Yr56b1PSjfdixuUaqWvlxbJdW/+vtnWZPcqc4/GrRpj4dCpGQRilGbjsNxvqdxaXEd1aw3EDbopUEiH1BGRUtc14AmLaI9qTk2k7wj/d+8v6Nj8K6Wvr6U/aQUu54lSPJJxCiiitCAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKx9Z1+10xvJAa4vD0gj5I92P8I+v61M5xguaTsiowc3aKNiq140LwyW8syI0qlMFgDyK467utV1Q/v52toT/yxtyV/Nup/Qe1ZsmgWmCWgQk9SeTXl1M1gnaEbo7IYJ/alYn0Dcmk28b43RgxnHTKnH9KvYJ5rH0EtBpsIXmMZG30GT0rei2ugZeQa8Oyk3Y9B6EODQRVvyxiopF203TshKdzK1WVkg8qBS9xMfLjQdWY13WkWn2DSrS0zuMMSxlh3IHJrnvCVslzqd7fSAM0DC3iz/CdoZj9TuFdbXu5Xh/Z0/aPdnn4yrzS5F0CiiivUOIKKKKACiiigAooqtqF9bafbNPeTLFEO57n0A6k+wpNpK7Gk27Is0VxV7r+o6gSunobO3PR2UGVvw6L+prJm0yeU757m6kf+88zE/zrzauaUoO0Vc7IYKTXvOx6WRkYPSvP9OiGmapqGmdEik3xf7jcgfhnH4VTs9Q1XRZQ0VxJdWwPzQTsW4/2SeQf09qseIbyG4vNM1yyJNtOv2WckYMbg5UN6Hlh+XrWGIrwxVLmhvE1pUZUZ2ezL1wCGFRU8vvAo2Z6V4r1d0di0WozqaCNoJ9KnjhPeknjwpHrT5Ha7DmRd+HkLDR7i6b/AJe7l5F/3RhR/wCgk/jXUVzngKcPoAtz/rLSV4W/PcP0YV0dfWYaypRt2PGr39pK4UUUVuZBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQByWv6zcT3s2n6dJ5CQ4WadfvFiM7V9ODyev0xVXTrCG3X5VwScljyWPqT3puv6VfWGp3N7ZwPdWlw3mMkYy8bYGeO4+lZ9trsDuYy22QcFHGCPwNfNY2VX2zdVadOx7FCMfZr2fzOhYIo4qB8HnPFV0uw44oMu7tXLKrF7FqDRlaL/x6Fe6SyIR9GIrUi3RHdH36r2NZdgfK1G/tzx+881R6hhn+ea14j61ktJGkti5DKsi8cMOoPUVDdGvKdMY/8NEa+NxGNEhIwenzrXd6vqMlpZSsw3sflTHUseldNZ2tHul+JjTXM7o6rwTHjSJZv+e9xJJ+R2D9FroKzvDzWp0a0WwmWaCOMIHHcgc59D7Vo19NRioU4xXRHlVXzTbCiiitTMKKKKACiiigDG8RaydNWKG3RZLyfPlq33VA6s3sMjjvXMxWkl3dfab+Zrm4/vv0X2UdAK1fGOm3klzbahYxGfykaOSJfvFScgr6/Sufttbg3GNm8uUHBRxtYH0INfP5lOr7Tll8B6uEhH2d47nQrEiLximsAeBVGO9DjjBqR7qOKN5JiFRAWJ9BXD7SL0RrySKmp+VBG0szqiDua52K+TzJ4rJvluVKSQTIQkw9vRh1B61Kzy6vdfaJwREv+qiPRR6n3pupwBEjYABldSD+IrWFJwfMnqdappx5ZGr4euftFkizHE8X7t1PqODW2iccVy+oxHTr1pG4huUKk+kgHH5j+Vcn+zdPInwm0jf86mSfr1/1z1nCK5XN91+N/wDI5pv3kl1PXEHFQ3SjbUkUiyLlDn+lR3J+WtJ25TOPxDPBr+Vreq2+PlkSOYfXlT/7LXYVxXhbc/i28I+7HaKrfUtkfyNdrXuZe26EbnBi1+9YUUUV2nMFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABVTUNOs9QTZe20U4HQuuSPoeo/CrdFJpNWY02ndHnmt6XJ4fnWWNnk0yQ4BY5MJ9CfT0P4fXM1DVpo7lLawSN5Sm9nkyVUHpwOpr1G5t4rq3kguEEkUilWU9CDXkc2nPo/iO9tJJDKqhDG56lMcZ9+1eHjMDGE/aRWnbzPYwVf2vuT3RK17NPcQtKscGox/KhziO4U/w5PRvTP8AXjRXWIIvluxJayd1mQr+R6H8Kr3FolxFtdA6nqCKjij1C2Xba30yoOiuA4H581xyoqXkdbgn8JwGnXyyftD6pJaJJdeboKYEQzkiVOvoPc13d9NJFcAzIk+oY/d26nKQA92Pr/ketcFDBd3Hx6ufPu5vOfw8MyRfuyV89fl47V6Va6dFbJhFC85PqT6mt6mHT5XvojKlHlvzdzMsb7UtBuzfpMroxBnt1TCOvt7+hr16GVJoY5Y2DI6hlI7g9K8p13aLSTthTXo3hhWXw1pKvneLSEHPrsFejgJOzh0Ry5jCNozS1Zp0UUV6J5QUUUUAFFFFABVS/wBOstQTbe2sM46DegJH0PUVbopNJqzGm1qjhde8PvpCm80re9ovMsBJYoP7ynqR6iuc1u9We2tYI2BWdtzY7quD/MivXa8m8b6KdG1u2uYBjTrhmCqOkTnBK/Q4JH414+MwMYyVWC9T1cDieeShPfoWdPXbGOKbqluZreRV4LDg+hotJBgYPFcd4l8evNfv4f8ABVoNZ17pIyn/AEe0HdpH6cegPXjrwcqMHVVkd85cjuze8b+MNB0zwVLc+IbxYJJEMaQpzK8w7IvU84OemCM4rmf2cbiNvhTpMIOJEafIPvM/NQ6V8Pn0uWbX9cu11fxJ5bMZ5kzFFwfljX+HHY8H0x0pPghJp/8AwqTQIrkz291D9oCXCIeQbiQ44zkc9DU16MfYuMe6/JnIoSVRO2ln+h6vvKHchww/WmXmoRxwCRsl2+VY1GWZvQDuc1hpJcTq4t9Xt5FXriH5x+G6ul+HWnwtbXF/cAz3QnZI5pOSFAH3R0HOelcuFoSrz9m2VXkqUedo1/CWlS6daTT3mBe3b+ZKBzsAGFX8B+pNb1FFfT04KnFRjsjxZyc5OTCiiirJCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK4L4gWog1WzviP3U6fZ3b0YZK/mC35V3tUdb0yDWNNms7kHY44YdUYdGHuDWVan7SDib4er7KopHnkMhjUbjlfWrSzKR1BFZt1DfaFL5GrRkR5wlyozHIPr2PsakR4nXKHAPdTXjPmg7M95cs1zLVHHb1T4+7h/F4a/8Abr/61d49wAMkivM7ggfHi3G9sHw+Rn/tu1dxcXNvCQGYvIThV6kn0ArStKT5bdkTTitfUj1FX1B4rWIHdcSLEMe5xXsESLFEkaDCqAoHsK4HRLNdHQ694h/0cIu23gPLgnuR/eI6Dtzn22tD8Z6dq96tqsdxbTP/AKsTAAP7Agnn2rswkVSVpPVnn41yrfArxidNRRRXceYFFFFABRRRQAUUUUAFcp8TrjS7Pwde3WtXtvYwQYkSaZsASDoo7knkYGTzWR8Q/ifp/hi8j0XSbaXXvFlxxb6TZ/M4OM7pSPuL355xzjGSMPw58MdR8Q6vB4l+LN1Fqupxnfa6RF/x42Oe23pI3qTkf73BpSSkrMqMnCSkt0eXW914g+IKeXYNcaH4VJw9x0ubpe4Ufwr7/wA+RXpnhTRtL8N6YljotslvAOSRyzn+8x6k/Wuv8VeGJGnbUdGQGY8zWw4En+0vYN7dD9evKQ3ETSNHIHhnQ4dGBVlPuDXkYiM6b5VpH+vxPeoVIVo827NO/kDafdZGf3TfyNcH8Cokf4T6GW/6b/8Ao+SurvpALC5xL/yzbqPY1w3wQlMnw00K1t1lnuG8/bDEMn/XyfkPeknz0mrX1X6lNcs16P8AQ6/VYVd0S0TddswWLb1LE4Ar1rRrCPTNMt7OI5Ea4Lf3mPJP4nNYXhbwz9hlF9qO173+BF5WEH+be/5epva74n03RZkhu5HedufLiXcyj1PpXXhaKoR557nnYus8RJU6etjcoqppeo2uq2i3NjKJYScZwQQfQg8g1brtTvqjz2mnZhRRRTEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBkeK9VfRdBub6GNZJY9qordMswUE+3NcHa+MvEMZEkqWk8bc7DGVwPYg/zzXoev6cNW0a7sWO0zIQrf3WHKn8CBXlOjzHDW12uyeFjHIh6qwOCK8/GVKlNpxeh6mAp0qkGpK7Ost/iBYTIYdX0+eAMMNgCWMj36H9KhNr4J1I77W/is3bnEc5g/8cfgflWZPYQzJkKDWFf6MhJ2rWH1uW1RJnUsHBO9OTic/qljoFh+0Bpsc+rvNpj6C7PP56sQ4mbCZQenOOtd3/wlmgaOSPDGktcXB4+0zAgfm2WP04rx6/0zy/i/pMKoBu02RsY/2mr0qz0kAguKurieRJwXQIYZSvzyb1Flmv8AX7xbnU5jIR91AMIg9AP8motdtntYVlt2Mc0ZDow6qw5BrorOBYxwAMVla+PMyg71xOUm+eT1OqNl7kVoek+ENdh8Q6FBexkCXGydB/BIOo/qPYitqvGfAV2+h+KIINxEF8RDIvbd/C31zx+NezV7dCr7WFzwMXQ9jUstmFFFFbHMFFFFAEF9d29hZzXd9PFb20Kl5JZXCoijqSTwBXjl7438SfEy8l0r4XK2naEjGK78T3MZx/tLbIeWb/a/9B4Y9B4u+G1z428Xm48V61LceErcI9roduDEkkgHzNOwOXGeg9+3O5nx5D6D8E9abw8/9lvYJbvam1Hl+TsnjICgYwMDH40Ab3w8+H2h+BbORNLiee/n+a61G5bzLi5bqSzntnsOPx5qHxf4uu9K1ZdP021iklCB3eXJHOcAAEenXNc58APiPq/jrw8n/CQ6Pd217EpH29YCLa62naSD0V89V/Eeg1PiZZNbX9lrEa5iI+zzH05yp/Uj8qwxDlGm3Dc6sHGEqqjPYfZ/ECaPA1TS2wOr2z5/8db/ABq/NrXhHxCoS+kgEg4BuFMTr9H4/Q1zdvHDcxg8c1UvtHiYE7BXnRxtS3vK6PUlgqTfu3i/I6bUfC/h8aTezQ3UsiLA7BRd5X7p7g5/WuO/Z21zRNE+Cfh9r67tobpxO0irzK3+kSYyBz0xWDruiqmn3j7B8sLnp/smud+EOmed4D0mQIPmWQ5x/wBNGreOKjGm5RjbX/MzlgnKajObaPYNX+Ist1ug0G2eMHj7TOOf+Ap/U/lWDZ2Ek7SXFy7yzSHczuckn1NTWGmJFywy1bWwR25x6Vx1K0671eh1U6VOgrQRleD9aGg+KVtbmTZY32IyT0WT+E+3p+I9K9frwPWLMXkrZGVFepfDjV5NV8PhLly9zaP5DuerAAFSffB/MGu3A1rr2bODMaH/AC9XzOqooor0DygooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvOPiXozWkw16yX5chLtR+Qf+QP4V6PUN5bRXlpNbXC7oZkMbr6gjBrOrTVSLizahWdGamjy3TbsTQqQeoqdzlqwNISSxu7ixmOZLaVoifXacZ/SuhUBhXz8k0+U+j03PONVx/wvTROg/4lMv8A6E1ei7gBgGvOtfXZ8cPDZ/vadOv5bjXoIrSvJpQ9P1ZFNLX1LCPgVQvgCd7dqtZ4rJ1i4wuBWSd9C0tRPDFsdS8a6ai/dgY3DkdgvI/8e2j8a9prgPhRpey2u9WlX5rhvKiJ/uKeT+Lf+g139e5hIclNeZ4ePqc9Wy6aBRRRXScQUUUUAFVNV06z1awlsdSt47m0lx5kMgyrgEEAjuMgcVbooA4bWT/whfiOTXUAXw7qTKmqKOBazABUuvZCAEk9MI3QMa6/UrKDU9Pns7pd8EybWH9R796nnhjuIZIZ40lhkUo6OoZWUjBBB6g1wdq158PGNvc/aL7wcW/cTqpkl0pf+ecgHLwD+FhkoOGyo3AGm07o5NY7jQ9Zm0u9JLxnKP2kQ9GFbol3xjnNWviZBb3+j6dr+nSxXEcbAefC4ZJIn6EMOCM4x9TWPpsnmQrz2rwsVT9lUstmfRYer7ampvci17H9h6iSBkW0n/oJrmfguoHwy0I8f6t//RjV1PiFc6DqR/6dpP8A0E1y3weGPhpoX/XFv/Q2qLtUX6r8mXa9Ren+R24bmnSvmPFRLRI4VSTWKky2jIv9sKMfWuv+EdqyaLe3bdLm4Oz/AHVGM/nn8q4HUnlurhYIAWllYRoo7sTgCva9E0+PStItLGL7sEYQn+8e5/E5NejgKfvORw5jU5aah3L1FFFeqeIFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAePeKYxbePb9V4EuyQD6qM/rmtKHoKq/EWMxeN4XxxJbI2fxYf0qzbnKrXhYhWqs+jou9GL8jz7xQmPjT4TPrZXQ/8dNd6K4nxcAvxg8GHu1reD/xwGu2HWoxK+D0/Vl0evr/kJIcKaw7uJ729htoOZZnEa/UnFa902IzSeA4PtnjCF2GVt0eX8cbR/wChVOHhzzSKqT9nBy7HqenWkVhY29pbjEUKBF/CrFFFfRHzDd3dhRRRQIKKKKAMTxRrN7okUFxbaLd6paZb7SbR082FQBhgjEbx1yAcjHANcj4r+JsafC6+8YeCYYNZitiVkE7tAIcfeLKRuJU7Rt4znrXYeI/DOleJBbJrcD3dtAxYWzSsIZCcf6yMHbJjHAYEDJqr4q8G6V4k8MjQLkT2mlZAMFjJ5AZQCNhC8bec46ZA9KAOG+I3xE8R+HrXw7d6Xpls2n3ti13qF9PaXM8NnhUI3eSCVB3Hk+ld34cutV1CW2v5biwn0i5so5o3tSSrsyoQy5GdpzIeT0MfAO7ONqfwx0bU9HstMvb/AF57O2ha2ZF1OVPtERYny5dpG9RnAz0HFdnYWkFhY29nZRJDa28axRRIMKiKMKo9gABQBwHjfwPFBomr3nhe7fR5Xieee1jQPaXLKN2WhPCsSPvoVJPXNeEeNvG2v+GPC0FyLeC2vFuUEU0UyyxTjB3KyNtcAjPQHBA5719aanF52m3cXXfE6/mCK8N8O2lrcmKS5toJpYs+W8kYZkz1wT06VwYxqMoykrnqYGLnTnGLsY3g7x6vjXwfqbTaZeWN5HaSF90LGB/lPKSYx+B5+uM1ofCMY+G2g/8AXAn/AMeNdXrYJ8P6ntBJ+yy4A7/Ia5r4WRtF8O9BSRGRxbDKsMEcmuGrZ0m4q2q/U76SamlJ30OrWq14+EPNWB0rL1WTahrkjudBqfDvTBfeIJLyUZisxlfd2yB+Qyfyr1SuT+GVqIPDQnI+e5leQ/QHaP8A0H9a6yvocNDkppHz+Nqc9Z+WgUUUVucgUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5f8AFNdviLTH/vQlfyb/AOvSWRyi1H8btQtdIOnajfyiG1gilZ3IJwAU7DqeRXMaJ450u7gPkx3nnxTLBNbyQ+XLEzLuXKsRnI6AZJ7A142Kg3VbSPew04qhFN6/8E6jUdNsri/tb+a2je8tVZYZiPmjDDDY+ooFXLr7grmbPxPpF34luNBtbtZdUt4TPNEgJCKGCkE9M5Ycdea5aycnp0OmDUVqX79sRNWp8KIt+panP/cjRAfqSf8A2UV57F470fV4LltNF9MkKO5f7I6IdpwQHYBc5969H+C8q3WlX94isqyyKBuxnge2QevUEg9q6sFTcai5kc+MqRdCXK/6uejUUUV7J4AUUUUAFFFFABRRRQAUUUUAB5GDXhfh9fKuJY+m1iv5GvdK8O035NUvF9JnH/jxrz8w+FHq5ZvJeh1Vv0NVrj75qxanIqvcffrzZ/Aj0YfERk4FYWttgVuP9w1zeut97HYVlT3Nkex+EoRb+GdMjHX7OjH6kZP6mtaoLGPybKCIDASNVx9BU9fTRVkkfKzfNJsKKKKZIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB4/+0doR8SaDaaUkqwyXCShHYZAZWiYZ9srXO/D7w/qOn6zr2s61JafbtWaDdFaszRxrFHsX5mAJJySeK9C+KqFptGcDIVpQfx2f4Vk2J+UV4+Mm1Ucen/Df5HuYOnF0Yy6/8F/5sgsNFg0uW5mhutRnac5Zbq9lnVeSflDsQvXtiuRGha9/wtL/AISLZpf9nfYP7N2faJPN2eb5m/Hl43Z4xnHvXoE7ZSqtclSo1JvudUaaaS7Hk+geDNS0XxE2o3C6XYWwt2hNtpskzJOxbO9xJ0I9s9ete7fCcf8AEkvf+vs/+gJXG6t92uz+FII0e9BGM3Of/HF/wrtwc3Opd9jlxlNU8O1HudtRRRXrHhhRRRQAUUUUAFFFFABRRRQAV4lbrt1nUcdrmQf+Pmvba8XC7Ne1RSOl3L/6Ga8/MPgR6mWfFI3rX7tQ3H36ktzhRUc5y1eXJ+4enFe8QyfcNcxqvzOwNdNJ9w1zWpjMj4GTippbmp72v3RS0DpRX0x8mFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGbrelQ6rAiTDlCSp9K55/DM0WfKIYflW1r/ijRfD95plrrWoRWc+pS+RaLJn96/Hy5xgfeHXHWp9L13TNVivZbC8jljsrqSzuG5URzRnDoc46H8Kwq4eFTWR0UsTUpK0XocnLo94DgxN+HNJHol0x/1bD68V3+B6VG8kSEh3RSFLkEgYUdT9Kw+oQvqdH9o1LbHGr4Ta4I88hR6dTXUaRpsOmWxigGATk+5q008KNGGljUyfcBYDd9PWs7Sdf0/VdT1awspWe60uVYLpShAR2QOACevBHSumnRhT+FHNVxE6ukmatFFFamAUUUUAFFFFABRRRQAUUUUAFclq3hZZbya5tiA0rF2B9Tya17TxJo934ivNBttRt5dYs4xLcWit88anbgkf8AAl/MU/w3runeJdEtdX0S4+06ddKWhl2Mm4AkH5WAI5B6ioqU41FaRpSqypO8Tln0a7hH+rY/TmqzaZdM3+pf/vk16KQD1pNq+grjlgIPZnZHMZrdHAR6HdSDHlkfXirFp4MDTeZcMMenWu32j0pa0p4OENSJ4+rLbQAMACis067pw8SLoBuP+Js1ob4QbG5hDhC+7G37xAxnPtWlXWcQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAebfFj4fv471/wAKrcRo2kWn20Xjb8PH5tuUjdB3YPtI9MA1wmifC3xVaeH9PXXrfTvEE9tr15qV5p1zOBDqKzRbVkYlSNytlwGHc19CUUAeJ+FvhNewan4OXxQttqVnpGkz28p85iFma4EkSqDgsqL8oJ/ujism0+C9zLrtjd6lplhKj6lq01+TJkzQTKxtlb+8A+Dt7HmvoKigD5l8S/CPxnqnhPRNMez0u5mstFjs0lM0SywXCSMeZHidym0jAjZOevGK9h+H3hzUtF8R+L77Ugnl6pdQTQMsm4sEgRGLeh3A13NFABRRRQAUUUUAFFFFABRRRQAU1yVRiqlyASFHU+3NOooA+ffCvw78caN410Txjcppsl/d6hcPq9rCdsqQXHUNKXKyLHsQqqgfjWR4V+FXiuy8PpbJo0OkX1v4f1GwuJ0vkdtTmnQiBCFOFCHnLHr0r6ZooA+ebz4S+ILaG9h8PQrZxX3h2yivk+2kC7vY5w0yM2SRujBXcOOcdCaup8NdduNOs7b+z107SZPFMGo/2RBe4FlZCFkkAdSPvMc7EPfjvXvNFAHgfjL4T6jf65r1xptiRDHJo66MwvSjQxwDbPtO7KkJgZPJ7Gq+ofDHxBHot1otpo9pPoZ8S3V3FbGWFpIrR4lEZi84PGvz78hlLDOQOa+hKKAPGfhF4J8S6Dr/AIcvfEEIAsvDMulzubhZCJjeCRF4JJHlgc9BjFezUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Measurement of the carpal bone angles helps to indentify carpal instability. The normal angle is depicted in the left image of each group. The drawing on the right depicts abnormal angles when there is a dorsal intercalation scaphoid pattern of carpal instability. A scapholunate angle of &gt;80&deg; indicates scapholunate dissociation or volarly displaced scaphoid fracture. The capitolunate angle is usually less than 15&deg;. The radiolunate angle is normally &lt;15&deg;.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_5_23637=[""].join("\n");
var outline_f23_5_23637=null;
var title_f23_5_23638="Acquired cystic disease of the kidney in adults";
var content_f23_5_23638=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acquired cystic disease of the kidney in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/5/23638/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/5/23638/contributors\">",
"     Arlene B Chapman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/5/23638/contributors\">",
"     Frederic F Rahbari-Oskoui, MD, MSCR",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/5/23638/contributors\">",
"     William M Bennett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/5/23638/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/5/23638/contributors\">",
"     Ronald D Perrone, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/5/23638/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/5/23638/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/5/23638/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic renal failure (particularly patients on maintenance hemodialysis or peritoneal dialysis) is frequently associated with the development of multiple and bilateral renal cysts which are usually less than 0.5 cm in diameter but can be as large as 2 to 3 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The diagnosis of acquired cystic disease is established by ultrasonography, CT scanning or MR, although each procedure can have false negative results. CT- and MR-based imaging offer increased sensitivity in detecting small cysts over ultrasonography [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/5\">",
"     5",
"    </a>",
"    ]. A diagnosis requires involvement of both kidneys with four or more cysts being present. Acquired cystic disease can be easily distinguished from autosomal dominant polycystic kidney disease (ADPKD), as the kidneys are small to normal in size as opposed to extremely large kidneys found in all ADPKD individuals with renal insufficiency.",
"   </p>",
"   <p>",
"    Often, acquired cystic disease can be detected prior to end stage renal disease, and has been reported in patients with creatinine clearances as high as 70",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    However, the majority of cases occur in patients with creatinine clearances below 50",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of acquired cystic disease increases progressively with duration of dialysis. In one study of 130 patients with advanced or end-stage renal disease, the incidence of multiple cysts was noted to be 7 percent in those with chronic renal failure and 22 percent in those on maintenance dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/3\">",
"     3",
"    </a>",
"    ]. An additional 30 to 50 percent had one to three renal cysts, potentially representing an early form of the disease. The duration of dialysis was 15 months in patients with no cysts, 28 months in those with one to three cysts, and 49 months in those with acquired cystic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/3\">",
"     3",
"    </a>",
"    ]. Fifty to 80 percent of patients are affected after 10 or more years on dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. Men and African Americans have been reported to be at much higher risk than women or Caucasians [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. However, additional studies have estimated a 31 percent prevalence of acquired cystic disease in black African dialysis patients, similar to reports in other ethnic groups [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations suggest that the duration of chronic kidney disease is a major risk factor for renal cyst development. In comparison, the etiology of the underlying renal disease does not appear to associate with the development of acquired cystic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of acquired cystic disease is incompletely understood. Nephron loss of any cause leads to compensatory hypertrophy in the remaining normal nephrons [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=see_link\">",
"     \"Secondary factors and progression of chronic kidney disease\"",
"    </a>",
"    .) The cysts are limited to the kidney (in comparison to polycystic kidney disease), suggesting that local intrarenal events are of primary importance [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/1\">",
"     1",
"    </a>",
"    ]. The cyst fluid, which is thought to derive from ultrafiltrate secreted into the cyst, typically has a composition similar to that in the plasma; this finding plus the presence of a brush border on the luminal membrane suggests that the cysts arise primarily from proliferation of proximal tubular epithelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compensatory renal hypertrophy is driven by activation of proto-oncogenes and release of growth factors (such as epidermal and hepatocyte growth factors) which, over a prolonged period of time, can lead to tubular hyperplasia and cyst formation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In addition, one of these proto-oncogenes has been implicated in pathogenesis of renal cell carcinoma in acquired cystic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cysts may stabilize or regress following successful renal transplantation, a setting in which the level of growth factors is reduced due to the restoration of normal renal function. As a result, the outcome of acquired cystic disease is generally better than in patients maintained on chronic dialysis. In one prospective study, the incidence of cystic disease was lower, the native kidneys were smaller and had lower cyst grades in transplant recipients when compared to patients treated with maintenance hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/12\">",
"     12",
"    </a>",
"    ]. This benefit was limited to patients not receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . Those treated with cyclosporine had an incidence of cystic disease similar to the dialyzed patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with acquired cystic disease are asymptomatic. In one review, for example, only 14 percent of patients developed symptoms, with hematuria being most common, followed by lumbar pain and urinary tract infection [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/13\">",
"     13",
"    </a>",
"    ]. However, even in asymptomatic patients, longitudinal radiologic studies demonstrate a progressive increase in the number and size of cysts which can associate with both bleeding and renal cell carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/14\">",
"     14",
"    </a>",
"    ]. Rupture of a cystic blood vessel occurs in up to 50 percent of cases at some time. Although most episodes are asymptomatic, local pain and gross hematuria can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/14\">",
"     14",
"    </a>",
"    ]. Less often, the hemorrhage may extend into the perirenal area and be severe enough to induce hypotension or death [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/2,7,15-17\">",
"     2,7,15-17",
"    </a>",
"    ]. This complication is most likely to occur in patients with very large cysts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Renal cell carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence in renal cell carcinoma as a complication of acquired cystic disease varies in different reports [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/7,13,14,18\">",
"     7,13,14,18",
"    </a>",
"    ]. Two prospective studies found an incidence of 4 percent (2 of 57) and 7 percent (2 of 30) over a seven to 10 year period [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/7,14\">",
"     7,14",
"    </a>",
"    ]. A review of published reports estimated an incidence of 0.18 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most reports, however, may misrepresent the true incidence of renal cell carcinoma because they primarily rely upon screening radiography, particularly ultrasonography, for detection. Perhaps a better estimate was provided by a single-center study in which most renal transplant patients undergo ipsilateral native nephrectomy at the time of transplant surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/19\">",
"     19",
"    </a>",
"    ]. Based upon strict pathologic criteria, renal cell carcinoma was found in 4.2 percent of 260 nephrectomies, which may be lower than the true incidence given that only one kidney was removed.",
"   </p>",
"   <p>",
"    The carcinomas are usually limited to the kidney and, in approximately 25 to 50 percent of cases, are multiple and bilateral, a finding that is consistent with the diffuse nature of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/1,2,13,20,21\">",
"     1,2,13,20,21",
"    </a>",
"    ]. Importantly, the bilateral presentation may not influence prognosis. Malignancy generally develops after at least 8 to 10 years of dialysis, although a shorter interval can be seen [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/22\">",
"     22",
"    </a>",
"    ]. Men (male-to-female ratio 7:1) and patients with large cysts and an increased kidney size are at increased risk for malignant transformation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/13,23\">",
"     13,23",
"    </a>",
"    ]. Malignancy associated with acquired cystic disease also can occur after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/4\">",
"     4",
"    </a>",
"    ]. Renal transplant patients with acquired cystic disease should be closely followed for this complication. Recommendations for the surveillance of such patients are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=see_link\">",
"     \"Development of malignancy following solid organ transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been suggested, however, that acquired cystic disease and renal cell carcinoma are two disorders that represent separate diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/24\">",
"     24",
"    </a>",
"    ]. The overall incidence of renal cell carcinoma and distant metastases in all patients with end-stage renal disease is approximately 1 to 2.6 percent and 0.2 to 0.5 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/20,24\">",
"     20,24",
"    </a>",
"    ]. Two large prospective studies showed similar prevalence rates in Japan (1.7 percent) and the United States (1.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Although these values are more than 30 times higher than in the general population, they are not much higher than those reported in autopsy studies in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/13\">",
"     13",
"    </a>",
"    ]. Furthermore, some patients with cancer do not have cystic disease and some develop the malignancy prior to the institution of dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/20,27\">",
"     20,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study assessed the genetic abnormalities in renal cell carcinomas occurring in patients with end-stage renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/28\">",
"     28",
"    </a>",
"    ]. These patients did not have the changes that are frequently seen in patients with sporadic renal cell carcinoma: inactivation of a tumor suppressor gene on the short arm of chromosome 3 or a mutation in the von Hippel-Lindau tumor suppressor gene. Somatic mutations in von Hippel-Lindau have been found in 1.3 percent of renal cell carcinomas in hemodialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/29\">",
"     29",
"    </a>",
"    ]. However, another study of 79 tumor samples from 69 ESRD patients with renal cell carcinoma showed no genomic profile differences between the sporadic versus ESRD cases of clear cell and papillary renal cell carcinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=see_link\">",
"     \"Clinical features, diagnosis, and management of von Hippel-Lindau disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acquired cystic kidney disease presents differently in kidney transplant recipients compared with the general population. A review of 1000 transplant recipients followed for 28 years showed that acquired cystic kidney disease is less common among transplant recipients compared with ESRD patients as a whole (23 versus 80 percent, respectively), but the prevalence of renal cell carcinoma is higher among transplant recipients with acquired cystic kidney disease compared with those without (19 versus 0.5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an attempt at early detection of premalignant or malignant lesions, it has been suggested that yearly screening for acquired cystic disease be performed in patients who have been on dialysis for three to five years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/1,2,23,27\">",
"     1,2,23,27",
"    </a>",
"    ]. The optimal imaging modality for screening is uncertain. Contrast-enhanced CT scanning is more sensitive than ultrasonography in detecting and characterizing cysts [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/3,31\">",
"     3,31",
"    </a>",
"    ] but may not be superior in detecting solid tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/4,31\">",
"     4,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, different CT scanning modalities may be associated with enhanced accuracy. In one study of 630 chronic hemodialysis patients screened for renal cell carcinoma, early contrast-enhanced helical CT scanning was 96 percent sensitive and 95 percent specific for the detection of malignancy (as identified at surgery) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/32\">",
"     32",
"    </a>",
"    ]. By comparison, the sensitivity and specificity of delayed contrast imaging was only 83 and 94 percent, respectively.",
"   </p>",
"   <p>",
"    We generally begin screening with ultrasonography. Once the ultrasonogram becomes positive for cysts, the more sensitive contrast-enhanced CT scan is performed at yearly intervals (particularly in patients with very large cysts) to screen for the possible occurrence of carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/4,14,27,33,34\">",
"     4,14,27,33,34",
"    </a>",
"    ]. An avascular hemorrhagic cyst can usually be distinguished from a malignant lesion by its lack of contrast enhancement and by its resolution over time on sequential studies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/1,14\">",
"     1,14",
"    </a>",
"    ]. In renal transplant recipients with acquired cystic kidney disease, screening may be performed every six months for Bosniak class 1 to 2 and every three months for Bosniak class 3 to 4 cysts. The Bosniak classification of renal cysts is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27704?source=see_link&amp;anchor=H2#H2\">",
"     \"Simple and complex renal cysts in adults\", section on 'Bosniak classification of renal cysts'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, these screening recommendations are not uniformly accepted. Given the low rate of death from metastatic renal cell carcinoma in dialysis patients, some investigators have suggested radiologic studies be performed only for symptoms such as new hematuria or flank pain, or in young patients with risk factors such as long duration of dialysis and large kidneys due to acquired cystic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/24,35\">",
"     24,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A decision analysis has been performed that more precisely determines the benefit of screening [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/17\">",
"     17",
"    </a>",
"    ]. Assuming an incidence of malignancy of 0.9 percent per year, it was estimated that screening could result in a 1.6 year gain in life expectancy over a 25 year period. However, only young patients with a long life span would achieve this benefit. The benefit is likely to be negligible in the more common older patients with significant comorbid diseases. In some non-United States populations, such as Japan, a strategy based on screening may be more appropriate given the increased mean survival of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23638/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management and prognosis of renal carcinoma is presented in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21192?source=see_link\">",
"     \"Prognostic factors in patients with renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a malignant tumor has been removed and the patient is being considered for a renal transplant, a waiting period of one to two years after the surgery seems prudent to ensure non-recurrence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=see_link\">",
"     \"Development of malignancy following solid organ transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33611124\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic kidney disease (CKD) is frequently associated with the development of multiple, bilateral, small renal cysts, particularly among patients with advanced CKD. These cysts can be detected with ultrasonography, computerized tomography (CT), or magnetic resonance imaging (MRI). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A diagnosis of acquired cystic disease of the kidney requires involvement of both kidneys with four or more cysts being present. Two features of acquired cystic disease make it easily distinguishable from autosomal dominant polycystic kidney disease; a family history of polycystic kidney disease will be absent; and the kidneys are small to normal in size with a smooth contour in contrast to the large kidneys and cysts and cystic contour observed in autosomal dominant polycystic disease. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incidence of acquired cystic disease rises progressively with increasing severity and duration of CKD and with increasing time on dialysis. The incidence may also be increased in men and in African Americans. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis of acquired cystic disease is incompletely understood. The cysts are limited to the kidney (in comparison to polycystic kidney disease), suggesting that local intrarenal events are of primary importance. It is possible that nephron loss due to the primary renal disease leads to compensatory hypertrophy in the unaffected nephrons. Over a prolonged period of time, this may lead to tubular hyperplasia and cyst formation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with acquired cystic disease are asymptomatic. When symptoms do occur, the most common is hematuria, followed by lumbar pain and urinary tract infection. Even in asymptomatic patients, cystic disease may be complicated by both bleeding and renal cell carcinoma. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Renal cell carcinomas occur with much greater frequency in patients with acquired cystic disease than they do in the general population. Renal transplant patients with acquired cystic kidney disease represent a high risk group for development of renal cell carcinoma. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Renal cell carcinoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Screening for acquired cystic disease and renal cell carcinoma in patients with advanced CKD is controversial. In patients who have been on dialysis for three or more years without life-limiting comorbidities, we suggest initial screening with ultrasonography. If cysts are detected, we then screen with a yearly contrast-enhanced CT. In renal transplant recipients with acquired cystic disease, screening may be performed every six months for Bosniak class 1 to 2 and every three months for Bosniak class 3 to 4 cysts. Those individuals who screen negative for acquired cystic disease should be rescreened either when symptomatic or after a period of three to five years. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management and prognosis of renal carcinoma is presented in detail separately. If a malignant tumor has been removed and the patient is being considered for a renal transplant, a waiting period seems prudent to ensure non-recurrence. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21192?source=see_link\">",
"       \"Prognostic factors in patients with renal cell carcinoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=see_link\">",
"       \"Development of malignancy following solid organ transplantation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23638/abstract/1\">",
"      Grantham JJ. Acquired cystic kidney disease. Kidney Int 1991; 40:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23638/abstract/2\">",
"      Ishikawa I. Acquired cystic disease: mechanisms and manifestations. Semin Nephrol 1991; 11:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23638/abstract/3\">",
"      Narasimhan N, Golper TA, Wolfson M, et al. Clinical characteristics and diagnostic considerations in acquired renal cystic disease. Kidney Int 1986; 30:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23638/abstract/4\">",
"      Matson MA, Cohen EP. Acquired cystic kidney disease: occurrence, prevalence, and renal cancers. Medicine (Baltimore) 1990; 69:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23638/abstract/5\">",
"      Ferda J, Hora M, Hes O, et al. Computed tomography of renal cell carcinoma in patients with terminal renal impairment. Eur J Radiol 2007; 63:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23638/abstract/6\">",
"      Liu JS, Ishikawa I, Horiguchi T. Incidence of acquired renal cysts in biopsy specimens. Nephron 2000; 84:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23638/abstract/7\">",
"      Ishikawa I, Saito Y, Shikura N, et al. Ten-year prospective study on the development of renal cell carcinoma in dialysis patients. Am J Kidney Dis 1990; 16:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23638/abstract/8\">",
"      Gnionsahe DA, Lagou DA, Tia WM. Prevalence of acquired cystic disease in black Africans on hemodialysis in West Africa. Saudi J Kidney Dis Transpl 2007; 18:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23638/abstract/9\">",
"      Herrera GA. C-erb B-2 amplification in cystic renal disease. Kidney Int 1991; 40:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23638/abstract/10\">",
"      Konda R, Sato H, Hatafuku F, et al. Expression of hepatocyte growth factor and its receptor C-met in acquired renal cystic disease associated with renal cell carcinoma. J Urol 2004; 171:2166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23638/abstract/11\">",
"      Oya M, Mikami S, Mizuno R, et al. C-jun activation in acquired cystic kidney disease and renal cell carcinoma. J Urol 2005; 174:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23638/abstract/12\">",
"      Lien YH, Hunt KR, Siskind MS, Zukoski C. Association of cyclosporin A with acquired cystic kidney disease of the native kidneys in renal transplant recipients. Kidney Int 1993; 44:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23638/abstract/13\">",
"      Truong LD, Krishnan B, Cao JT, et al. Renal neoplasm in acquired cystic kidney disease. Am J Kidney Dis 1995; 26:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23638/abstract/14\">",
"      Levine E, Slusher SL, Grantham JJ, Wetzel LH. Natural history of acquired renal cystic disease in dialysis patients: a prospective longitudinal CT study. AJR Am J Roentgenol 1991; 156:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23638/abstract/15\">",
"      Rainio J, De Giorgio F, Carbone A. Death from renal cyst: spontaneous or traumatic rupture? Am J Forensic Med Pathol 2006; 27:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23638/abstract/16\">",
"      Moore AE, Kujubu DA. Spontaneous retroperitoneal hemorrhage due to acquired cystic kidney disease. Hemodial Int 2007; 11 Suppl 3:S38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23638/abstract/17\">",
"      Sarasin FP, Wong JB, Levey AS, Meyer KB. Screening for acquired cystic kidney disease: a decision analytic perspective. Kidney Int 1995; 48:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23638/abstract/18\">",
"      Farivar-Mohseni H, Perlmutter AE, Wilson S, et al. Renal cell carcinoma and end stage renal disease. J Urol 2006; 175:2018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23638/abstract/19\">",
"      Denton MD, Magee CC, Ovuworie C, et al. Prevalence of renal cell carcinoma in patients with ESRD pre-transplantation: a pathologic analysis. Kidney Int 2002; 61:2201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23638/abstract/20\">",
"      Terasawa Y, Suzuki Y, Morita M, et al. Ultrasonic diagnosis of renal cell carcinoma in hemodialysis patients. J Urol 1994; 152:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23638/abstract/21\">",
"      Takagi T, Kondo T, Izuka J, et al. Prognosis and characteristics of renal cell carcinoma in hemodialysis patients: bilateral occurrence does not influence cancer-specific survival. Int J Urol 2011; 18:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23638/abstract/22\">",
"      Smith JW, Sallman AL, Williamson MR, Lott CG. Acquired renal cystic disease: two cases of associated adenocarcinoma and a renal ultrasound survey of a peritoneal dialysis population. Am J Kidney Dis 1987; 10:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23638/abstract/23\">",
"      MacDougall ML, Welling LW, Wiegmann TB. Prediction of carcinoma in acquired cystic disease as a function of kidney weight. J Am Soc Nephrol 1990; 1:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23638/abstract/24\">",
"      Chandhoke PS, Torrence RJ, Clayman RV, Rothstein M. Acquired cystic disease of the kidney: a management dilemma. J Urol 1992; 147:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23638/abstract/25\">",
"      Kojima Y, Takahara S, Miyake O, et al. Renal cell carcinoma in dialysis patients: a single center experience. Int J Urol 2006; 13:1045.",
"     </a>",
"    </li>",
"    <li>",
"     Farivar-Mohseni, H, Pelmutter, AE, Wilson, S, et al. Renal cell carcinoma and end stage renal disease. J Urol. 2006 175-2018.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23638/abstract/27\">",
"      Marple JT, MacDougall M, Chonko AM. Renal cancer complicating acquired cystic kidney disease. J Am Soc Nephrol 1994; 4:1951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23638/abstract/28\">",
"      Hughson MD, Schmidt L, Zbar B, et al. Renal cell carcinoma of end-stage renal disease: a histopathologic and molecular genetic study. J Am Soc Nephrol 1996; 7:2461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23638/abstract/29\">",
"      Inoue H, Nonomura N, Kojima Y, et al. Somatic mutations of the von Hippel-Lindau disease gene in renal carcinomas occurring in patients with long-term dialysis. Nephrol Dial Transplant 2007; 22:2052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23638/abstract/30\">",
"      Schwarz A, Vatandaslar S, Merkel S, Haller H. Renal cell carcinoma in transplant recipients with acquired cystic kidney disease. Clin J Am Soc Nephrol 2007; 2:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23638/abstract/31\">",
"      Taylor AJ, Cohen EP, Erickson SJ, et al. Renal imaging in long-term dialysis patients: a comparison of CT and sonography. AJR Am J Roentgenol 1989; 153:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23638/abstract/32\">",
"      Takebayashi S, Hidai H, Chiba T, et al. Using helical CT to evaluate renal cell carcinoma in patients undergoing hemodialysis: value of early enhanced images. AJR Am J Roentgenol 1999; 172:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23638/abstract/33\">",
"      Chung WY, Nast CC, Ettenger RB, et al. Acquired cystic disease in chronically rejected renal transplants. J Am Soc Nephrol 1992; 2:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23638/abstract/34\">",
"      Rudge CJ. Acquired cystic disease of the kidney: serious or irrelevant? Br Med J (Clin Res Ed) 1986; 293:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23638/abstract/35\">",
"      Fick GM, Gabow PA. Hereditary and acquired cystic disease of the kidney. Kidney Int 1994; 46:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23638/abstract/36\">",
"      Ishikawa I, Honda R, Yamada Y, Kakuma T. Renal cell carcinoma detected by screening shows better patient survival than that detected following symptoms in dialysis patients. Ther Apher Dial 2004; 8:468.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1683 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-4F267068D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_5_23638=[""].join("\n");
var outline_f23_5_23638=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33611124\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33611124\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=related_link\">",
"      Clinical features, diagnosis, and management of von Hippel-Lindau disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=related_link\">",
"      Development of malignancy following solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21192?source=related_link\">",
"      Prognostic factors in patients with renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=related_link\">",
"      Secondary factors and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27704?source=related_link\">",
"      Simple and complex renal cysts in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_5_23639="Ethanol intoxication in children: Epidemiology, estimation of toxicity, and toxic effects";
var content_f23_5_23639=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ethanol intoxication in children: Epidemiology, estimation of toxicity, and toxic effects",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/5/23639/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/5/23639/contributors\">",
"     Carl R Baum, MD, FAAP, FACMT",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/5/23639/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/5/23639/contributors\">",
"     Michele Burns Ewald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/5/23639/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/5/23639/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/5/23639/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite its abuse potential, ethanol is broadly tolerated in a social context and is therefore ubiquitous in society. It is available in a multitude of alcoholic beverages but also concentrated in household products (eg, vanilla extract, mouthwash,",
"    <span class=\"nowrap\">",
"     perfume/cologne)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef69276 \" href=\"UTD.htm?5/26/5548\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Exploratory ethanol ingestion by children under six years of age typically results in minor symptoms. However, infants and young children are prone to profound hypoglycemia, coma, and hypothermia despite ingesting relatively small amounts of ethanol. Deaths have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Binge drinking and other forms of ethanol abuse is a common problem in preteens and adolescents. Toxicity and treatment generally is similar to adults. Comorbidities include motor vehicle crashes, physical assault, sexual assault, and mental illness.",
"   </p>",
"   <p>",
"    Supportive care is the mainstay of managing ethanol intoxication in children. Treatment of respiratory depression, hypoglycemia, hypovolemia, and hypothermia are the key interventions to ensure good outcomes.",
"   </p>",
"   <p>",
"    The epidemiology, pharmacokinetics, and estimation of toxicity of ethanol intoxication in children are discussed in this review. Evaluation and management of pediatric ethanol exposure are discussed separately (",
"    <a class=\"graphic graphic_table graphicRef76987 \" href=\"UTD.htm?33/51/34620\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/5/2137?source=see_link\">",
"     \"Ethanol intoxication in children: Clinical features, evaluation, and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Young children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children under six years of age, particularly toddlers, often ingest ethanol when their exploratory behaviors lead them to unattended alcoholic beverages or to unsecured household products with high ethanol concentrations (",
"    <a class=\"graphic graphic_table graphicRef69276 \" href=\"UTD.htm?5/26/5548\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Thousands of ethanol exposures in children under six years of age are reported to poison control centers annually in the US [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/4\">",
"     4",
"    </a>",
"    ]. Ethanol-containing products other than alcoholic beverages (eg, perfumes, colognes, mouthwash, medicinals, ethanol based hand sanitizers) account for 85 to 90 percent of these exposures [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/1,4-6\">",
"     1,4-6",
"    </a>",
"    ]. In many instances, these exposures result in little to no toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rarely, a caretaker may intentionally give ethanol to quiet an infant or young child or as part of a pattern of physical abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/1,8\">",
"     1,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=see_link&amp;anchor=H20#H20\">",
"     \"Physical abuse in children: Epidemiology and clinical manifestations\", section on 'Forced ingestion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Preteens and teenagers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ethanol use and abuse among youth (under 21 years of age) is a pervasive problem worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/9\">",
"     9",
"    </a>",
"    ]. In the US, children and adolescents account for almost 11 percent of all alcoholic beverages consumed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/10\">",
"     10",
"    </a>",
"    ]. A national survey indicates that almost 40 percent of US high school students report current ethanol use and about one quarter binge drink (ingest 4 or more drinks on one occasion) making ethanol the most widely used and abused drug among US adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the US, underage drinking is associated with significant negative societal outcomes, including [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fatal motor vehicle crashes &ndash; Approximately 2000 fatal motor vehicle collisions involve drunk teenage drivers annually in the US [",
"      <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Emergency department visits &ndash; 150,000 emergency department visits are associated with ethanol intoxication in the US [",
"      <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Secondary analysis of US national survey data also links binge drinking (4 or more drinks on one occasion) with risky behaviors in high school students [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Violence &ndash; Underage drinkers are more likely to be involved in fights than nondrinkers (50 versus 22 percent).",
"     </li>",
"     <li>",
"      Sexual assault &ndash; Girls who binge drink increase their absolute risk of sexual assault by 9 percent (14 versus 5 percent, respectively).",
"     </li>",
"     <li>",
"      Suicidal thoughts &ndash; Underage drinkers are more than twice as likely to have suicidal ideation as nondrinkers (24 versus 12 percent).",
"     </li>",
"     <li>",
"      Unplanned pregnancy &ndash; Occasional drinkers and binge drinkers are more likely to have been pregnant or to have impregnated someone (4 and 7 percent, respectively, versus 2 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prevention of underage drinking in the US requires collaborative efforts that are implemented at the local, state, and federal levels. Potential strategies advocated by the Surgeon General and Institute of Medicine are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/14,16,17\">",
"     14,16,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Enforcement of minimum drinking age laws",
"     </li>",
"     <li>",
"      Increased taxes on alcoholic beverages",
"     </li>",
"     <li>",
"      National media campaigns targeting youth and young adults",
"     </li>",
"     <li>",
"      Decreased exposure of youth and young adults to advertising of alcoholic beverages",
"     </li>",
"     <li>",
"      Multidisciplinary, community-based alcohol abuse prevention programs",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PHARMACOKINETICS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Absorption and distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ethanol is typically absorbed rapidly; with peak serum levels achieved within 60 minutes of ingestion on an empty stomach [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/18\">",
"     18",
"    </a>",
"    ]. High concentrations of ethanol may cause pylorospasm and delayed gastric emptying [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition, a full stomach also slows absorption. Delayed gastrointestinal transport or absorption of ethanol may translate into rapid onset of action, but delayed peak (up to 3 hours) and prolonged duration of effect [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ethanol has a Vd of 0.6",
"    <span class=\"nowrap\">",
"     L/kg",
"    </span>",
"    with low protein binding. Thus, it is amenable to elimination enhancement by hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Elimination'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Duration of symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The elimination of ethanol in acute overdose is typically constant over time, regardless of peak levels (zero-order kinetics). In nontolerant individuals, the decline in ethanol ranges from 10 to 25",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    per hour (2.2 to 5.6",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    per hour). Chronic drinkers may achieve an elimination rate as high as 30",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    per hour (6.7",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    per hour) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The estimated time to no ethanol in the blood stream in hours is calculated by dividing the peak serum ethanol concentration",
"    <span class=\"nowrap\">",
"     (mg/dL)",
"    </span>",
"    by 10 (longest likely duration) or 25 (shortest likely duration). However, signs of intoxication may wane in a much shorter time period, especially in habituated drinkers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Elimination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once absorbed, ethanol should be considered as a metabolic fuel that undergoes oxidation in order to liberate energy stored in its chemical bonds. The major, but rate-limiting, metabolic pathway utilizes the enzyme alcohol dehydrogenase to convert ethanol to acetaldehyde and the reduction of nicotinamide adenine dinucleotide (NAD+) to NADH [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/23\">",
"     23",
"    </a>",
"    ]. Acetaldehyde, in turn, is metabolized via aldehyde dehydrogenase to acetate. In children under about five years of age, however, relative immaturity of hepatic dehydrogenase activity diminishes their capacity to metabolize ethanol, leading to rapid increases in blood levels and intoxication [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/22,24\">",
"     22,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The microsomal ethanol oxidizing system comprises a secondary and inducible pathway for ethanol elimination [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/25\">",
"     25",
"    </a>",
"    ]. In the absence of chronic ethanol consumption, little ethanol is metabolized by this pathway in children and adolescents.",
"   </p>",
"   <p>",
"    The catalase system normally metabolizes a fraction of ingested ethanol but may be active in pediatric cases where very high blood ethanol levels occur. Liver catalase content in perinatal infants has been shown to be equal to or greater than that of adults [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/24\">",
"     24",
"    </a>",
"    ]. Some experts have proposed that the decline in very high ethanol levels that appear to follow first order kinetics (decline in ethanol level as a percentage of total ethanol) may reflect catalase enzyme activity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/24,26\">",
"     24,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/5/2137?source=see_link&amp;anchor=H14#H14\">",
"     \"Ethanol intoxication in children: Clinical features, evaluation, and management\", section on 'Extracorporeal removal'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ESTIMATION OF TOXICITY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Formulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical concentration of ethanol in alcoholic beverages varies widely (",
"    <a class=\"graphic graphic_table graphicRef69276 \" href=\"UTD.htm?5/26/5548\">",
"     table 1",
"    </a>",
"    ). Ethanol content in alcoholic beverages is often expressed as \"proof.\" In Australia and the UK 100-proof spirit contains 57 percent alcohol by volume, versus 50 percent alcohol by volume in the US. For example, 151-proof rum contains 75.5 percent ethanol in the US. In addition, many common household products and medications have high ethanol content (",
"    <a class=\"graphic graphic_table graphicRef69276 \" href=\"UTD.htm?5/26/5548\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Estimation of serum ethanol",
"    </span>",
"    &nbsp;&mdash;&nbsp;A calculator provides an estimate of the peak blood ethanol level based on volume and concentration of ethanol ingested and patient weight (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?11/29/11730?source=see_link\">",
"     calculator 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Ingestion of one gram per kg of ethanol results in a peak serum ethanol concentration of approximately 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (22",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/27\">",
"     27",
"    </a>",
"    ]. This amount of ethanol corresponds to about 10 to 15",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of beer (5 percent), 4 to 6",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of wine (14 percent), and 1 to 2",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of liquor (40 percent).",
"   </p>",
"   <p>",
"    A more precise estimate of expected peak serum ethanol concentration can be calculated from the patient's weight, amount of ethanol containing liquid ingested in mL, and the percent ethanol concentration by volume (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?11/29/11730?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/20\">",
"     20",
"    </a>",
"    ]. When estimating volume ingested, a swallow of liquid in a toddler is approximately 5 mL (one teaspoon).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Toxic dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The toxic dose in infants and young children is 0.4",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of 100 percent ethanol and would be expected to result in a peak serum ethanol level of 50",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (11",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?11/29/11730?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/1,28\">",
"     1,28",
"    </a>",
"    ]. The life-threatening dose expected to cause deep coma with respiratory depression is estimated at 4",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of 100 percent ethanol and would result in a peak ethanol level of greater than 500",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (111",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?11/29/11730?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Estimation of serum ethanol'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Infants and young children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatal hypoglycemia has occurred in young children with blood ethanol concentrations below 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (22",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    a serum level associated with minimal inebriation in adolescents and adults (",
"    <a class=\"graphic graphic_table graphicRef64642 \" href=\"UTD.htm?11/53/12123\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/30\">",
"     30",
"    </a>",
"    ]. Thus, any symptoms after exposure to ethanol in the young child warrant emergent medical evaluation regardless of estimated amount ingested. In addition, asymptomatic children who have ingested an amount of ethanol expected to result in a serum level more than 50",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (11",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    should be promptly referred for observation and measurement of blood glucose [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Older children and adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unhabituated older children and adolescents develop increasing intoxication with elevation of serum ethanol levels similar to adults [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Most show signs of inebriation at serum ethanol levels of 50 to 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (11 to 22",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    This peak blood level is typically achieved after one or two 12-ounce (360 mL) beers (5 percent ethanol content), one glass of wine, or one shot of liquor in a 50 kg child (",
"    <a class=\"graphic graphic_table graphicRef64642 \" href=\"UTD.htm?11/53/12123\">",
"     table 3",
"    </a>",
"    ). Severe toxicity is expected with an ingestion equivalent to 6",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of 100 percent ethanol.",
"   </p>",
"   <p>",
"    The clinical effect of ethanol may not precisely correlate with the degree of intoxication in a chronic drinker. Due to tolerance, alcoholics may show few or no signs of intoxication at serum levels well over 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (22",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20694?source=see_link&amp;anchor=H5#H5\">",
"     \"Ethanol intoxication in adults\", section on 'Serum alcohol concentration and associated signs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TOXIC EFFECTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Central nervous system (CNS) depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ethanol acts as a CNS sedative in a dose-dependent manner in overdose (",
"    <a class=\"graphic graphic_table graphicRef64642 \" href=\"UTD.htm?11/53/12123\">",
"     table 3",
"    </a>",
"    ). In part, this action is mediated by interaction with the GABA-A receptor, resulting in increased GABA-mediated CNS inhibition [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/21\">",
"     21",
"    </a>",
"    ]. Ethanol also suppresses excitatory neurotransmission controlled by activation of the N-methyl-D-aspartate (NMDA) type glutamate receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition, ethanol has wide ranging effects on calcium channels, dopamine and adenosine receptors, the central adrenergic system, and the hypothalamic-pituitary-adrenal axis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CNS sedation is increased when ethanol is coingested with other sedative-hypnotic agents (eg, benzodiazepines, barbiturates) and may lead to profound coma with respiratory depression or failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Ethanol-induced hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decreased blood glucose below 40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.22",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    is well described in children who have ingested ethanol [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/1-3,30,31\">",
"     1-3,30,31",
"    </a>",
"    ]. Hypoglycemic seizures may occur and, if not promptly treated, result in death [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/1-3,30,31\">",
"     1-3,30,31",
"    </a>",
"    ]. In one series, profound hypoglycemia occurred in 6 of 25 intoxicated young children [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/30\">",
"     30",
"    </a>",
"    ]. While associated with fasting and poor nutrition in adults, ethanol-induced hypoglycemia in infants and young children occurs despite adequate nourishment [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Susceptibility to hypoglycemia in children appears to be related to metabolism of ethanol with imbalance of oxidized and reduced nicotinamide adenine dinucleotide (NAD+ and NADH). Oxidation of ethanol occurs during ethanol metabolism and requires that NAD+ be reduced, thereby decreasing the ratio of NAD+ to NADH [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/32\">",
"     32",
"    </a>",
"    ]. Alteration of this ratio inhibits gluconeogenesis, and thus energy production, via the Krebs cycle [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/33\">",
"     33",
"    </a>",
"    ]. As ethanol is metabolized in the child, glycogen stores are required to maintain blood glucose. Once glycogen stores are exhausted, the child becomes hypoglycemic. For this reason, hypoglycemia may occur several hours after ethanol ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because ethanol-induced hypoglycemia results from exhausted glycogen reserves, it does not respond to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/0/37891?source=see_link\">",
"     glucagon",
"    </a>",
"    administration [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/33\">",
"     33",
"    </a>",
"    ] and does not appear to be dose-related [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Other effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The alteration of the NAD+ to NADH ratio during ethanol metabolism also favors the conversion of pyruvate to lactate [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/32,34\">",
"     32,34",
"    </a>",
"    ]. These metabolic changes result in mild to moderate metabolic acidosis.",
"   </p>",
"   <p>",
"    In addition to reducing energy production, ethanol suppresses shivering, thus increasing the intoxicated patient's risk for hypothermia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Older children and adolescents may also be at risk of environmental exposure, including hypothermia and frostbite, if they drink to the point of passing out while outdoors.",
"   </p>",
"   <p>",
"    Ethanol is a direct irritant of the gastric mucosa and may cause vomiting, gastritis with abdominal pain, and hematemesis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ethanol inhibits antidiuretic hormone action in the kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23639/abstract/19\">",
"     19",
"    </a>",
"    ]. This effect commonly leads to polyuria and mild to moderate dehydration, especially if accompanied by vomiting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rapid overview provides guidance for evaluation and management of children with ethanol intoxication (",
"    <a class=\"graphic graphic_table graphicRef76987 \" href=\"UTD.htm?33/51/34620\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/5/2137?source=see_link\">",
"     \"Ethanol intoxication in children: Clinical features, evaluation, and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children under six years of age, particularly toddlers, often ingest ethanol when their exploratory behaviors lead them to unattended alcoholic beverages or to unsecured household products with high ethanol concentrations (",
"      <a class=\"graphic graphic_table graphicRef69276 \" href=\"UTD.htm?5/26/5548\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Young children'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Binge drinking and other forms of ethanol abuse is a common problem in preteens and adolescents. Toxicity and treatment is similar to adults. Comorbidities include motor vehicle crashes, physical assault, sexual assault, and mental illness. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Preteens and teenagers'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Kinetics",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The elimination of ethanol in acute overdose is typically constant over time, regardless of peak levels (zero-order kinetics). In nontolerant individuals, the decline in ethanol ranges from 10 to 25",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      per hour. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Duration of symptoms'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Toxic dose",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ingestion of one gram per kg of ethanol results in a peak serum ethanol concentration of approximately 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (22",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?11/29/11730?source=see_link\">",
"       calculator 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Estimation of serum ethanol'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fatal hypoglycemia has occurred in young children with blood ethanol concentrations below 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (22",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      a serum level associated with minimal inebriation in adolescents and adults. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Toxic dose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The minimum toxic dose in infants and young children is 0.4",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of 100 percent ethanol and would be expected to result in a peak serum ethanol level of 50",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (11",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?11/29/11730?source=see_link\">",
"       calculator 1",
"      </a>",
"      ). The life-threatening dose expected to cause deep coma with respiratory depression is estimated at 4",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of 100 percent ethanol with an expected peak level of 500",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (111",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Estimation of serum ethanol'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Toxic dose'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Toxic effects",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ethanol acts as a CNS sedative in a dose-dependent manner in overdose (",
"      <a class=\"graphic graphic_table graphicRef64642 \" href=\"UTD.htm?11/53/12123\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Central nervous system (CNS) depression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Decreased blood glucose below 40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.22",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      is well described in children who have ingested ethanol. Hypoglycemic seizures may occur and, if not promptly treated, can result in death. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Ethanol-induced hypoglycemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because ethanol induced hypoglycemia results from exhausted glycogen reserves, it does not respond to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/0/37891?source=see_link\">",
"       glucagon",
"      </a>",
"      administration and does not appear to be dose related. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Ethanol-induced hypoglycemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23639/abstract/1\">",
"      Vogel C, Caraccio T, Mofenson H, Hart S. Alcohol intoxication in young children. J Toxicol Clin Toxicol 1995; 33:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23639/abstract/2\">",
"      Selbst SM, DeMaio JG, Boenning D. Mouthwash poisoning. Report of a fatal case. Clin Pediatr (Phila) 1985; 24:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23639/abstract/3\">",
"      Ricci LR, Hoffman SA. Ethanol-induced hypoglycemic coma in a child. Ann Emerg Med 1982; 11:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23639/abstract/4\">",
"      Bronstein AC, Spyker DA, Cantilena LR Jr, et al. 2010 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 28th Annual Report. Clin Toxicol (Phila) 2011; 49:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23639/abstract/5\">",
"      Miller, M, Borys, D, Morgan, D. Alcohol-based hand sanitizers and unintended pediatric exposures: a retrospective review. clin Pediatr 2009; 48:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23639/abstract/6\">",
"      Engel JS, Spiller HA. Acute ethanol poisoning in a 4-year-old as a result of ethanol-based hand-sanitizer ingestion. Pediatr Emerg Care 2010; 26:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23639/abstract/7\">",
"      Mrvos R, Krenzelok EP. Pediatric ingestions of hand sanitizers: debunking the myth. Pediatr Emerg Care 2009; 25:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23639/abstract/8\">",
"      Dine MS, McGovern ME. Intentional poisoning of children--an overlooked category of child abuse: report of seven cases and review of the literature. Pediatrics 1982; 70:32.",
"     </a>",
"    </li>",
"    <li>",
"     Jernigan DH. Global status report: alcohol and young people.World Health Organization. file://www.who.int/substance_abuse/publications/alcohol/en/index.html (Accessed on December 03, 2008).",
"    </li>",
"    <li>",
"     Drinking in America: Myths, realities, and prevention policy. US Department of Justice, Office of Justice Programs, Office of Juvenile Justice and Delinquency Prevention, Washington, DC 2005. file://www.udetc.org/documents/Drinking_in_America.pdf (Accessed on December 03, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23639/abstract/11\">",
"      Eaton DK, Kann L, Kinchen S, et al. Youth risk behavior surveillance - United States, 2011. MMWR Surveill Summ 2012; 61:1.",
"     </a>",
"    </li>",
"    <li>",
"     Substance Abuse and Mental Health Services Administration. Drug Abuse Warning Network, 2005: National Estimates of Drug-Related Emergency Department Visits. Office of Applied Studies 2007. file://dawninfo.samhsa.gov/pubs/edpubs/default.asp (Accessed on December 03, 2008).",
"    </li>",
"    <li>",
"     Alcohol involvement in fatal motor vehicle traffic crashes, 2003. National Highway Traffic Safety Administration, National Center for Statistics and Analysis, Springfield, VA 2005. file://www-nrd.nhtsa.dot.gov/pdf/nrd-30/NCSA/Rpts/2005/809822.pdf (Accessed on December 03, 2008).",
"    </li>",
"    <li>",
"     Centers for Disease control and Prevention. Quick stats: Underage drinking. file://www.cdc.gov/alcohol/quickstats/underage_drinking.htm (Accessed on December 03, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23639/abstract/15\">",
"      Miller JW, Naimi TS, Brewer RD, Jones SE. Binge drinking and associated health risk behaviors among high school students. Pediatrics 2007; 119:76.",
"     </a>",
"    </li>",
"    <li>",
"     The Surgeon General's call to action to prevent and reduce underage drinking. U.S. Department of Health and Human Services 2007. file://www.surgeongeneral.gov/topics/underagedrinking/ (Accessed on December 03, 2008).",
"    </li>",
"    <li>",
"     National Research Council and Institute of Medicine. Reducing underage drinking: A collective responsibility. Bonnie RJ, O'Connell ME (Eds), National Academies, Washington 2004. file://www.nap.edu/catalog.php?record_id=10729 (Accessed on March 08, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23639/abstract/18\">",
"      Norberg A, Jones AW, Hahn RG, Gabrielsson JL. Role of variability in explaining ethanol pharmacokinetics: research and forensic applications. Clin Pharmacokinet 2003; 42:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23639/abstract/19\">",
"      Linnoila M, Mattila MJ, Kitchell BS. Drug interactions with alcohol. Drugs 1979; 18:299.",
"     </a>",
"    </li>",
"    <li>",
"     Kleinschmidt KC. Ethanol. In: Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose, 4th, Shannon MW, Borron SW, Burns MJ.  (Eds), Saunders, Philadelphia 2007. p.591.",
"    </li>",
"    <li>",
"     Yip L. Ethanol. In: Goldfrank's Toxicologic Emergencies, 8th, Flomenbaum NE, Goldfrank LR, Hoffman RS, et al.  (Eds), McGraw-Hill, New York 2006. p.1147.",
"    </li>",
"    <li>",
"     Erickson TB, Brent J. Toxic alcohols. In: Pediatric Toxicology: Diagnosis and management of the poisoned child, Erickson TB.  (Ed), McGraw-HIll, New York 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23639/abstract/23\">",
"      Caballer&iacute;a J. Current concepts in alcohol metabolism. Ann Hepatol 2003; 2:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23639/abstract/24\">",
"      Tran MN, Wu AH, Hill DW. Alcohol dehydrogenase and catalase content in perinatal infant and adult livers: potential influence on neonatal alcohol metabolism. Toxicol Lett 2007; 169:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23639/abstract/25\">",
"      Lieber CS. The discovery of the microsomal ethanol oxidizing system and its physiologic and pathologic role. Drug Metab Rev 2004; 36:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23639/abstract/26\">",
"      Lopez GP, Yealy DM, Krenzelok EP. Survival of a child despite unusually high blood ethanol levels. Am J Emerg Med 1989; 7:283.",
"     </a>",
"    </li>",
"    <li>",
"     Osterhoudt KC, Burns Ewald M, Shannon M, Henretig FM. Toxicologic emergencies. In: Textbook of Pediatric Emergency Medicine, 6th, Fleisher GR, Ludwig S, Henretig FM.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.965.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23639/abstract/28\">",
"      Riordan M, Rylance G, Berry K. Poisoning in children 4: household products, plants, and mushrooms. Arch Dis Child 2002; 87:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23639/abstract/29\">",
"      Ethanol in liquid preparations intended for children. Pediatrics 1984; 73:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23639/abstract/30\">",
"      Leung AK. Ethyl alcohol ingestion in children. A 15-year review. Clin Pediatr (Phila) 1986; 25:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23639/abstract/31\">",
"      Weller-Fahy ER, Berger LR, Troutman WG. Mouthwash: a source of acute ethanol intoxication. Pediatrics 1980; 66:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23639/abstract/32\">",
"      Crabb DW, Bosron WF, Li TK. Ethanol metabolism. Pharmacol Ther 1987; 34:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23639/abstract/33\">",
"      Madison LL. Ethanol-induced hypoglycemia. Adv Metab Disord 1968; 3:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23639/abstract/34\">",
"      Marks V. Alcohol and carbohydrate metabolism. Clin Endocrinol Metab 1978; 7:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23639/abstract/35\">",
"      Lamminp&auml;&auml; A. Alcohol intoxication in childhood and adolescence. Alcohol Alcohol 1995; 30:5.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6486 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-7D04F74F15-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_5_23639=[""].join("\n");
var outline_f23_5_23639=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Young children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Preteens and teenagers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PHARMACOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Absorption and distribution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Duration of symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Elimination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ESTIMATION OF TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Formulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Estimation of serum ethanol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Toxic dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Infants and young children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Older children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TOXIC EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Central nervous system (CNS) depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Ethanol-induced hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Other effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Kinetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Toxic dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Toxic effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6486\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6486|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/26/5548\" title=\"table 1\">",
"      Ethanol content in beverages and other products",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/51/34620\" title=\"table 2\">",
"      Ethanol intoxication in children - Rapid overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/53/12123\" title=\"table 3\">",
"      Clinical effects of blood alcohol concentration",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?11/29/11730?source=related_link\" title=\"calculator 1\">",
"      Calculator: Blood ethanol concentration estimation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20694?source=related_link\">",
"      Ethanol intoxication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/5/2137?source=related_link\">",
"      Ethanol intoxication in children: Clinical features, evaluation, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=related_link\">",
"      Physical abuse in children: Epidemiology and clinical manifestations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_5_23640="Breast cancer development";
var content_f23_5_23640=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F53453&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F53453&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Breast cancer development",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 703px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The earliest breast cancers are called \"in situ\" cancers. In situ means the tumor has stayed inside the place where it first formed and has not spread to nearby tissues.",
"    <br>",
"     The most common form of in situ cancer is called \"ductal carcinoma in situ,\" or DCIS. DCIS forms inside the ducts of the breast, which are tubes that carry milk to the nipple when a woman is breastfeeding.",
"     <br>",
"      Lobular carcinoma in situ, or LCIS has a similar name but is not considered a true cancer. Instead, it is considered a risk factor for developing cancer in the future. LCIS refers to abnormal cells in the lobules of the breast, which is where milk is made.",
"      <br>",
"       When breast cancers spread beyond the ducts or lobules of the breast into the nearby tissue, they are called \"locally invasive cancers.\"",
"       <br>",
"        When tumors spread to areas outside the breast through the blood and lymph vessels, they are called \"metastatic cancers.\"",
"        <div class=\"footnotes\">",
"        </div>",
"        <div class=\"reference\">",
"        </div>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_5_23640=[""].join("\n");
var outline_f23_5_23640=null;
var title_f23_5_23641="Management of acute exacerbations of chronic obstructive pulmonary disease";
var content_f23_5_23641=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of acute exacerbations of chronic obstructive pulmonary disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/5/23641/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/5/23641/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/5/23641/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/5/23641/contributors\">",
"     Peter J Barnes, DM, DSc, FRCP, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/5/23641/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/5/23641/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/5/23641/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Global Initiative for Chronic Obstructive Lung Disease (GOLD), a report produced by the National Heart, Lung, and Blood Institute (NHLBI) and the World Health Organization (WHO), defines an exacerbation of chronic obstructive pulmonary disease (COPD) as an acute increase in symptoms beyond normal day-to-day variation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/1\">",
"     1",
"    </a>",
"    ]. This generally includes an acute increase in one or more of the following cardinal symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cough increases in frequency and severity",
"     </li>",
"     <li>",
"      Sputum production increases in volume",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      changes character",
"     </li>",
"     <li>",
"      Dyspnea increases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Constitutional symptoms, an unchanged chest radiograph, a variable decrease in pulmonary function, and tachypnea are typical in acute exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, severe cases can lead to respiratory failure and death.",
"   </p>",
"   <p>",
"    The management of patients with acute exacerbations of COPD is discussed in detail here. A table to assist with emergency management of severe acute exacerbations of COPD is provided (",
"    <a class=\"graphic graphic_table graphicRef65420 \" href=\"UTD.htm?9/42/9901\">",
"     table 1",
"    </a>",
"    ). The diagnosis and treatment of infection in acute exacerbations, and the management of stable COPD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7866?source=see_link\">",
"     \"Management of infection in acute exacerbations of chronic obstructive pulmonary disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=see_link\">",
"     \"Management of stable chronic obstructive pulmonary disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRECIPITANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is estimated that 70 to 80 percent of COPD exacerbations are due to respiratory infections (",
"    <a class=\"graphic graphic_table graphicRef70203 \" href=\"UTD.htm?28/48/29451\">",
"     table 2",
"    </a>",
"    ). Viral and bacterial infections cause most exacerbations, whereas atypical bacteria are a relatively uncommon cause [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/3\">",
"     3",
"    </a>",
"    ]. The remaining 20 to 30 percent are due to environmental pollution or have an unknown etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7866?source=see_link\">",
"     \"Management of infection in acute exacerbations of chronic obstructive pulmonary disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some COPD exacerbations of unknown etiology may be related to other medical conditions, such as myocardial ischemia, heart failure, aspiration, or pulmonary embolism [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. The relationship between COPD exacerbation and pulmonary embolism was illustrated by a meta-analysis of five observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/7\">",
"     7",
"    </a>",
"    ]. Among the 550 patients having a COPD exacerbation, the prevalence of pulmonary embolism was 20 percent. The prevalence was even higher (25 percent) among those hospitalized. An important limitation of the meta-analysis was its inability to determine whether the pulmonary embolism was the cause of the COPD exacerbation, a result of the COPD exacerbation, or a mere bystander.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to observational studies, the risk of developing an exacerbation of COPD correlates with advanced age, productive cough, duration of COPD, history of antibiotic therapy, COPD-related hospitalization within the previous year, chronic mucous hypersecretion,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    therapy, and having one or more comorbidities (eg, ischemic heart disease, chronic heart failure, or diabetes mellitus) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. In general, worsening airflow limitation (lower forced expiratory volume in one second [FEV",
"    <sub>",
"     1",
"    </sub>",
"    ]) is associated with an increasing risk of COPD exacerbation, although airflow limitation alone does not provide a good assessment of exacerbation risk [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/1\">",
"     1",
"    </a>",
"    ]. In the prospective Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study, 2138 patients with moderate to severe COPD (GOLD stages 2, 3, or 4 (",
"    <a class=\"graphic graphic_table graphicRef82690 \" href=\"UTD.htm?34/28/35275\">",
"     table 3",
"    </a>",
"    )) were followed for three years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/12\">",
"     12",
"    </a>",
"    ]. The single best predictor of exacerbations was a history of exacerbations, regardless of COPD severity.",
"   </p>",
"   <p>",
"    The GOLD guidelines suggest using a combination of an individual&rsquo;s FEV",
"    <sub>",
"     1",
"    </sub>",
"    and history of exacerbations to assess the exacerbation risk [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/1\">",
"     1",
"    </a>",
"    ]. The number of exacerbations in the previous 12 months is stratified: a history of zero or one exacerbation suggests a low future risk of exacerbations, while two or more suggest a high future risk [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/1\">",
"     1",
"    </a>",
"    ]. The severity of lung function impairment is stratified based on the postbronchodilator FEV",
"    <sub>",
"     1",
"    </sub>",
"    , using the GOLD classification of airflow limitation (",
"    <a class=\"graphic graphic_table graphicRef82690 \" href=\"UTD.htm?34/28/35275\">",
"     table 3",
"    </a>",
"    ). These components are combined as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low risk: Typically GOLD 1 or 2 (mild to moderate airflow limitation)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      0 to 1 exacerbation per year",
"     </li>",
"     <li>",
"      High risk: Typically GOLD 3 or 4 (severe or very severe airflow limitation)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      &ge;2 exacerbations per year",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Gastroesophageal reflux disease (GERD) may be an additional risk factor for COPD exacerbations. In the ECLIPSE study noted above, occurrence of two or more exacerbations in a year was associated with a history of GERD or heartburn [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/12\">",
"     12",
"    </a>",
"    ]. A similar observation was made in a case-control study that assessed the presence of GERD symptoms and frequency of COPD exacerbations in 80 patients with COPD. The presence of GERD symptoms was associated with an increased risk of COPD exacerbations (RR 6.55, 95% CI 1.86 to 23.11) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/13\">",
"     13",
"    </a>",
"    ]. Additional studies are needed to determine whether GERD contributes to the development of COPD exacerbations.",
"   </p>",
"   <p>",
"    In a follow-up to the ECLIPSE study, the potential role of pulmonary vascular disease as a risk factor for exacerbations was assessed by using computed tomography scans to compute the ratio of the diameter of the pulmonary artery to the diameter of the aorta (PA:A ratio) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/14\">",
"     14",
"    </a>",
"    ]. In the study, a PA:A ratio greater than 1 was an independent risk factor for a future severe exacerbation (OR 3.44, 95% CI 2.78-4.25). However, a ratio &gt;1 suggests the presence of pulmonary hypertension, although it does not clarify the cause of pulmonary hypertension (eg, hypoxemia due to COPD or other lung disease, left heart failure, sleep apnea). The clinical usefulness of this observation in terms of treatment decisions is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial evaluation of a patient with a suspected exacerbation of COPD includes a medical history, physical examination, chest radiograph, and routine laboratory studies. Arterial blood gas analysis should be performed in most patients to assess the severity of the exacerbation and to establish a baseline from which improvement or deterioration can be measured. Sputum examination, which is also part of the evaluation, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7866?source=see_link\">",
"     \"Management of infection in acute exacerbations of chronic obstructive pulmonary disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The patient must be triaged to inpatient or outpatient management following initial evaluation. Several criteria for hospitalization were proposed in a 2004 position paper from the American Thoracic",
"    <span class=\"nowrap\">",
"     Society/European",
"    </span>",
"    Respiratory Society",
"    <span class=\"nowrap\">",
"     (ATS/ERS)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inadequate response of symptoms to outpatient management",
"     </li>",
"     <li>",
"      Marked increase in dyspnea",
"     </li>",
"     <li>",
"      Inability to eat or sleep due to symptoms",
"     </li>",
"     <li>",
"      Worsening hypoxemia",
"     </li>",
"     <li>",
"      Worsening hypercapnia",
"     </li>",
"     <li>",
"      Changes in mental status",
"     </li>",
"     <li>",
"      Inability to care for oneself (ie, lack of home support)",
"     </li>",
"     <li>",
"      Uncertain diagnosis",
"     </li>",
"     <li>",
"      High risk comorbidities including pneumonia, cardiac arrhythmia, heart failure, diabetes mellitus, renal failure, or liver failure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, there is general consensus that acute respiratory acidosis justifies hospitalization.",
"   </p>",
"   <p>",
"    Many triage decisions are made by the emergency department. One study identified the following as risk factors for relapse after discharge from the emergency department: a greater number of doses of nebulized bronchodilator required in the emergency department, use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    in the emergency department, use of supplemental oxygen at home, an emergency department visit within the past week, prior relapse after an emergency department visit, and prescription of glucocorticoids, antibiotics, or both at the time of emergency department discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of controlled trials have compared hospitalization with intensive home care, which generally includes nurse visits, home oxygen, and physical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/16-20\">",
"     16-20",
"    </a>",
"    ]. A meta-analysis of seven of these trials noted that home care resulted in equivalent clinical outcomes and substantial cost savings compared to hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/21\">",
"     21",
"    </a>",
"    ]. However, these trials excluded sicker patients with an impaired level of consciousness, respiratory acidosis (arterial pH &lt;7.35), acute electrocardiographic or chest radiographic changes, or coexisting medical morbidities. Although care at home is feasible in highly selected patients without these characteristics, implementation requires a dedicated support team to conduct ongoing clinical assessments and provide home care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with COPD who present to the hospital with acute worsening of dyspnea should be evaluated for potential alternative diagnoses, such as heart failure, pulmonary thromboembolism, and pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. This was illustrated in an autopsy study of 43 patients with COPD who died within 24 hours of admission for a COPD exacerbation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/22\">",
"     22",
"    </a>",
"    ]. The primary causes of death were heart failure, pneumonia, pulmonary thromboembolism, and COPD in 37, 28, 21, and 14 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT GOALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful management of acute exacerbations of COPD in either the inpatient or outpatient setting requires attention to a number of key issues [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Identifying and ameliorating the cause of the acute exacerbation, if possible",
"     </li>",
"     <li>",
"      Optimizing lung function by administering bronchodilators and other pharmacologic agents",
"     </li>",
"     <li>",
"      Assuring adequate oxygenation and secretion clearance",
"     </li>",
"     <li>",
"      Averting the need for intubation, if possible",
"     </li>",
"     <li>",
"      Preventing complications of immobility, such as thromboemboli and deconditioning",
"     </li>",
"     <li>",
"      Addressing nutritional needs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A table to assist with emergency management of severe acute exacerbations of COPD is provided (",
"    <a class=\"graphic graphic_table graphicRef65420 \" href=\"UTD.htm?9/42/9901\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     OXYGEN THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supplemental oxygen is a critical component of acute therapy. It should target an arterial oxygen tension (PaO",
"    <sub>",
"     2",
"    </sub>",
"    ) of 60 to 70 mmHg, with an oxyhemoglobin saturation of 90 to 94 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/26-28\">",
"     26-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are numerous devices available to deliver supplemental oxygen during an acute exacerbation of COPD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Venturi masks are the preferred means of oxygen delivery because they permit a precise delivered fraction of inspired oxygen (FiO",
"      <sub>",
"       2",
"      </sub>",
"      ). Venturi masks can deliver an FiO",
"      <sub>",
"       2",
"      </sub>",
"      of 24, 28, 31, 35, 40, or 60 percent.",
"     </li>",
"     <li>",
"      Nasal cannulae can provide flow rates up to 6 L per minute with an associated FiO",
"      <sub>",
"       2",
"      </sub>",
"      of approximately 40 percent (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?34/7/34928?source=see_link\">",
"       calculator 1",
"      </a>",
"      ). They are more comfortable and convenient for the patient, especially during oral feedings.",
"     </li>",
"     <li>",
"      When higher inspired concentrations of oxygen are needed, simple facemasks can provide an FiO",
"      <sub>",
"       2",
"      </sub>",
"      up to 55 percent using flow rates of 6 to 10 L per minute. However, variations in minute ventilation and inconsistent entrainment of room air affect the FiO",
"      <sub>",
"       2",
"      </sub>",
"      when simple facemasks (or nasal cannulae) are used.",
"     </li>",
"     <li>",
"      Non-rebreathing masks with a reservoir, one-way valves, and a tight face seal can deliver an inspired oxygen concentration up to 90 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A high FiO",
"    <sub>",
"     2",
"    </sub>",
"    is not required to correct the hypoxemia associated with most acute exacerbations of COPD. Inability to correct hypoxemia with a relatively low FiO",
"    <sub>",
"     2",
"    </sub>",
"    (eg, 4",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    by nasal cannula or 35 percent by mask) should prompt consideration of pulmonary emboli, acute respiratory distress syndrome, pulmonary edema, or severe pneumonia as the cause of respiratory failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33925?source=see_link\">",
"     \"Oxygenation and mechanisms of hypoxemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adequate oxygenation must be assured, even if it leads to acute hypercapnia. Hypercapnia is generally well tolerated in patients whose arterial carbon dioxide tension (PaCO",
"    <sub>",
"     2",
"    </sub>",
"    ) is chronically elevated. However, mechanical ventilation may be required if hypercapnia is associated with depressed mental status, profound acidemia, or cardiac dysrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3064?source=see_link&amp;anchor=H9#H9\">",
"     \"Use of oxygen in patients with hypercapnia\", section on 'Hypercapnia in COPD'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28407?source=see_link&amp;anchor=H5#H5\">",
"     \"Oxygen toxicity\", section on 'Accentuation of hypercapnia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major components of managing an acute exacerbation of COPD include inhaled short-acting bronchodilators (beta adrenergic agonists and anticholinergic agents), glucocorticoids, and antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Beta adrenergic agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled short-acting beta adrenergic agonists (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    ) are the mainstay of therapy for an acute exacerbation of COPD because of their rapid onset of action and efficacy in producing bronchodilation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. These medications may be administered via a nebulizer or a metered dose inhaler (MDI) with a spacer device [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18762?source=see_link\">",
"     \"Delivery of inhaled medication in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18856?source=see_link\">",
"     \"The use of inhaler devices in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite evidence that MDI devices may have equal efficacy during acute exacerbations of COPD, many clinicians prefer nebulized therapy on the presumption of more reliable delivery of drug to the airway [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/1\">",
"     1",
"    </a>",
"    ]. We favor nebulized therapy because many patients with COPD have difficulty using proper MDI technique in the setting of an acute exacerbation.",
"   </p>",
"   <p>",
"    Typical doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    for this indication are 2.5 mg (diluted to a total of 3 mL) by nebulizer every one to four hours as needed, or four to eight puffs (90 mcg per puff) by MDI with a spacer every one to four hours as needed. Increasing the dose of nebulized albuterol to 5 mg does not have a significant impact on spirometry or clinical outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/32\">",
"     32",
"    </a>",
"    ]. Similarly, continuously nebulized beta agonists have not been shown to confer an advantage.",
"   </p>",
"   <p>",
"    Patients with severe COPD are at risk for hypercapnia with administration of supplemental oxygen, so concern has been raised about the risk of hypercapnia during bronchodilator treatments using oxygen-driven nebulizers [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/33\">",
"     33",
"    </a>",
"    ]. We concur with the British Thoracic Society guidelines that suggest using air-, rather than oxygen-driven bronchodilator nebulization, or limiting oxygen-driven treatments to 6 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subcutaneous injection of short-acting beta adrenergic agonists is reserved for situations in which inhaled administration is not possible. Parenteral use of these agents results in greater inotropic and chronotropic effects, which may cause arrhythmias or myocardial ischemia in susceptible individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Anticholinergic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled short-acting anticholinergic agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    bromide) are used with inhaled short-acting beta adrenergic agonists to treat exacerbations of COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/1\">",
"     1",
"    </a>",
"    ]. This is based on several studies that found that combination therapy produces bronchodilation in excess of that achieved by either agent alone in patients with a COPD exacerbation, an asthma exacerbation, or stable COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/31,35,36\">",
"     31,35,36",
"    </a>",
"    ]. However, this finding has not been universal in patients having an exacerbation of COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/35,37\">",
"     35,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Typical doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    for this indication are 500 mcg by nebulizer every four hours as needed. Alternatively, two puffs (18 mcg per puff) by MDI with a spacer every four hours as needed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33305?source=see_link\">",
"     \"Role of anticholinergic therapy in COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H344158021\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic glucocorticoids, when added to the bronchodilator therapies described above, improve symptoms and lung function, and decrease the length of hospital stay [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/1,38-40\">",
"     1,38-40",
"    </a>",
"    ]. This was illustrated by a trial that randomly assigned 271 patients with a COPD exacerbation to receive either systemic glucocorticoids or placebo for up to two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/39\">",
"     39",
"    </a>",
"    ]. Systemic glucocorticoid therapy significantly reduced the 30 day treatment failure rate (23 versus 33 percent), the 90 day treatment failure rate (37 versus 48 percent), and hospital stay (eight versus ten days), while improving lung function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/7/10360?source=see_link\">",
"     \"Role of systemic glucocorticoid therapy in COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H344158046\">",
"    <span class=\"h3\">",
"     Route",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral glucocorticoids are rapidly absorbed (peak serum levels achieved at one hour after ingestion) with virtually complete bioavailability and appear equally efficacious as intravenous glucocorticoids for treating most exacerbations of COPD. As an example, a randomized trial assigned 210 patients hospitalized with a COPD exacerbation to receive oral or intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    (60 mg daily) for five days and found no difference between the two groups in the rate of treatment failure, length of hospital stay, improvement in spirometry, or improvement in quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, intravenous glucocorticoids are typically administered to patients who present with a severe exacerbation, who respond poorly to oral glucocorticoids, who are unable to take oral medication, or who may have impaired absorption due to decreased splanchnic perfusion (eg, patients in shock).",
"   </p>",
"   <p>",
"    The efficacy of inhaled glucocorticoids on the course of a COPD exacerbation has not been studied in randomized trials. Thus, they should not be used as a substitute for systemic glucocorticoid therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H344158097\">",
"    <span class=\"h3\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal dose of systemic glucocorticoids for treating a COPD exacerbation is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/1\">",
"     1",
"    </a>",
"    ]. Frequently used regimens range from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    30 to 60 mg, once daily, to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    60 to 125 mg, two to four times daily. A growing body of evidence favors using a moderate, rather than high dose of glucocorticoids, for the majority of patients with an exacerbation of COPD. As an example, a comparative analysis of glucocorticoid dosing examined outcomes of 79,985 patients admitted to the hospital with an exacerbation of COPD, excluding those requiring intensive care [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/42\">",
"     42",
"    </a>",
"    ]. The median glucocorticoid dose administered in the first two days was 60 mg for those on oral therapy and 556 mg for intravenous therapy. The risk of treatment failure was no greater with the lower dose. As this was an observational study and did not include objective measures of airflow limitation, it is possible that less ill patients were more likely to receive oral treatment.",
"   </p>",
"   <p>",
"    The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines advise using the equivalent of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    30 to 40 mg once daily for the majority of COPD exacerbations (",
"    <a class=\"graphic graphic_table graphicRef64138 \" href=\"UTD.htm?41/61/42972\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/1\">",
"     1",
"    </a>",
"    ]. For patients with impending or actual acute respiratory failure due to a COPD exacerbation, most clinicians would use an intravenous formulation at a higher dose, such as the equivalent of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    60 mg intravenously, one to four times daily, although outcomes data to guide this practice are not available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H344158053\">",
"    <span class=\"h3\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal duration of systemic glucocorticoid therapy is not clearly established and often depends on the severity of the exacerbation and the observed response to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/43\">",
"     43",
"    </a>",
"    ]. The Systemic Corticosteroids in COPD Exacerbations (SCCOPE) trial compared two and eight week regimens and did not find any additional benefit to the longer course [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/39\">",
"     39",
"    </a>",
"    ]. Patients in the eight week group experienced more glucocorticoid-related side effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/7/10360?source=see_link&amp;anchor=H7#H7\">",
"     \"Role of systemic glucocorticoid therapy in COPD\", section on 'Hospitalized patients'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/7/10360?source=see_link&amp;anchor=H13#H13\">",
"     \"Role of systemic glucocorticoid therapy in COPD\", section on 'Short-term therapy and complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a rough guide, most exacerbations are treated with full dose therapy (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    30 to 40 mg daily) for 10 to 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/1\">",
"     1",
"    </a>",
"    ]. After this time, glucocorticoid therapy may be discontinued, if the patient has substantially recovered. Alternatively, the dose is tapered over another seven days, as a trial to determine whether continued glucocorticoid therapy is required. Tapering solely because of concerns about adrenal suppression is not necessary if the duration of therapy is less than three weeks (a duration too brief to cause adrenal atrophy). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22103?source=see_link&amp;anchor=H16#H16\">",
"     \"Glucocorticoid withdrawal\", section on 'Recommended tapering regimen'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotics are indicated for many patients having a COPD exacerbation. The importance, diagnosis, and treatment of infection in exacerbations of COPD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7866?source=see_link&amp;anchor=H19#H19\">",
"     \"Management of infection in acute exacerbations of chronic obstructive pulmonary disease\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Mucoactive agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little evidence supporting the use of mucoactive agents (eg, N-acetylcysteine) in acute exacerbations of COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/29,30,44\">",
"     29,30,44",
"    </a>",
"    ]. Some mucoactive agents may worsen bronchospasm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34648?source=see_link\">",
"     \"Role of mucoactive agents in the treatment of COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The lack of efficacy of mucoactive agents in the treatment of COPD exacerbations was best demonstrated by a double-blind trial that randomly assigned 50 patients with a COPD exacerbation to receive N-acetylcysteine (600 mg, twice daily) or placebo for seven days [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/44\">",
"     44",
"    </a>",
"    ]. There was no difference in the rate of change of FEV",
"    <sub>",
"     1",
"    </sub>",
"    , vital capacity, oxygen saturation, breathlessness, or length of stay between the two groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Methylxanthines",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/19/14648?source=see_link\">",
"     Aminophylline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    are NOT recommended for the treatment of acute exacerbations of COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/29\">",
"     29",
"    </a>",
"    ]. Randomized controlled trials of intravenous aminophylline in this setting have failed to show efficacy beyond that induced by inhaled bronchodilator and glucocorticoid therapy. In addition to lack of efficacy, methylxanthines caused significantly more nausea and vomiting than placebo and trended toward more frequent tremor, palpitations, and arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25031?source=see_link&amp;anchor=H7#H7\">",
"     \"Role of methylxanthines in the treatment of COPD\", section on 'Acute exacerbation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CHEST PHYSIOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanical techniques to augment sputum clearance, such as directed coughing, chest physiotherapy with percussion and vibration, intermittent positive pressure breathing, and postural drainage, have not been shown to be beneficial in COPD and may provoke bronchoconstriction. Their use in acute exacerbations of COPD is not supported by clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/26,29,30\">",
"     26,29,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     MECHANICAL VENTILATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Noninvasive ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninvasive positive pressure ventilation (NPPV) refers to mechanical ventilation delivered through a noninvasive interface, such as a face mask, nasal mask, or nasal prongs. It improves numerous clinical outcomes and is the preferred method of ventilatory support in many patients with an acute exacerbation of COPD.",
"   </p>",
"   <p>",
"    Optimal initial settings for NPPV have not been established. A reasonable approach is to initiate NPPV in a spontaneously triggered mode with a backup respiratory rate, an inspiratory pressure of 8 to 12 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O, and an expiratory pressure of 3 to 5 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O. The inspiratory pressure is gradually increased as needed to achieve alleviation of dyspnea and good patient-ventilator synchrony. NPPV is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=see_link\">",
"     \"Noninvasive positive pressure ventilation in acute respiratory failure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Invasive ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasive mechanical ventilation should be administered when patients fail NPPV, do not tolerate NPPV, or have contraindications to NPPV. Invasive mechanical ventilation for acute respiratory failure due to a COPD exacerbation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/59/8120?source=see_link\">",
"     \"Mechanical ventilation in acute respiratory failure complicating COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute exacerbations of COPD are associated with increased mortality after hospital discharge.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is estimated that 14 percent of patients admitted for an exacerbation of COPD will die within three months of admission [",
"      <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/45,46\">",
"       45,46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 1016 patients with an acute exacerbation of COPD and a PaCO",
"      <sub>",
"       2",
"      </sub>",
"      of 50 mmHg or more, the 6 and 12 month mortality rates were 33 and 43 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 260 patients admitted with a COPD exacerbation, the one year mortality was 28 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/48\">",
"       48",
"      </a>",
"      ]. Independent risk factors for mortality were age, male gender, prior hospitalization for COPD, PaCO",
"      <sub>",
"       2",
"      </sub>",
"      &ge;45 mmHg (6 kPa), and urea &gt;8",
"      <span class=\"nowrap\">",
"       mmol/L.",
"      </span>",
"     </li>",
"     <li>",
"      Patients hospitalized for a COPD exacerbation who have a",
"      <em>",
"       Pseudomonas aeruginosa",
"      </em>",
"      in their sputum have an increased risk of mortality at three years than those without (59 versus 35 percent, HR 2.33, 95% CI 1.29-3.86), independent of age, comorbidity, or COPD severity [",
"      <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Even if the acute exacerbation resolves, many patients never return to their baseline level of health [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the patient begins to improve, measures should be taken to prevent future exacerbations, including smoking cessation, pulmonary rehabilitation, proper use of medications (including metered dose inhaler technique), and vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38840?source=see_link\">",
"     \"Pulmonary rehabilitation in COPD\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18856?source=see_link\">",
"     \"The use of inhaler devices in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=see_link&amp;anchor=H24#H24\">",
"     \"Management of stable chronic obstructive pulmonary disease\", section on 'Supplemental therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately two-thirds of patients know when an exacerbation of COPD is imminent because symptoms tend to be similar from one exacerbation to another [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/52\">",
"     52",
"    </a>",
"    ]. As a result, some clinicians advocate a COPD exacerbation \"action plan.\" An action plan encourages early intervention by giving patients guidelines on how to recognize an exacerbation, how to change their medication regimen accordingly, and when to contact their healthcare provider. A meta-analysis of three randomized, controlled trials (367 patients) revealed that use of an action plan was associated with earlier recognition of an exacerbation by the patient, earlier initiation of antibiotics, and earlier initiation of glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/53\">",
"     53",
"    </a>",
"    ]. However, there was no significant effect on healthcare utilization, quality of life, lung function, functional capacity, symptom scores, or mortality.",
"   </p>",
"   <p>",
"    The effect of high dose vitamin D supplementation on the incidence of COPD exacerbations was assessed in patients with moderate or more severe COPD who were randomly assigned to take vitamin D 100,000 IU or placebo orally every four weeks for a year [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/54\">",
"     54",
"    </a>",
"    ]. The median time to first exacerbation did not differ between the groups, nor did exacerbation rates, FEV",
"    <sub>",
"     1",
"    </sub>",
"    , hospitalization, quality of life, or death. However, patients with severe vitamin D deficiency (serum 25-[OH] D levels &lt;10",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    at baseline had a significant reduction in exacerbations. Further research is needed to determine whether daily dosing of vitamin D supplementation for a longer period would be beneficial and whether this effect is dependent on the baseline vitamin D level [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23641/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prevention of infection, a precipitant of exacerbations of COPD, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7866?source=see_link&amp;anchor=H18#H18\">",
"     \"Management of infection in acute exacerbations of chronic obstructive pulmonary disease\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/48/15107?source=see_link\">",
"       \"Patient information: Chronic bronchitis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/11/24755?source=see_link\">",
"       \"Patient information: Medicines for chronic obstructive pulmonary disease (COPD) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/52/14148?source=see_link\">",
"       \"Patient information: Chronic obstructive pulmonary disease (COPD) treatments (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A table to assist with emergency management of severe acute exacerbations of COPD is provided (",
"      <a class=\"graphic graphic_table graphicRef65420 \" href=\"UTD.htm?9/42/9901\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      An acute exacerbation of COPD is characterized by an acute increase in symptoms beyond normal day-to-day variation. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      We recommend that all patients having a COPD exacerbation receive both an inhaled short-acting beta adrenergic agonist and an inhaled short-acting anticholinergic agent, rather than either medication alone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Beta adrenergic agonists'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Anticholinergic agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that all patients having a COPD exacerbation receive systemic glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). A reasonable dose for patients not requiring intensive care unit admission is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      30 to 60 mg orally once daily, or the equivalent, for 10 to 14 days. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antibiotics are indicated for many patients having a COPD exacerbation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7866?source=see_link&amp;anchor=H19#H19\">",
"       \"Management of infection in acute exacerbations of chronic obstructive pulmonary disease\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mucoactive agents, mechanical techniques to augment sputum clearance, and methylxanthines have not been shown to confer benefit for patients with a COPD exacerbation. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Mucoactive agents'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Chest physiotherapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Methylxanthines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that all patients who are hypoxemic be given supplemental oxygen targeting a PaO",
"      <sub>",
"       2",
"      </sub>",
"      of 60 to 70 mmHg, with an oxyhemoglobin saturation of 90 to 94 percent (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Oxygen therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Noninvasive positive pressure ventilation (NPPV) improves numerous clinical outcomes and is the preferred method of ventilatory support in many patients with an acute exacerbation of COPD. Invasive mechanical ventilation is required in patients with respiratory failure who fail NPPV, do not tolerate NPPV, or have contraindications to NPPV. Both NPPV and invasive mechanical ventilation for patients with an acute exacerbation of COPD are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=see_link\">",
"       \"Noninvasive positive pressure ventilation in acute respiratory failure in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/59/8120?source=see_link\">",
"       \"Mechanical ventilation in acute respiratory failure complicating COPD\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Global strategy for the diagnosis, management, and prevention of COPD: Revised 2011. Global initiative for Chronic obstructive lung disease (GOLD). file://www.goldcopd.org (Accessed on April 30, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/2\">",
"      Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/3\">",
"      Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008; 359:2355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/4\">",
"      Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000; 343:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/5\">",
"      Sapey E, Stockley RA. COPD exacerbations . 2: aetiology. Thorax 2006; 61:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/6\">",
"      Tillie-Leblond I, Marquette CH, Perez T, et al. Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors. Ann Intern Med 2006; 144:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/7\">",
"      Rizkallah J, Man SF, Sin DD. Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and metaanalysis. Chest 2009; 135:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/8\">",
"      Miravitlles M, Guerrero T, Mayordomo C, et al. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. The EOLO Study Group. Respiration 2000; 67:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/9\">",
"      Rascon-Aguilar IE, Pamer M, Wludyka P, et al. Role of gastroesophageal reflux symptoms in exacerbations of COPD. Chest 2006; 130:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/10\">",
"      Niewoehner DE, Lokhnygina Y, Rice K, et al. Risk indexes for exacerbations and hospitalizations due to COPD. Chest 2007; 131:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/11\">",
"      Burgel PR, Nesme-Meyer P, Chanez P, et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 2009; 135:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/12\">",
"      Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/13\">",
"      Terada K, Muro S, Sato S, et al. Impact of gastro-oesophageal reflux disease symptoms on COPD exacerbation. Thorax 2008; 63:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/14\">",
"      Wells JM, Washko GR, Han MK, et al. Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med 2012; 367:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/15\">",
"      Murata GH, Gorby MS, Kapsner CO, et al. A multivariate model for the prediction of relapse after outpatient treatment of decompensated chronic obstructive pulmonary disease. Arch Intern Med 1992; 152:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/16\">",
"      Hernandez C, Casas A, Escarrabill J, et al. Home hospitalisation of exacerbated chronic obstructive pulmonary disease patients. Eur Respir J 2003; 21:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/17\">",
"      Ojoo JC, Moon T, McGlone S, et al. Patients' and carers' preferences in two models of care for acute exacerbations of COPD: results of a randomised controlled trial. Thorax 2002; 57:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/18\">",
"      Cotton MM, Bucknall CE, Dagg KD, et al. Early discharge for patients with exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Thorax 2000; 55:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/19\">",
"      Davies L, Wilkinson M, Bonner S, et al. \"Hospital at home\" versus hospital care in patients with exacerbations of chronic obstructive pulmonary disease: prospective randomised controlled trial. BMJ 2000; 321:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/20\">",
"      Skwarska E, Cohen G, Skwarski KM, et al. Randomized controlled trial of supported discharge in patients with exacerbations of chronic obstructive pulmonary disease. Thorax 2000; 55:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/21\">",
"      Ram FS, Wedzicha JA, Wright J, Greenstone M. Hospital at home for patients with acute exacerbations of chronic obstructive pulmonary disease: systematic review of evidence. BMJ 2004; 329:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/22\">",
"      Zvezdin B, Milutinov S, Kojicic M, et al. A postmortem analysis of major causes of early death in patients hospitalized with COPD exacerbation. Chest 2009; 136:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/23\">",
"      Myint PK, Lowe D, Stone RA, et al. U.K. National COPD Resources and Outcomes Project 2008: patients with chronic obstructive pulmonary disease exacerbations who present with radiological pneumonia have worse outcome compared to those with non-pneumonic chronic obstructive pulmonary disease exacerbations. Respiration 2011; 82:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/24\">",
"      Choi PP, Day A, Etchells E. Gaps in the care of patients admitted to hospital with an exacerbation of chronic obstructive pulmonary disease. CMAJ 2004; 170:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/25\">",
"      Saudny-Unterberger H, Martin JG, Gray-Donald K. Impact of nutritional support on functional status during an acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 156:794.",
"     </a>",
"    </li>",
"    <li>",
"     Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: Updated 2007 file://www.goldcopd.org (Accessed on March 03, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/27\">",
"      Stoller JK. Clinical practice. Acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 346:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/28\">",
"      Tarpy SP, Celli BR. Long-term oxygen therapy. N Engl J Med 1995; 333:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/29\">",
"      Snow V, Lascher S, Mottur-Pilson C, Joint Expert Panel on Chronic Obstructive Pulmonary Disease of the American College of Chest Physicians and the American College of Physicians-American Society of Internal Medicine. Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 2001; 134:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/30\">",
"      Bach PB, Brown C, Gelfand SE, et al. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. Ann Intern Med 2001; 134:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/31\">",
"      Cydulka RK, Emerman CL. Effects of combined treatment with glycopyrrolate and albuterol in acute exacerbation of chronic obstructive pulmonary disease. Ann Emerg Med 1995; 25:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/32\">",
"      Nair S, Thomas E, Pearson SB, Henry MT. A randomized controlled trial to assess the optimal dose and effect of nebulized albuterol in acute exacerbations of COPD. Chest 2005; 128:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/33\">",
"      Edwards L, Perrin K, Williams M, et al. Randomised controlled crossover trial of the effect on PtCO2 of oxygen-driven versus air-driven nebulisers in severe chronic obstructive pulmonary disease. Emerg Med J 2012; 29:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/34\">",
"      O'Driscoll BR, Howard LS, Davison AG, British Thoracic Society. BTS guideline for emergency oxygen use in adult patients. Thorax 2008; 63 Suppl 6:vi1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/35\">",
"      O'Driscoll BR, Taylor RJ, Horsley MG, et al. Nebulised salbutamol with and without ipratropium bromide in acute airflow obstruction. Lancet 1989; 1:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/36\">",
"      In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group. Chest 1994; 105:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/37\">",
"      Karpel JP. Bronchodilator responses to anticholinergic and beta-adrenergic agents in acute and stable COPD. Chest 1991; 99:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/38\">",
"      Albert RK, Martin TR, Lewis SW. Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency. Ann Intern Med 1980; 92:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/39\">",
"      Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999; 340:1941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/40\">",
"      Quon BS, Gan WQ, Sin DD. Contemporary management of acute exacerbations of COPD: a systematic review and metaanalysis. Chest 2008; 133:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/41\">",
"      de Jong YP, Uil SM, Grotjohan HP, et al. Oral or IV prednisolone in the treatment of COPD exacerbations: a randomized, controlled, double-blind study. Chest 2007; 132:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/42\">",
"      Lindenauer PK, Pekow PS, Lahti MC, et al. Association of corticosteroid dose and route of administration with risk of treatment failure in acute exacerbation of chronic obstructive pulmonary disease. JAMA 2010; 303:2359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/43\">",
"      Cochrane B, Quinn S, Walters H, Young I. Investigating the adverse respiratory effects of beta-blocker treatment: six years of prospective longitudinal data in a cohort with cardiac disease. Intern Med J 2012; 42:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/44\">",
"      Black PN, Morgan-Day A, McMillan TE, et al. Randomised, controlled trial of N-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease [ISRCTN21676344]. BMC Pulm Med 2004; 4:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/45\">",
"      Roberts CM, Lowe D, Bucknall CE, et al. Clinical audit indicators of outcome following admission to hospital with acute exacerbation of chronic obstructive pulmonary disease. Thorax 2002; 57:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/46\">",
"      Donaldson GC, Wedzicha JA. COPD exacerbations .1: Epidemiology. Thorax 2006; 61:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/47\">",
"      Connors AF Jr, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996; 154:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/48\">",
"      Slenter RH, Sprooten RT, Kotz D, et al. Predictors of 1-year mortality at hospital admission for acute exacerbations of chronic obstructive pulmonary disease. Respiration 2013; 85:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/49\">",
"      Almagro P, Salvad&oacute; M, Garcia-Vidal C, et al. Pseudomonas aeruginosa and mortality after hospital admission for chronic obstructive pulmonary disease. Respiration 2012; 84:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/50\">",
"      Cote CG, Dordelly LJ, Celli BR. Impact of COPD exacerbations on patient-centered outcomes. Chest 2007; 131:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/51\">",
"      Au DH, Bryson CL, Chien JW, et al. The effects of smoking cessation on the risk of chronic obstructive pulmonary disease exacerbations. J Gen Intern Med 2009; 24:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/52\">",
"      Kessler R, St&aring;hl E, Vogelmeier C, et al. Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study. Chest 2006; 130:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/53\">",
"      Turnock AC, Walters EH, Walters JA, Wood-Baker R. Action plans for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005; :CD005074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/54\">",
"      Lehouck A, Mathieu C, Carremans C, et al. High doses of vitamin D to reduce exacerbations in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2012; 156:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23641/abstract/55\">",
"      Gold DR, Manson JE. Severe vitamin D deficiency: a prerequisite for COPD responsiveness to vitamin D supplementation? Ann Intern Med 2012; 156:156.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1461 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-197.136.42.3-3357F5F93E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_5_23641=[""].join("\n");
var outline_f23_5_23641=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRECIPITANTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INITIAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT GOALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      OXYGEN THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PHARMACOLOGIC TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Beta adrenergic agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Anticholinergic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H344158021\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H344158046\">",
"      - Route",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H344158097\">",
"      - Dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H344158053\">",
"      - Duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Mucoactive agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Methylxanthines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CHEST PHYSIOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      MECHANICAL VENTILATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Noninvasive ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Invasive ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1461\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1461|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/42/9901\" title=\"table 1\">",
"      Rapid overview severe acute COPD exacerbation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/48/29451\" title=\"table 2\">",
"      Bacterial pathogens in AECOPD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/28/35275\" title=\"table 3\">",
"      Severity of airflow limitation in COPD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/61/42972\" title=\"table 4\">",
"      Relative potency glucocorticoids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?34/7/34928?source=related_link\" title=\"calculator 1\">",
"      Calculator: Nasal Canula Oxygen Fractional Inspired O2 (FIO2) Estimate",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18762?source=related_link\">",
"      Delivery of inhaled medication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22103?source=related_link\">",
"      Glucocorticoid withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7866?source=related_link\">",
"      Management of infection in acute exacerbations of chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=related_link\">",
"      Management of stable chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/59/8120?source=related_link\">",
"      Mechanical ventilation in acute respiratory failure complicating COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=related_link\">",
"      Noninvasive positive pressure ventilation in acute respiratory failure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28407?source=related_link\">",
"      Oxygen toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33925?source=related_link\">",
"      Oxygenation and mechanisms of hypoxemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/48/15107?source=related_link\">",
"      Patient information: Chronic bronchitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/52/14148?source=related_link\">",
"      Patient information: Chronic obstructive pulmonary disease (COPD) treatments (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/11/24755?source=related_link\">",
"      Patient information: Medicines for chronic obstructive pulmonary disease (COPD) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38840?source=related_link\">",
"      Pulmonary rehabilitation in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33305?source=related_link\">",
"      Role of anticholinergic therapy in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25031?source=related_link\">",
"      Role of methylxanthines in the treatment of COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34648?source=related_link\">",
"      Role of mucoactive agents in the treatment of COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/7/10360?source=related_link\">",
"      Role of systemic glucocorticoid therapy in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18856?source=related_link\">",
"      The use of inhaler devices in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3064?source=related_link\">",
"      Use of oxygen in patients with hypercapnia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_5_23642="Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults";
var content_f23_5_23642=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/5/23642/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/5/23642/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/5/23642/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/5/23642/contributors\">",
"     Bob Lowenberg, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/5/23642/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/5/23642/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/5/23642/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of acute lymphoblastic leukemia (ALL) is established, induction chemotherapy is given with the following primary goals:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rapid restoration of bone marrow function, using multiple chemotherapy drugs at acceptable toxicities, in order to prevent the emergence of resistant subclones.",
"     </li>",
"     <li>",
"      Use of adequate initial and prophylactic treatment of sanctuary sites, such as the central nervous system (CNS), since CNS relapse is associated with a poor prognosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Induction therapy aims to reduce the total body leukemia cell population from approximately 10",
"    <sup>",
"     12",
"    </sup>",
"    to below the cytologically detectable level of about 10",
"    <sup>",
"     9",
"    </sup>",
"    cells. A substantial burden of leukemia cells persists undetected (eg, \"minimal residual disease\"), leading to relapse if no further therapy were administered.",
"   </p>",
"   <p>",
"    The induction chemotherapy for adults with newly diagnosed ALL is reviewed here. The following related subjects are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical and pathologic features, and diagnosis of ALL in adults (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26007?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of precursor B cell acute lymphoblastic leukemia/lymphoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30023?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Post-remission therapy for ALL (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/15/39161?source=see_link\">",
"       \"Post-remission therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Treatment of relapsed or refractory ALL (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/15/21753?source=see_link\">",
"       \"Treatment of relapsed or refractory acute lymphoblastic leukemia in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Treatment of ALL in children (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31850?source=see_link\">",
"       \"Overview of the treatment of acute lymphoblastic leukemia in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Detection of minimal residual disease following treatment of ALL (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15880?source=see_link\">",
"       \"Detection of minimal residual disease in acute lymphoblastic leukemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31625?source=see_link\">",
"       \"Clinical use of minimal residual disease detection in acute lymphoblastic leukemia\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to a history and physical examination, it is our practice to perform the following pretreatment studies in patients with ALL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laboratory studies include a complete blood count with differential, chemistries with liver and renal function and electrolytes, glucose, lactate dehydrogenase (LDH), calcium, phosphorus, uric acid, albumin and total protein, serum lysozyme, and serology for hepatitis B, herpes simplex virus (HSV) and cytomegalovirus (CMV) infection. Human leukocyte antigen (HLA) typing should be performed for patients who are candidates for hematopoietic cell transplantation (HCT). Women of child-bearing age should undergo a pregnancy test.",
"     </li>",
"     <li>",
"      Unilateral bone marrow aspiration and biopsy is recommended for all patients. This sample should be sent for pathologic review, immunophenotyping, cytochemistry, and cytogenetics. Marrow aspirate or peripheral blood blasts should be sent for reverse transcriptase polymerase chain reaction (RT-PCR) analysis for BCR-ABL in order to rapidly identify Philadelphia chromosome positive ALL. If the bone marrow is not aspirable, RT-PCR can be performed on peripheral blood blast cells. In some centers, a FISH analysis aimed at excluding BCR-ABL can be performed rapidly. If a satisfactory aspirate for cytogenetics is not obtained, peripheral blood analysis for 11q23 abnormalities at least should be done using FISH analysis.",
"     </li>",
"     <li>",
"      A chest x-ray, an electrocardiogram (EKG), and a study of cardiac function (eg, ejection fraction measured by echocardiogram or MUGA) should be performed at baseline, especially for patients with a cardiac history, prior anthracycline exposure, or cardiovascular symptoms.",
"     </li>",
"     <li>",
"      Dental evaluation for possible infection foci is warranted [",
"      <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with neurologic signs or symptoms should undergo imaging studies to evaluate for meningeal disease, or central nervous system bleeding. Lumbar puncture is indicated in all patients to examine the cerebrospinal fluid (CSF) for leukemic involvement. Care must be taken to avoid contaminating the CSF specimen with peripheral blood if blasts are present. CSF should be sent for both cytology (examination of stained cytospin slides) and flow cytometry.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Central venous access must be placed. Two or three independent ports aid medical management of transfusions, chemotherapy, antibiotics, and other intravenous support. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44553?source=see_link\">",
"     \"Overview of central venous access\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Men and women with child-bearing potential should receive counseling about the potential effect of treatment on their fertility and options for fertility-preserving measures. Given the urgent need for treatment, options for women are limited, but men can often participate in sperm banking. Typically, the drugs used to induce remission in ALL may not cause sterility in younger patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=see_link\">",
"     \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The speed with which intensive remission induction chemotherapy should begin varies with the individual patient's condition and treatment options. In general, it is far more important to stabilize a patient's condition and correct or control co-morbidities, such as infection, bleeding, hyperuricemia, dehydration, renal dysfunction, anemia, and thrombocytopenia, than it is to immediately start chemotherapy. Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    can be used for cytoreduction of an elevated peripheral blast cell count while these problems are addressed. This interval of several days also allows for complete genetic screening where the results will have an impact on the choice of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination chemotherapy is the primary treatment modality for patients with ALL. There is no role for surgery or radiation therapy in the induction phase. Multiple induction regimens have been developed, most often based upon pediatric regimens. None have been directly compared in a prospective randomized trial. As such, there is no single best regimen for induction therapy in ALL and patients should be encouraged to participate in clinical trials whenever possible.",
"   </p>",
"   <p>",
"    These chemotherapy regimens have evolved empirically into complex schemes that use numerous agents in various doses, combinations, and schedules. Few of the individual components have been tested rigorously in randomized trials. Thus, it is difficult to critically analyze the absolute contribution of each drug or dose schedule to the ultimate outcome. Numerous nonrandomized trials have attempted to answer these questions, but multiple alterations in study design between sequential trials have made it difficult to assess the exact merit of each modification.",
"   </p>",
"   <p>",
"    Most chemotherapy regimens for ALL contain",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , a corticosteroid (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ), and an anthracycline (",
"    <a class=\"graphic graphic_table graphicRef61620 \" href=\"UTD.htm?19/51/20286\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/2-8\">",
"     2-8",
"    </a>",
"    ]. In addition, some form of central nervous system (CNS) prophylaxis is incorporated. With these regimens, more than 80 percent of newly diagnosed adults with ALL enter complete remission (CR). Protocols that have added other agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , 6-mercaptopurine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/55/4983?source=see_link\">",
"     teniposide",
"    </a>",
"    , or asparaginase) have not improved the CR rate; however, some have demonstrated a faster time to achievement of CR, which may be associated with prolonged remissions [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following are examples of the most commonly used regimens:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cancer and Leukemia Group B (CALGB study 8811 or 9111) ALL regimen (",
"      <a class=\"graphic graphic_table graphicRef67471 \" href=\"UTD.htm?12/56/13198\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Standard or augmented Berlin-Frankfurt-Munster (BFM) has been used by the Children&rsquo;s Cancer Group for children and adolescents (",
"      <a class=\"graphic graphic_table graphicRef81231 \" href=\"UTD.htm?30/12/30927\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hyperfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (Hyper-CVAD) alternating with high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      &nbsp;(",
"      <a class=\"graphic graphic_table graphicRef50617 \" href=\"UTD.htm?19/26/19886\">",
"       table 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      French GRAALL-2003 regimen for younger adults (",
"      <a class=\"graphic graphic_table graphicRef54375 \" href=\"UTD.htm?22/26/22959\">",
"       table 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Details on these specific regimens are provided in the sections that follow. All patients with newly diagnosed ALL require induction chemotherapy with the goal of achieving a complete remission. Patients should be encouraged to participate in clinical trials whenever possible. If a clinical trial is not available or if the patient chooses not to participate in a clinical trial, any of the regimens above would be reasonable and a choice should be made based upon the physician's comfort with administration. We typically use CALGB ALL clinical trial regimens at our institution (",
"    <a class=\"graphic graphic_table graphicRef67471 \" href=\"UTD.htm?12/56/13198\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     General considerations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Anthracyclines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of an anthracycline in the treatment of all adults with ALL was perhaps best illustrated by an early randomized trial (CALGB 7612) that incorporated the anthracycline",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    during the first three days of induction therapy into a chemotherapy program that included",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , and L-asparaginase; patients who received daunorubicin demonstrated superior CR rates (83 versus 47 percent) and median remission duration (18 versus 5 months) when compared with those who did not receive daunorubicin [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/17\">",
"     17",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     Doxorubicin",
"    </a>",
"    , daunorubicin, zorubicin, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    appear to produce comparable results [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/3,10,12,17-24\">",
"     3,10,12,17-24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prospective trial that randomly assigned treatment of 778 adults with newly diagnosed ALL to receive induction therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    , asparaginase) with or without a single dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    reported similar rates of CR (81 and 83 percent) and eight-year disease-free survival (34 and 31 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/21\">",
"     21",
"    </a>",
"    ]. Other trials that have investigated the addition of cyclophosphamide into the treatment regimen of ALL have suggested that cyclophosphamide may increase the rapidity with which CR is achieved and may increase remission duration. Two sequential cooperative group trials involving 379 adults reported a similar CR rate (85 percent) and a median remission duration of 28 months [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/25\">",
"     25",
"    </a>",
"    ]. However, the median remission duration varied according to the rapidity of CR attainment, being 34 months for the 237 patients who achieved CR within 30 days, compared with 20 months for the 88 patients who required more than 30 days to enter into remission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Asparaginase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asparaginase is a key component of the ALL regimens for children leading to superior CR and disease-free survival rates [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/18,26\">",
"     18,26",
"    </a>",
"    ]. It is a component of the CALGB ALL regimen, the BFM regimen, the GRAALL 2003 regimen, and the modified Hyper-CVAD regimen, but not the standard Hyper-CVAD regimen.",
"   </p>",
"   <p>",
"    The importance of asparagine depletion was illustrated in one study of 85 adults receiving pegylated asparaginase [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/27\">",
"     27",
"    </a>",
"    ]. The median overall survival of patients who demonstrated plasma asparagine depletion was significantly longer when compared with patients who still had measurable plasma asparagine (31 versus 13 months, respectively).",
"   </p>",
"   <p>",
"    Asparaginase can be associated with allergic reactions, coagulopathies, acute pancreatitis, and increased liver transaminases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/28\">",
"     28",
"    </a>",
"    ]. There are three formulations of asparaginase available, each with different half-lives and risk of allergic reactions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Native",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/20/10567?source=see_link\">",
"       Escherichia coli Asparaginase",
"      </a>",
"      &mdash; half-life approximately one day",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/39/12917?source=see_link\">",
"       Erwinia Asparaginase",
"      </a>",
"      &mdash; half-life approximately 14 hours",
"     </li>",
"     <li>",
"      Pegylated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/20/10567?source=see_link\">",
"       Escherichia coli Asparaginase",
"      </a>",
"      (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/9/42133?source=see_link\">",
"       pegaspargase",
"      </a>",
"      , Oncaspar&reg;) &mdash; half-life approximately six days",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The schedule of asparaginase administration varies depending upon the formulation chosen. In general, the pegylated asparaginase appears to be less immunogenic while providing equal or greater efficacy when compared with the other formulations [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/27,29-31\">",
"     27,29-31",
"    </a>",
"    ]. It can be administered once per week or every two weeks as opposed to daily or every other day for the other formulations. In addition, patients who receive pegylated asparaginase appear to be less likely to develop antibodies that result in increased clearance of asparaginase from the circulation and possibly to reduced efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/32-39\">",
"     32-39",
"    </a>",
"    ]. As such, pegylated asparaginase has become the preferred preparation for most circumstances. Infusion reactions to asparaginase are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43930?source=see_link&amp;anchor=H45#H45\">",
"     \"Infusion reactions to systemic chemotherapy\", section on 'L-asparaginase'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The dose of L-asparaginase used varies from 6000",
"    <span class=\"nowrap\">",
"     units/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    (in the CALGB regimen) to 20,000",
"    <span class=\"nowrap\">",
"     units/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    (in the modified Hyper-CVAD regimen) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/12,40\">",
"     12,40",
"    </a>",
"    ]. Dosing with pegylated asparaginase is lower and typically 2500",
"    <span class=\"nowrap\">",
"     units/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"    However, the ideal dosing for either formulation is not known. Preliminary results of an analysis by the German Multicenter ALL study group involving 1226 patients 15 to 56 years old showed no improvement in the CR rate but a significant prolongation of survival when higher doses of pegylated asparaginase were used during remission induction and consolidation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Choice of steroid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    has been incorporated as the steroid in the majority of ALL induction regimens. However, studies in children comparing induction regimens containing prednisone and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    have reported that patients treated with dexamethasone have lower rates of relapse, fewer thrombotic complications, and perhaps fewer opportunistic infections than those treated with prednisone [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. On the other hand, dexamethasone has been associated with a higher rate of avascular necrosis of hips and shoulders than prednisone; this is more commonly seen in adolescents and young adults. The ideal steroid choice for adults has yet to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H783962\">",
"    <span class=\"h3\">",
"     Addition of rituximab for CD20+ ALL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The humanized anti-CD20 monoclonal antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    has been successfully administered in combination with ALL induction regimens and appears to improve outcomes for younger adults with CD20 positive ALL. As described below, nonrandomized studies have suggested a benefit from adding rituximab to the hyper-CVAD and BFM regimens.",
"   </p>",
"   <p>",
"    A benefit from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    was initially demonstrated in a single center study that reported superior survival rates among adolescents and younger adults (&lt;60 years) with de novo Philadelphia chromosome negative precursor B cell ALL treated with a modified hyper-CVAD regimen plus rituximab when compared with historical controls treated with standard hyper-CVAD without rituximab [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/40\">",
"     40",
"    </a>",
"    ]. In contrast, older adults (&ge;60 years) did not appear to benefit from the addition of rituximab. The GMALL study group subsequently evaluated 196 standard risk patients and 67 high risk patients and reported that those cohorts which had received rituximab with chemotherapy had significantly higher molecular remission rates and longer overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For younger adults (&lt;60 years) with CD20 positive ALL, we suggest the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    therapy to the hyper-CVAD and BFM regimens. Further studies are needed to assess its use in combination with other chemotherapy regimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     CNS prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact risk of central nervous system (CNS) involvement for ALL is difficult to ascertain because all current treatment regimens include CNS prophylaxis. ALL has a high risk of CNS involvement with some studies reporting rates as high as 78 percent at some point in the disease course in patients not given CNS prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. This rate appears to decrease to less than 20 percent when CNS prophylaxis is routinely administered. Less than 10 percent of patients will have CNS involvement at the time of diagnosis.",
"   </p>",
"   <p>",
"    The method of CNS prophylaxis used should be consistent with that included in the prospective studies investigating the particular treatment regimen chosen (eg, intrathecal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    plus cranial irradiation used in the CALGB ALL regimen). The treatment of central nervous system involvement at diagnosis is discussed below. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Central nervous system involvement'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     CALGB ALL regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Cancer and Leukemia Group B (CALGB) ALL regimen uses a five-drug combination modified from regimens used for high risk pediatric ALL (",
"    <a class=\"graphic graphic_table graphicRef67471 \" href=\"UTD.htm?12/56/13198\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Treatment is given in five courses that span 24 months.",
"   </p>",
"   <p>",
"    A phase II multicenter prospective clinical trial was performed in 197 patients with newly diagnosed ALL (age 16 to 80; median age 32) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/12\">",
"     12",
"    </a>",
"    ]. Complete remission (CR) was obtained in 85 percent, 7 percent were refractory and 9 percent (17 patients) died during induction. After a median follow-up of 43 months, the median survival was 36 months and the median remission duration was 29 months. Severe (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    toxicities included leukopenia (98 percent), thrombocytopenia (94 percent), anemia (65 percent), infection (54 percent), and increased transaminases (25 percent). There were eight episodes of clinically significant pancreatitis. Most deaths were related to gram negative bacteremia or fungemia in older patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     BFM regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Berlin-Frankfurt-Munster (BFM) regimen is frequently used for the treatment of pediatric ALL and can be considered for young adults with a good performance status (",
"    <a class=\"graphic graphic_table graphicRef81231 \" href=\"UTD.htm?30/12/30927\">",
"     table 3",
"    </a>",
"    ). There are two basic versions: the standard BFM regimen and a more intensive \"augmented BFM\" regimen. Both versions include the same induction therapy that consists of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , asparaginase, intrathecal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    , and intrathecal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    A retrospective comparison of 321 adolescents (age 16 to 20 years) with newly diagnosed ALL reported that patients treated by the Children's Cancer Group (CCG) using BFM had superior rates of seven-year event-free survival (63 versus 34 percent) and overall survival (67 versus 46 percent) when compared with those treated by the CALGB using the CALGB ALL regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/14\">",
"     14",
"    </a>",
"    ]. Patients receiving BFM received more intensive central nervous system prophylaxis and higher doses of nonmyelosuppressive agents. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Young adults/adolescents'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A single institution retrospective study of standard or augmented BFM in 29 adults (age 19 to 70) with newly diagnosed ALL reported a CR rate of 93 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/49\">",
"     49",
"    </a>",
"    ]. At a median follow-up of 6.7 years, rates of five-year event-free survival were 39 and 50 percent for patients who received standard and augmented BFM, respectively. There were two toxic deaths. The most common nonhematologic toxicities were infections (89 percent severe) and sensory neuropathy (mostly mild).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Hyper CVAD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of hyperfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (Hyper-CVAD) alternating with high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    has also been used in adults with ALL (",
"    <a class=\"graphic graphic_table graphicRef50617 \" href=\"UTD.htm?19/26/19886\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/15,50-53\">",
"     15,50-53",
"    </a>",
"    ]. This regimen includes a risk-stratified schedule of central nervous system prophylaxis with intrathecal methotrexate and intrathecal cytarabine. The dose-intensive phase spans six to seven months and is followed by 24 to 30 months of maintenance therapy.",
"   </p>",
"   <p>",
"    A prospective trial of a Hyper-CVAD-based regimen in 204 patients with newly diagnosed ALL (median age 39) reported a 91 percent complete remission rate and 6 percent mortality rate during induction [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/15\">",
"     15",
"    </a>",
"    ]. Five-year overall survival was 39 percent. Severe, prolonged myelosuppression was universal. Median times to granulocyte and platelet recovery were 18 and 21 days, respectively. Common toxicities included infection (55 percent), fever of unknown origin (45 percent), neurotoxicity (6 percent), moderate to severe mucositis (6 percent), moderate to severe diarrhea (3 percent), ileus (2 percent), and disseminated intravascular coagulation (2 percent).",
"   </p>",
"   <p>",
"    Further follow-up (median of 63 months) of 288 patients with newly diagnosed ALL treated with this hyper-CVAD-based regimen reported a CR rate of 92 percent and five-year overall survival rates of 38 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/52\">",
"     52",
"    </a>",
"    ]. Induction mortality varied with patient age being 2 and 15 percent for patients &lt;60 or &ge;60 years of age, respectively.",
"   </p>",
"   <p>",
"    Further studies are required to determine whether the hyper-CVAD regimen may be modified further for certain patient populations. As an example, one study using historical controls reported that the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    to the hyper-CVAD regimen resulted in superior survival rates in younger patients with ALL that expressed CD20 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/40\">",
"     40",
"    </a>",
"    ]. There was no benefit for older patients. (See",
"    <a class=\"local\" href=\"#H783962\">",
"     'Addition of rituximab for CD20+ ALL'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     GRAALL 2003 regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The GRAALL-2003 regimen is another pediatric-inspired therapy that includes remission induction with high doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , and asparaginase in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and intrathecal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef54375 \" href=\"UTD.htm?22/26/22959\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A phase II trial of GRAALL-2003 in 225 adults patients (median age 31 years) with Philadelphia chromosome negative ALL reported a complete remission rate of 94 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/16\">",
"     16",
"    </a>",
"    ]. Severe (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    non-hematologic toxicities during induction included liver toxicity (20 percent), thromboembolism (4 percent), intolerance to asparaginase (2 percent), and peripheral neuropathy (1 percent). There were 14 deaths during induction due to sepsis (nine patients), stroke (four patients), and liver failure (one patient). Estimated event-free and overall survival rates at 42 months were 55 and 60 percent, respectively. In an exploratory subgroup analysis, patients over the age of 45 years had a similar incidence of relapse (30 versus 32 percent), but significantly higher rates of chemotherapy-related deaths (23 versus 5 percent) and deaths during first complete remission (22 versus 5 percent) when compared with patients 45 years or younger.",
"   </p>",
"   <p>",
"    Based upon this phase II trial, the GRAALL-2003 regimen appears to be an acceptable treatment option for young adults with newly diagnosed ALL. However, treatment-related toxicities limit its use in patients over the age of 45 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MONITORING DURING TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy for ALL is highly toxic, primarily to the hematopoietic system. Most patients will require hospitalization with blood product support, but select patients may be treated as outpatients. Daily laboratory testing should be performed and generally includes a complete blood count and chemistries with renal function, glucose, and electrolytes. Calcium, phosphorus, and uric acid levels should be monitored until normal. Liver function tests should be assessed at least weekly.",
"   </p>",
"   <p>",
"    If there is unexpectedly severe or prolonged myelosuppression in patients taking 6-mercaptopurine or 6-thioguanine, the medication should be stopped and a genetic analysis obtained for determining thiopurine methyltransferase activity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/32/22026?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of pharmacogenomics\", section on 'Thiopurine methyltransferase'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUPPORTIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive care is a critical component to the treatment of patients with acute leukemia. This includes the management of cytopenias, infections, tumor lysis, and other complications that accompany the treatment of acute leukemia. These are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=see_link&amp;anchor=H14#H14\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\", section on 'Supportive care'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     EVALUATION OF RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial response to treatment is typically evaluated with a unilateral bone marrow aspirate and biopsy once adequate values for absolute neutrophil count",
"    <span class=\"nowrap\">",
"     (&gt;1000/microL)",
"    </span>",
"    and platelet count",
"    <span class=\"nowrap\">",
"     (&gt;100,000/microL)",
"    </span>",
"    are obtained. A core biopsy is required to assess marrow cellularity.",
"   </p>",
"   <p>",
"    The primary goal of ALL therapy is achievement of an initial complete remission (CR), defined as the eradication of all detectable leukemia cells (less than 5 percent blasts) from the bone marrow and blood and the restoration of normal hematopoiesis (&gt;25 percent cellularity and normal peripheral blood counts). The importance of achieving a CR was shown in the International ALL trial; patients achieving or not achieving CR had overall survival rates of 45 versus 5 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/9\">",
"     9",
"    </a>",
"    ]. However, once a CR is achieved, therapy must continue for an extended period of time to eliminate subclinical disease (minimal residual disease) known to contribute to relapse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/15/39161?source=see_link\">",
"     \"Post-remission therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While CR has historically been defined based upon morphologic criteria, it has been proposed that an assessment of minimal residual disease using immunological or molecular techniques can better define prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/54\">",
"     54",
"    </a>",
"    ]. As yet, prospective studies have not demonstrated that altering therapy based upon evidence of minimal residual disease leads to a better outcome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15880?source=see_link\">",
"     \"Detection of minimal residual disease in acute lymphoblastic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31625?source=see_link\">",
"     \"Clinical use of minimal residual disease detection in acute lymphoblastic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who do not achieve a CR with initial induction therapy are considered to have resistant disease. Early allogeneic transplantation can rescue some of these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/15/21753?source=see_link\">",
"     \"Treatment of relapsed or refractory acute lymphoblastic leukemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     POST-REMISSION TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attainment of a CR is the first step in the treatment of ALL. However, relapse can be expected in the following weeks to months if no further therapy is given. Post-induction therapy is an essential component of the treatment of ALL. This is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/15/39161?source=see_link\">",
"     \"Post-remission therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SPECIAL SCENARIOS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of high risk ALL variants that may require special treatment programs. Some of these are listed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Philadelphia chromosome positive ALL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ALL who demonstrate the Philadelphia chromosome (Ph+) or its gene fusion product",
"    <span class=\"nowrap\">",
"     (BCR/ABL)",
"    </span>",
"    should be treated with a regimen that incorporates a tyrosine kinase inhibitor (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    ). Many questions regarding the treatment of Ph+ ALL remain to be answered, including the preferred tyrosine kinase inhibitor to combine with chemotherapy, the optimal scheduling of this TKI with chemotherapy, and the role for hematopoietic cell transplantation after remission is achieved. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44489?source=see_link\">",
"     \"Induction therapy for Philadelphia chromosome positive acute lymphoblastic leukemia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/26/3497?source=see_link&amp;anchor=H4420436#H4420436\">",
"     \"Post-remission therapy for Philadelphia chromosome positive acute lymphoblastic leukemia in adults\", section on 'Post-remission therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Central nervous system involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact risk of central nervous system (CNS) involvement for ALL is difficult to ascertain because all current treatment regimens include CNS prophylaxis. ALL has a high risk of CNS involvement with some studies reporting rates as high as 78 percent at some point in the disease course in patients not given CNS prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. This rate appears to decrease to less than 20 percent when CNS prophylaxis is routinely administered. Less than 10 percent of patients will have CNS involvement at the time of diagnosis.",
"   </p>",
"   <p>",
"    CNS leukemia is defined by the presence of leukemic blasts in a centrifuged preparation of cerebrospinal fluid (CSF) that does not have evidence of blood contamination. While the ideal treatment of patients with CNS involvement at the time of diagnosis is unknown, these patients are felt to be at higher risk for relapse. Cranial irradiation plus intrathecal chemotherapy is the mainstay of treatment of CNS involvement. Typically, 2400 cGy of radiation is given to the entire cranium over 12 doses. In addition, at least six doses of intrathecal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    should be administered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26458?source=see_link\">",
"     \"Treatment of leptomeningeal metastases (carcinomatous meningitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is not clear if patients who present with CNS involvement require more intensive therapy, such as allogeneic hematopoietic cell transplantation, after clearing of their CNS disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An exploratory subgroup analysis of 48 patients with CNS disease at presentation cleared with CNS directed therapy reported outcomes similar to those for the over 700 patients without CNS disease at presentation [",
"      <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective, international trial designed to evaluate the role of HCT in newly diagnosed adult ALL performed an exploratory subset analysis on the 77 of 1508 total patients (5 percent) that had CNS involvement at diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/56\">",
"       56",
"      </a>",
"      ]. Sixty-nine of the 77 patients (90 percent) attained a complete response. Post-remission therapy included allogeneic HCT (30 patients), autologous HCT (six patients), and chemotherapy (27 patients). Thirteen of 30 patients (43 percent) that went on to allogeneic HCT and 7 of the 27 patients (26 percent) treated with chemotherapy alone were alive after follow-up that ranged from 21 to 137 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     T cell lymphoblastic lymphoma/T cell ALL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biologically, T cell lymphoblastic lymphoma and T cell ALL appear to be a single disease; by convention, T cell ALL has greater than 25 percent blasts in the marrow or blasts in the blood. Patients with T cell lineage ALL are generally treated with the same regimens as those used for B cell lineage ALL. Often, these are young males with mediastinal lymphadenopathy. The initial white blood cell count may be markedly elevated, but this does not have the same poor prognostic importance in T cell ALL as does hyperleukocytosis in precursor B cell ALL. There is a high incidence of CNS involvement so prophylaxis is routine even for limited stage T-lymphoblastic lymphoma cases with no visible involvement of the blood or marrow. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30023?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a study from the German Multicenter Group for Adult ALL, 45 patients with T cell lymphoblastic",
"    <span class=\"nowrap\">",
"     lymphoma/T",
"    </span>",
"    cell ALL were treated with a regimen designed for adult ALL, which included an eight-drug standard induction regimen, prophylactic cranial and mediastinal irradiation, followed by consolidation and reinduction therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/57\">",
"     57",
"    </a>",
"    ]. Total treatment time was 6 to 12 months, with a CR rate of 93 percent; estimated disease-free survival at seven years was 62 percent. The majority of relapses occurred in the mediastinum (47 percent) despite 24 Gy of irradiation in six of seven patients. Neither stage, age, nor LDH had an influence on outcome.",
"   </p>",
"   <p>",
"    In the Italian GIMEMA 0288 trial, one of the largest adult ALL trials to date, 778 patients were randomly assigned to receive induction therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    , asparaginase) with or without a single dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/21\">",
"     21",
"    </a>",
"    ]. The rates of initial CR and continuous CR at eight years were similar in the two arms, being 81 versus 83 percent and 34 versus 31 percent for the five-drug versus the four-drug combination, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complete remission rates for B-lineage ALL (precursor B lymphoblastic leukemia), T-lineage ALL (precursor T lymphoblastic leukemia), and ALL with co-expression of myeloid markers were 83, 85, and 71 percent, respectively, while overall survival rates at eight years were similar at 30, 27, and 26 percent, respectively. A discussion of the differences among these disease variants can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26007?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of precursor B cell acute lymphoblastic leukemia/lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30023?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Burkitt-type ALL-L3",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended treatment for Burkitt-type ALL, a highly aggressive non-Hodgkin lymphoma variant, is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36217?source=see_link\">",
"     \"Treatment of Burkitt leukemia/lymphoma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Young adults/adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients diagnosed with ALL between the ages of 16 and 21 are a special group in that they may be treated by either adult or pediatric hematologists [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/58\">",
"     58",
"    </a>",
"    ]. Several retrospective comparative analyses have reported that young",
"    <span class=\"nowrap\">",
"     adults/adolescents",
"    </span>",
"    with ALL treated on pediatric protocols demonstrate superior event-free and overall survival rates when compared with similar patients enrolled on adult ALL protocols [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/14,59-62\">",
"     14,59-62",
"    </a>",
"    ]. Accordingly, a number of prospective trials are evaluating the outcomes of young adults when treated by adult hematologists using pediatric regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. Preliminary data suggest that pediatric regimens can be used without excess toxicity in young adults up to 30 years old [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14717280\">",
"    <span class=\"h2\">",
"     Older adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians often have concerns over the ability of older adults (ie, over age 55 to 65 years) to tolerate intensive chemotherapy. The management of ALL in older adults can be complicated by an increased number of comorbidities. A comprehensive geriatric assessment may be useful in assessing comorbidity and functional status in an elderly patient, thus permitting the formulation of an appropriate, individualized treatment plan. Special considerations for the use of chemotherapy in the elderly population are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41864?source=see_link\">",
"     \"Comprehensive geriatric assessment for patients with cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/42/10922?source=see_link\">",
"     \"Systemic chemotherapy for cancer in elderly persons\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is a paucity of data regarding the treatment of the older adult with ALL as this population is less likely to be represented in clinical trials. Outcomes are worse than for younger adults. As an example, a post hoc analysis compared the outcomes of 100 older adults (age 55 to 65 years) to that of 1814 younger patients (age 14 to 54 years) treated on a prospective trial of intensive chemotherapy in patients with newly diagnosed ALL [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/67\">",
"     67",
"    </a>",
"    ]. When compared with the younger cohort, the older adults had a lower complete remission rate (73 versus 93 percent) and lower rates of overall (21 versus 41 percent) and event-free (19 versus 37 percent) survival at five years.",
"   </p>",
"   <p>",
"    At least part of the worse outcomes noted for older adults are related to the higher rate of high risk cytogenetics in this population. Approximately half of older patients with ALL have",
"    <span class=\"nowrap\">",
"     Ph+/BCR-ABL",
"    </span>",
"    positive disease. For these patients, the prognosis has improved recently with the incorporation of tyrosine kinase inhibitors into frontline therapy. Drugs such as asparaginase,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , and anthracyclines, which are critical for the treatment of ALL in younger patients, are poorly tolerated by patients older than 60 years. Nevertheless, current treatment strategies for older adults still incorporate these agents, often at reduced doses. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Philadelphia chromosome positive ALL'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23301004\">",
"    <span class=\"h2\">",
"     Patients with Down syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Down syndrome who develop ALL have more treatment-related complications, including an increased frequency and severity of infections and mucositis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/68\">",
"     68",
"    </a>",
"    ]. Although this increased sensitivity relates to numerous chemotherapy agents, such patients have a particular sensitivity to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. As an example, a retrospective analysis of 131 children with ALL (44 of whom also had Down syndrome) receiving methotrexate demonstrated that children with Down syndrome had significantly higher rates of severe (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    mucositis (26 versus 4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/71\">",
"     71",
"    </a>",
"    ]. There was also a trend toward an increased rate of leukopenia (23 versus 10 percent of courses). There did not appear to be a difference in pharmacokinetics between the two populations in this study. However, other studies have suggested that an increased rate of methotrexate toxicity in this population may be due to increased activity of the reduced folate carrier gene on chromosome 21, which enhances the intracellular transport of methotrexate [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/72\">",
"     72",
"    </a>",
"    ]. In addition, the increased rate of infections may be due to a higher incidence of hyperglycemia among patients with Down syndrome treated with corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. They also have an increased risk of developing cardiotoxicity after treatment with anthracyclines [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40649?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of the outcome of acute lymphoblastic leukemia in children\", section on 'Down syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362238536\">",
"    <span class=\"h2\">",
"     Mixed-phenotype acute leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mixed-phenotype acute leukemia is a rare entity accounting for less than 5 percent of acute leukemias [",
"    <a class=\"abstract\" href=\"UTD.htm?23/5/23642/abstract/77\">",
"     77",
"    </a>",
"    ]. There is no standard therapy for patients with this condition and practice varies widely. Some patients are treated with AML-type induction therapy, some with ALL-type induction therapy, and some with hybrid treatment regimens. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=see_link&amp;anchor=H9675567#H9675567\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\", section on 'Mixed-phenotype acute leukemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"     www.clinicaltrials.gov",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?15/15/15602?source=see_link\">",
"       \"Patient information: Acute lymphoblastic leukemia (ALL) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/13/38098?source=see_link\">",
"       \"Patient information: Leukemia in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/34/17955?source=see_link\">",
"       \"Patient information: Acute lymphoblastic leukemia (ALL) treatment in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Once the diagnosis of acute lymphoblastic leukemia (ALL) is established, induction chemotherapy is given with the goal of rapidly restoring bone marrow function and attaining a complete remission. Combination chemotherapy is the primary treatment modality for patients with ALL. There is no role for surgery or total body radiation therapy in the induction phase. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiple induction regimens have been developed, most often based upon pediatric regimens. None have been directly compared in a prospective randomized trial. As such, there is no single best regimen for induction therapy in ALL, and patients should be encouraged to participate in clinical trials whenever possible.",
"     </li>",
"     <li>",
"      If a clinical trial is not available or if the patient chooses not to participate in a clinical trial, any of the following regimens would be reasonable and a choice should be made based upon the patient's age and performance status and the physician's comfort with administration:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Cancer and Leukemia Group B (CALGB) ALL regimen (",
"      <a class=\"graphic graphic_table graphicRef67471 \" href=\"UTD.htm?12/56/13198\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Standard or augmented Berlin-Frankfurt-Munster (BFM) for adolescents (",
"      <a class=\"graphic graphic_table graphicRef81231 \" href=\"UTD.htm?30/12/30927\">",
"       table 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hyperfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      alternating with high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      (Hyper-CVAD) (",
"      <a class=\"graphic graphic_table graphicRef50617 \" href=\"UTD.htm?19/26/19886\">",
"       table 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      French GRAALL-2003 regimen for younger adults (",
"      <a class=\"graphic graphic_table graphicRef54375 \" href=\"UTD.htm?22/26/22959\">",
"       table 5",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      These chemotherapy regimens contain",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      , a corticosteroid (ie,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      ), and an anthracycline in addition to other agents. Some form of central nervous system (CNS) prophylaxis is also incorporated. With these regimens, more than 80 percent of newly diagnosed adults with ALL enter complete remission (CR). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For younger adults (&lt;60 years) with CD20 positive ALL, we suggest the addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      therapy to the hyper-CVAD and BFM regimens (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Further studies are needed to assess its use in combination with other chemotherapy regimens. (See",
"      <a class=\"local\" href=\"#H783962\">",
"       'Addition of rituximab for CD20+ ALL'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with ALL who demonstrate the Philadelphia chromosome (Ph+) or its gene fusion product",
"      <span class=\"nowrap\">",
"       (BCR/ABL)",
"      </span>",
"      should be treated with a regimen that incorporates a",
"      <span class=\"nowrap\">",
"       BCR/ABL",
"      </span>",
"      tyrosine kinase inhibitor (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44489?source=see_link\">",
"       \"Induction therapy for Philadelphia chromosome positive acute lymphoblastic leukemia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chemotherapy for ALL is highly toxic, primarily to the hematopoietic system. Most patients will require hospitalization with daily laboratory monitoring and supportive care with blood products and antibiotics. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Monitoring during treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=see_link&amp;anchor=H14#H14\">",
"       \"Induction therapy for acute myeloid leukemia in younger adults\", section on 'Supportive care'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Attainment of a CR is the first step in the treatment of ALL. However, relapse can be expected in the following weeks to months if no further therapy is given. Postinduction therapy is an essential component of the treatment of ALL. This is presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/15/39161?source=see_link\">",
"       \"Post-remission therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/1\">",
"      Williford SK, Salisbury PL 3rd, Peacock JE Jr, et al. The safety of dental extractions in patients with hematologic malignancies. J Clin Oncol 1989; 7:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/2\">",
"      Laport GF, Larson RA. Treatment of adult acute lymphoblastic leukemia. Semin Oncol 1997; 24:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/3\">",
"      Hoelzer D. Treatment of acute lymphoblastic leukemia. Semin Hematol 1994; 31:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/4\">",
"      Preti A, Kantarjian HM. Management of adult acute lymphocytic leukemia: present issues and key challenges. J Clin Oncol 1994; 12:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/5\">",
"      Copelan EA, McGuire EA. The biology and treatment of acute lymphoblastic leukemia in adults. Blood 1995; 85:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/6\">",
"      Hoelzer D, G&ouml;kbuget N. New approaches to acute lymphoblastic leukemia in adults: where do we go? Semin Oncol 2000; 27:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/7\">",
"      Takeuchi J, Kyo T, Naito K, et al. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia 2002; 16:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/8\">",
"      Storring JM, Minden MD, Kao S, et al. Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen. Br J Haematol 2009; 146:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/9\">",
"      Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 2005; 106:3760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/10\">",
"      Cuttner J, Mick R, Budman DR, et al. Phase III trial of brief intensive treatment of adult acute lymphocytic leukemia comparing daunorubicin and mitoxantrone: a CALGB Study. Leukemia 1991; 5:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/11\">",
"      Stock W, Johnson JL, Stone RM, et al. Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. Cancer 2013; 119:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/12\">",
"      Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 1995; 85:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/13\">",
"      Larson RA, Dodge RK, Linker CA, et al. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood 1998; 92:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/14\">",
"      Stock W, La M, Sanford B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood 2008; 112:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/15\">",
"      Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000; 18:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/16\">",
"      Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol 2009; 27:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/17\">",
"      Gottlieb AJ, Weinberg V, Ellison RR, et al. Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomized trial by cancer and leukemia group B. Blood 1984; 64:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/18\">",
"      Linker CA, Levitt LJ, O'Donnell M, et al. Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report. Blood 1991; 78:2814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/19\">",
"      Hoelzer D, Thiel E, L&ouml;ffler H, et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988; 71:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/20\">",
"      Fi&egrave;re D, Lepage E, Sebban C, et al. Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. The French Group on Therapy for Adult Acute Lymphoblastic Leukemia. J Clin Oncol 1993; 11:1990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/21\">",
"      Annino L, Vegna ML, Camera A, et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 2002; 99:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/22\">",
"      Cassileth PA, Andersen JW, Bennett JM, et al. Adult acute lymphocytic leukemia: the Eastern Cooperative Oncology Group experience. Leukemia 1992; 6 Suppl 2:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/23\">",
"      Kantarjian HM, Walters RS, Keating MJ, et al. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia. J Clin Oncol 1990; 8:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/24\">",
"      Hussein KK, Dahlberg S, Head D, et al. Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy. Blood 1989; 73:57.",
"     </a>",
"    </li>",
"    <li>",
"     Larson RA, Dodge RK, Bloomfield CD, Schiffer CA. Treatment of biologically determined subsets of acute lymphoblastic leukemia in adults: Cancer and Leukemia Group B studies. In: Acute Leukemias VI: Prognostic factors and treatment strategies, Buchner T, Hiddeman W, Wormann B, et al. (Eds), Springer-Verlag, Berlin 1997. p.677.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/26\">",
"      Clavell LA, Gelber RD, Cohen HJ, et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med 1986; 315:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/27\">",
"      Wetzler M, Sanford BL, Kurtzberg J, et al. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood 2007; 109:4164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/28\">",
"      Earl M. Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia. Clin Adv Hematol Oncol 2009; 7:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/29\">",
"      Douer D, Yampolsky H, Cohen LJ, et al. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood 2007; 109:2744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/30\">",
"      Armstrong JK, Hempel G, Koling S, et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 2007; 110:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/31\">",
"      Dinndorf PA, Gootenberg J, Cohen MH, et al. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist 2007; 12:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/32\">",
"      Woo MH, Hak LJ, Storm MC, et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol 2000; 18:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/33\">",
"      Wang B, Relling MV, Storm MC, et al. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. Leukemia 2003; 17:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/34\">",
"      Albertsen BK, Schr&oslash;der H, Jakobsen P, et al. Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase. Med Pediatr Oncol 2002; 38:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/35\">",
"      Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 2002; 99:1986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/36\">",
"      Panosyan EH, Seibel NL, Martin-Aragon S, et al. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J Pediatr Hematol Oncol 2004; 26:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/37\">",
"      Pieters R, Hunger SP, Boos J, et al. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer 2011; 117:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/38\">",
"      Larson RA, Fretzin MH, Dodge RK, Schiffer CA. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia 1998; 12:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/39\">",
"      Kawedia JD, Liu C, Pei D, et al. Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood 2012; 119:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/40\">",
"      Thomas DA, O'Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol 2010; 28:3880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/41\">",
"      Goekbuget N, Baumann A, Beck J, et al. PEG-Asparaginase intensification in adult acute lymphoblastic leukemia (ALL): Significant improvement of outcome with moderate increase of liver toxicity in the German Multicenter Study Group for adult ALL (GMALL) Study 07/2003 (abstract 494). Blood (ASH Annual Meeting Abstracts) 2010; 116:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/42\">",
"      Caruso V, Iacoviello L, Di Castelnuovo A, et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood 2006; 108:2216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/43\">",
"      Nowak-G&ouml;ttl U, Ahlke E, Fleischhack G, et al. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration. Blood 2003; 101:2529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/44\">",
"      Vrooman LM, Stevenson KE, Supko JG, et al. Postinduction Dexamethasone and Individualized Dosing of Escherichia Coli L-Asparaginase Each Improve Outcome of Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia: Results From a Randomized Study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol 2013; 31:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/45\">",
"      Hoelzer D, Huettmann A, Kaul F, et al. Immunochemotherapy with rituximab improves molecular CR rate and outcome in CD20+ B-lineage standard and high risk patients; results of 263 CD20+ patients studied prospectively in GMALL Study 07/2003. Blood (ASH Annual Meeting Abstracts) 2010; 116:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/46\">",
"      Surapaneni UR, Cortes JE, Thomas D, et al. Central nervous system relapse in adults with acute lymphoblastic leukemia. Cancer 2002; 94:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/47\">",
"      Sancho JM, Ribera JM, Oriol A, et al. Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis. Cancer 2006; 106:2540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/48\">",
"      Hollender A, Kvaloy S, Nome O, et al. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol 2002; 13:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/49\">",
"      Chang JE, Medlin SC, Kahl BS, et al. Augmented and standard Berlin-Frankfurt-Munster chemotherapy for treatment of adult acute lymphoblastic leukemia. Leuk Lymphoma 2008; 49:2298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/50\">",
"      Weiser MA, O'Brien S, Thomas DA, et al. Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen. Cancer 2002; 94:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/51\">",
"      Weiser MA, Cabanillas ME, Konopleva M, et al. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Cancer 2004; 100:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/52\">",
"      Kantarjian H, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004; 101:2788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/53\">",
"      Garg R, Kantarjian H, Thomas D, et al. Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemotherapy. Cancer 2009; 115:2147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/54\">",
"      Bassan R, Spinelli O, Oldani E, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood 2009; 113:4153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/55\">",
"      Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 2004; 22:4075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/56\">",
"      Lazarus HM, Richards SM, Chopra R, et al. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. Blood 2006; 108:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/57\">",
"      Hoelzer D, G&ouml;kbuget N, Digel W, et al. Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood 2002; 99:4379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/58\">",
"      Nakano TA, Hunger SP. Blood consult: therapeutic strategy and complications in the adolescent and young adult with acute lymphoblastic leukemia. Blood 2012; 119:4372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/59\">",
"      Nachman J. Clinical characteristics, biologic features and outcome for young adult patients with acute lymphoblastic leukaemia. Br J Haematol 2005; 130:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/60\">",
"      Boissel N, Auclerc MF, Lh&eacute;ritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 2003; 21:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/61\">",
"      de Bont JM, Holt Bv, Dekker AW, et al. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia 2004; 18:2032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/62\">",
"      Pui CH, Pei D, Campana D, et al. Improved prognosis for older adolescents with acute lymphoblastic leukemia. J Clin Oncol 2011; 29:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/63\">",
"      Schiffer CA. Differences in outcome in adolescents with acute lymphoblastic leukemia: a consequence of better regimens? Better doctors? Both? J Clin Oncol 2003; 21:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/64\">",
"      Barry E, DeAngelo DJ, Neuberg D, et al. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol 2007; 25:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/65\">",
"      Nachman JB, La MK, Hunger SP, et al. Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group. J Clin Oncol 2009; 27:5189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/66\">",
"      Tricoli JV, Seibel NL, Blair DG, et al. Unique characteristics of adolescent and young adult acute lymphoblastic leukemia, breast cancer, and colon cancer. J Natl Cancer Inst 2011; 103:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/67\">",
"      Sive JI, Buck G, Fielding A, et al. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. Br J Haematol 2012; 157:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/68\">",
"      Whitlock JA. Down syndrome and acute lymphoblastic leukaemia. Br J Haematol 2006; 135:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/69\">",
"      Peeters M, Poon A. Down syndrome and leukemia: unusual clinical aspects and unexpected methotrexate sensitivity. Eur J Pediatr 1987; 146:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/70\">",
"      Ragab AH, Abdel-Mageed A, Shuster JJ, et al. Clinical characteristics and treatment outcome of children with acute lymphocytic leukemia and Down's syndrome. A Pediatric Oncology Group study. Cancer 1991; 67:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/71\">",
"      Buitenkamp TD, Math&ocirc;t RA, de Haas V, et al. Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia. Haematologica 2010; 95:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/72\">",
"      Taub JW, Ge Y. Down syndrome, drug metabolism and chromosome 21. Pediatr Blood Cancer 2005; 44:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/73\">",
"      Kalwinsky DK, Raimondi SC, Bunin NJ, et al. Clinical and biological characteristics of acute lymphocytic leukemia in children with Down syndrome. Am J Med Genet Suppl 1990; 7:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/74\">",
"      Sonabend RY, McKay SV, Okcu MF, et al. Hyperglycemia during induction therapy is associated with poorer survival in children with acute lymphocytic leukemia. J Pediatr 2009; 155:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/75\">",
"      Krischer JP, Epstein S, Cuthbertson DD, et al. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol 1997; 15:1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/5/23642/abstract/76\">",
"      O'Brien MM, Taub JW, Chang MN, et al. Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group Study POG 9421. J Clin Oncol 2008; 26:414.",
"     </a>",
"    </li>",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. World Health Organization classification of tumours of haematopoietic and lymphoid tissues, IARC Press, Lyon 2008.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4524 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.181.191-AA596B28AF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_5_23642=[""].join("\n");
var outline_f23_5_23642=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      General considerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Anthracyclines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Asparaginase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Choice of steroid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H783962\">",
"      - Addition of rituximab for CD20+ ALL",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - CNS prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CALGB ALL regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      BFM regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Hyper CVAD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      GRAALL 2003 regimen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MONITORING DURING TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUPPORTIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      EVALUATION OF RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      POST-REMISSION TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SPECIAL SCENARIOS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Philadelphia chromosome positive ALL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Central nervous system involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      T cell lymphoblastic lymphoma/T cell ALL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Burkitt-type ALL-L3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Young adults/adolescents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14717280\">",
"      Older adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23301004\">",
"      Patients with Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H362238536\">",
"      Mixed-phenotype acute leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4524\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4524|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/51/20286\" title=\"table 1\">",
"      Trials of ALL in adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/56/13198\" title=\"table 2\">",
"      CALGB regimen ALL adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/12/30927\" title=\"table 3\">",
"      BFM regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/26/19886\" title=\"table 4\">",
"      Modified Hyper CVAD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/26/22959\" title=\"table 5\">",
"      GRAALL 2003 regimen",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26007?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of precursor B cell acute lymphoblastic leukemia/lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30023?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31625?source=related_link\">",
"      Clinical use of minimal residual disease detection in acute lymphoblastic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41864?source=related_link\">",
"      Comprehensive geriatric assessment for patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15880?source=related_link\">",
"      Detection of minimal residual disease in acute lymphoblastic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=related_link\">",
"      Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44489?source=related_link\">",
"      Induction therapy for Philadelphia chromosome positive acute lymphoblastic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=related_link\">",
"      Induction therapy for acute myeloid leukemia in younger adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43930?source=related_link\">",
"      Infusion reactions to systemic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44553?source=related_link\">",
"      Overview of central venous access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/32/22026?source=related_link\">",
"      Overview of pharmacogenomics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40649?source=related_link\">",
"      Overview of the outcome of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31850?source=related_link\">",
"      Overview of the treatment of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/15/15602?source=related_link\">",
"      Patient information: Acute lymphoblastic leukemia (ALL) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/34/17955?source=related_link\">",
"      Patient information: Acute lymphoblastic leukemia (ALL) treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/13/38098?source=related_link\">",
"      Patient information: Leukemia in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/15/39161?source=related_link\">",
"      Post-remission therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/26/3497?source=related_link\">",
"      Post-remission therapy for Philadelphia chromosome positive acute lymphoblastic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/42/10922?source=related_link\">",
"      Systemic chemotherapy for cancer in elderly persons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36217?source=related_link\">",
"      Treatment of Burkitt leukemia/lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26458?source=related_link\">",
"      Treatment of leptomeningeal metastases (carcinomatous meningitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/15/21753?source=related_link\">",
"      Treatment of relapsed or refractory acute lymphoblastic leukemia in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_5_23643="Classification MTC";
var content_f23_5_23643=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F85653&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F85653&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of medullary thyroid cancer (MTC)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td>",
"        Hereditary&nbsp;MTC (germline RET mutation present)",
"       </td>",
"       <td>",
"        25 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Sporadic MTC (no germline RET mutation identified)",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        75 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Sporadic MTC (no germline RET mutation identified)",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; No somatic RET mutations found",
"       </td>",
"       <td>",
"        35 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Somatic RET mutations found",
"       </td>",
"       <td>",
"        65 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        - Exon 16, codon 918",
"       </td>",
"       <td>",
"        60 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        - Exon 11, codon 630, 634",
"       </td>",
"       <td>",
"        21 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        - Exon 10, codon 609, 620",
"       </td>",
"       <td>",
"        9 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        - Exon 15, codon 891",
"       </td>",
"       <td>",
"        9 percent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_5_23643=[""].join("\n");
var outline_f23_5_23643=null;
var title_f23_5_23644="Dentin dysplasia";
var content_f23_5_23644=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77566&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77566&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Heritable conditions of dentin",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Radiographic features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Molecular defect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dentinogenesis imperfecta type 1 (occurs in some forms of osteogenesis imperfecta)",
"        <br/>",
"        (OMIM #166200)",
"       </td>",
"       <td>",
"        Variable blue-gray to yellow-brown teeth, enamel fracturing, excessive wear, primary teeth usually more affected than permanent",
"       </td>",
"       <td>",
"        Variable pulp obliteration, bulbous crowns, altered root morphology, increased risk for dentigerous cysts",
"       </td>",
"       <td>",
"        Mutations of collagen type 1 genes (",
"        <em>",
"         COL1A1",
"        </em>",
"        and",
"        <em>",
"         COLl1A2",
"        </em>",
"        )",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Dentinogenesis imperfecta type 2",
"        <br/>",
"        (OMIM #125490)",
"       </td>",
"       <td>",
"        Same appearance and variability as in DI type 1, often similar severity in primary and permanent dentitions",
"       </td>",
"       <td>",
"        Pulp chamber obliteration that can begin before tooth eruption, abnormal crown and root morphology",
"       </td>",
"       <td>",
"        Unknown, linked to 4q21 locus",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Dentinogenesis imperfecta type 3",
"        <br/>",
"        (OMIM #125500)",
"       </td>",
"       <td>",
"        Similar clinical phenotype as DI types 1 and 2 although typically severe expression with enamel loss and extensive wear occurring early",
"       </td>",
"       <td>",
"        Large pulp chambers, very thin dentin, bulbous crowns, and diminished root structure",
"       </td>",
"       <td>",
"        Unknown, linked to 4q2l locus",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Dentin dysplasia type 1",
"        <br/>",
"        (OMIM #125400)",
"       </td>",
"       <td>",
"        Normal clinical crown morphology and coloration in primary and permanent dentitions, malaligned teeth, frequent dental abscess",
"       </td>",
"       <td>",
"        Pulp obliteration and short blunt roots in both primary and permanent dentitions",
"       </td>",
"       <td>",
"        Unknown, no locus identified",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Dentin dysplasia type 2",
"        <br/>",
"        (OMIM #125420)",
"       </td>",
"       <td>",
"        Primary dentition has same phenotype as DI, permanent dentition has normal to slight blue-gray discoloration",
"       </td>",
"       <td>",
"        Pulp obliteration in primary dentition, abnormal pulp morphology, and pulp stones in permanent dentition",
"       </td>",
"       <td>",
"        Unknown, linked to 4q2l locus",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     DI: dentinogenesis imperfecta.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wright JT. Pediatr Clin North Am 2000; 47:986. Copyright 2000 W.B. Saunders Company.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_5_23644=[""].join("\n");
var outline_f23_5_23644=null;
var title_f23_5_23645="Light box retailers";
var content_f23_5_23645=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F65208&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F65208&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Partial list of light box retailers",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            United States suppliers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Hughes Lighting Technologies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            34 Yacht Club Drive",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Lake Hopatcong, NJ 07849",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            800-544-4825",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            973-663-1214",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            The SunBox Company",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            19217 Orbit Drive",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Gaithersburg, MD 20879-4149",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            800-548-3968",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            301-869-5980",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            www.sunbox.com",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Apollo BriteLite",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            376 South Commerce Loop",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Orem, UT 84057",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            800-545-9667",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            801-226-2370",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            www.apollolight.com",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Enviro-Med Bio-Light",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            1600 SE 141st Ave",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Vancouver, WA 98683",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            800-222-3296",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            360-256-6989",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            www.bio-light.com",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Canadian suppliers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Uplift Technologies, Inc.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            125-11 Morris Drive",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Dartmouth, NS, B3B 1M2",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            CANADA",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            800-387-0896",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            www.up-lift.com",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Health Light Inc.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            P.O. Box 3899",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hamilton, ON, L8H 7P2",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            CANADA",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            800-265-6020",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            www.healthlight.net",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Northern Light Technologies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            8971 Henri-Bourassa West",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Montreal, QB, H4S 1P7",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            CANADA",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            800-263-0066",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            www.northernlighttechnologies.com",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Sunnex Biotechnologies Inc.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            657-167 Lombard Avenue",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Winnipeg, MB, R3B 0V3",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            CANADA",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            877-778-6639",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            204-956-2476",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            www.sunnexbiotech.com",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_5_23645=[""].join("\n");
var outline_f23_5_23645=null;
var title_f23_5_23646="Mitral valve prolapse apical long axis echocardiogram";
var content_f23_5_23646=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/57557/aplaxmvp_conv.mp4?title=Mitral+valve+prolapse+apical+long+axis+echocardiogram\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mitral valve prolapse apical long axis echocardiogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 342px; height: 234px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_5_23646=[""].join("\n");
var outline_f23_5_23646=null;
var title_f23_5_23647="Calcinosis systemic sclerosis";
var content_f23_5_23647=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F67757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F67757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 482px\">",
"   <div class=\"ttl\">",
"    Calcinosis in scleroderma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 462px; height: 247px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Calcinosis on the fingertip of a patient with limited cutaneous systemic sclerosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD, FRCP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_5_23647=[""].join("\n");
var outline_f23_5_23647=null;
